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ABSTRACT 
 
Wesley Langdon Storm: Combined Bactericidal/Bacterial Adhesion-Resistant Coatings 
through Nitric Oxide Release 
 
(Under the direction of Mark H. Schoenfisch) 
 
In response to the health and economic burdens associated with implant-related 
infections, researchers have developed coatings that resist bacterial adhesion and/or kill 
bacteria. Herein, the synthesis of coatings that release nitric oxide (NO) to inhibit 
bacterial adhesion and kill bacteria are described.  
In order to expand the clinical utility of NO-releasing surfaces, xerogels were 
synthesized from N-diazeniumdiolate-modified silane precursors. Release kinetics and 
totals were tunable through careful selection of the silane precursor and its concentration, 
respectively. To demonstrate the versatility of this approach, NO-releasing xerogels were 
cast as outer membrane on glucose sensors. The sensors exhibited a linear response 
towards glucose and maintained glucose sensitivity in phosphate buffered saline for up to 
one week. 
"Active" and "passive" antimicrobial surface approaches were combined by 
synthesizing NO-releasing superhydrophobic xerogels. These reduced viable adhesion of 
Pseudomonas aeruginosa by two orders of magnitude. Release of NO conferred biocidal 
properties to the coating, while superhydrophobicity reduced bacterial adhesion. 
Furthermore, the superhydrophobic coatings were also used to extend drug release rates.
iv 
 
The release of two antibacterial agents simultaneously (silver and NO) was 
pursued as a strategy for enhancing bacterial killing. To this end, xerogels were 
synthesized that released silver and NO at doses sufficient to kill Pseudomonas 
aeruginosa and Staphylococcus aureus. Confocal microscopy experiments revealed that 
NO primarily operated by reducing bacterial adhesion, while silver actively killed 
bacteria. Together, the two agents killed bacteria more effectively than either agent alone. 
Poly(amido amine) dendrimers that release NO were used as dopants within 
polyurethane dispersions to make films and electrospun fibers. The NO flux from these 
materials could be tuned for antimicrobial or wound-healing purposes. Independent 
tuning of NO-release and hydrophobicity through multiple surface modifiers was used to 
minimize leaching of the dendrimers from polyurethane fibers while extending their NO-
release duration. 
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Chapter 1: 
The Development of Antifouling and Biocidal Coatings for Biomedical Implants 
 
 The advent of modern biomaterials research began when clinicians serendipitously 
discovered that certain polymers (e.g., poly(methyl methacrylate) canopies “implanted” into 
the eyes of fighter jet pilots via machinegun fire) evoked a favorable healing response when 
compared to other materials.
1
  As the scientific understanding of molecular biology and 
materials science has grown, researchers have studied the processes governing the tissue 
biocompatibility of implants.  Given the seemingly endless combination of polymer 
chemistries, 3D-architectures and mechanical properties that have been developed, it is best 
to categorize these materials by their function rather than their form. A clear delineation in 
function appears between two types of biomaterials: 1) implantable devices, where the 
material in-and-of-itself is the purpose of the implant (e.g., prosthetic joints, catheters, stints, 
engineered tissue scaffolds, drug-release reservoirs, etc.); and, 2) device coatings, where the 
biomaterial serves as a companion to an existing implant to improve its utility. This 
introductory chapter focuses on the latter, specifically coatings that reduce bacterial adhesion 
or kill bacteria on implanted materials.   
1.1  Microbial colonization on medical devices  
 Implanted medical devices are widespread in clinical care. Unfortunately, many 
devices cause infections which result in massive economic and health costs. Urinary and 
central venous catheters, pacemakers, and prosthetics are all prone to bacterial colonization, 
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with infection rates ranging from 1—20% depending on the implant type as well as the 
expertise of the surgical staff performing the procedure.
2, 3
 At worst, bacterial colonization on 
an implanted material may lead to life-threatening infections.
4
 In milder cases, the presence 
of bacteria on a surface discourages successful integration of the device into native tissue, 
necessitating device removal.
5,6
 These episodes are costly; for instance, the expense of 
arthoplasty infections exceed >$50,000 per case and extend average hospital stays by an 
average of 11 days.
3,7
 Mechanisms to reduce the incidence of infection on implanted devices 
are greatly needed. 
 The critical density of bacteria required to infect an implant is much lower than the 
amount required when an implant is absent.
2
 This discrepancy arises from bacteria’s ability 
to adhere readily to surfaces. Furthermore, surgical implantation procedures themselves 
cause inflammation and a localized immuno-incompetent zone, weakening the natural 
response of the host to microbes introduced during surgery.
5
 The weakened host response is 
evident from the vast number of implant infections caused by Staphylococcus epidermidis; in 
normal tissue, S. epidermidis is virtually avirulent.
5,8
 Following implantation, localized 
inflammatory responses produce reactive oxygen intermediates such as superoxide, while 
production of interferon-γ and interleukin-1 are inhibited.9 As a result, macrophages 
(immune cells that combat bacteria) become less effective and the activity of other immune 
cells such as lympochytes, monocytes and neutrophils is depleted.
8
 Moreover, some immune 
cells (e.g., leukocytes) are not adept at killing surface-adhered bacteria due to shear stresses 
at the fluid-solid interface.
10
  
 To compensate for the weakened host immune response, antibiotics are typically 
administered before/following surgery.
6
 However, some bacteria on surfaces form “biofilms” 
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that render conventional antibiotic treatments ineffective.
11,12
 Biofilms are extremely 
common and implicated in at least 90% of catheter related infections.
13
 Biofilm bacteria are 
thus best considered the norm rather than the exception. Biofilms form when bacteria adhere 
to a surface and secrete a thick polysaccharide matrix. Bacteria within biofilms also occupy a 
broad range of phenotypes and metabolic states, many of which are less susceptible to 
antibiotics.
12
 The environmental heterogeneity within biofilms causes broad variations in 
nutrient concentrations, oxygen levels and pH that interfere with the action of many 
antibiotics.
12, 14-17
 While still not fully understood, cells in biofilms utilize quorum sensing 
(e.g., cell-to-cell communication) to rapidly change gene expression patterns within the 
colony.
18
 This form of communication may control biofilm dispersal, where bacteria within 
the sessile biofilm are “released” into the local environment in their planktonic form to 
colonize new surfaces.
19
 As a result, biofilms on clinical devices cause repeated incidents of 
acute infection (Figure 1.1). 
 Complicating matters further, most biofilms are polymicrobial.
20
 Polymicrobial 
biofilms are even less susceptible to antibiotics. Harriott et al. examined the efficacy of 
vancomycin against polymicrobial biofilms containing Staphylococcus aureus and Candida 
albicans, finding that C. albicans caused S. aureus to become highly resistant to treament.
21
 
Polymicrobial biofilms can also grow faster; for example, Peters et al. found that 
polymicrobial biofilms of C. albicans and S. aureus grew synergistically.
22
 
 In summary, nosocomial infections emerge from the practicalities of clinical 
procedures and the highly evolved survival mechanisms of bacteria. Infection and implant 
damage that results from biofilm formation is best treated by preventing (or limiting) viable 
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Figure 1.1 The stages of biofilm formation that occur when bacteria interact with 
surfaces. After adhering to a surface, bacteria excrete a protective exopolysaccharide 
matrix (represented in the graphic as a yellow film), multiply, and disperse into planktonic 
bacteria.  
I. Non-specific 
adhesion
II. Irreversible 
adhesion
III. Biofilm formation IV. Biofilm growth V. Biofilm dispersal
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microbial adhesion from the start.
23
 To this end, researchers have developed antimicrobial 
materials that quell the adhesion of bacteria to surfaces and/or kill bacteria that do adhere. 
The two major branches of antifouling/antimicrobial materials, passive and active, are 
discussed in sections 1.3 and 1.4. 
 
1.2  Passive surface modifications for reducing infection 
 A number of coatings feature topographies or covalently bound chemical moieties 
that reduce bacterial adhesion or kill bacteria. Coatings of this type (“passive”) rely on 
mechanisms intrinsic to the surface itself (Figure 1.2) to combat infection. In this section, the 
strengths and limitations of such surfaces as they relate to clinical applications are discussed. 
 
1.2.1  Non-fouling surfaces 
 Surfaces that resist fouling (i.e., adherence of proteins and bacteria) represent perhaps 
the simplest route towards antimicrobial coatings.
24
 Perhaps the most thoroughly studied 
antifouling interface utilizes poly(ethylene glycol) (PEG) to resist protein adhesion.
25
 The 
PEG macromolecule is easily grafted onto a number of existing surfaces (“PEGylation”), 
including polyurethanes,
26
 silicon,
27
 silica,
28
 and stainless steel.
29
 Not limited to grafting, 
PEG can also comprise 3-dimensional scaffolds such as hydrogels.
30
  
 The protein-resistant capabilities of PEGylated materials arise from its hydrophilic 
nature. When proteins in solution come in contact with these surfaces, the hydrated PEG 
chains become compressed, forcing steric interactions that are not energetically favorable.
31, 
32
 Sheth et al. found that repulsive forces between proteins in solution and PEG-grafted 
surfaces dominate over short distances.
33
 However, attractive forces begin to emerge if 
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Figure 1.2 Passive strategies for reducing bacterial adhesion and viability on a surface. 
(A) Poly (ethylene glycol) and (B) superhydrophobic modifications prevent bacterial 
adhesion, while (C) polycationic quaternary ammonium surfaces kill adhered bacteria via 
membrane disruption. 
A B C
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proteins are forced into the PEGylated layer. As such, it was concluded that steric hindrance 
alone does not fully account for the antifouling properties of PEG.
33
 A second, more likely 
mechanism involves competition between the adhesion of water molecules and the adhesion 
of larger macromolecules to the PEG chains.
33
 
 Despite a proven ability to resist protein adhesion, the ability for PEGylated surfaces 
to resist bacterial adhesion is less promising. Whitesides and coworkers found that a 
resistance to protein adhesion does not correlate with a resistance to bacterial adhesion,
34
 
owing to mechanisms of bacterial adhesion that do not rely on proteins. Likewise, PEG 
surfaces on stainless steel that were highly resistant to protein showed very little resistance in 
adhesion to Pseudomonas sp. and Listeria monocytogenes.
29
 These shortcomings were 
initially attributed to the instability of such coatings in physiological solutions. Roosjen et al. 
observed hydrolysis of the bond connecting poly(ethylene oxide) to its substrate in saliva and 
urine. Kingshott et al. also demonstrated that stable, covalent attachment of PEG is critical 
for any success in resisting bacterial adhesion. By grafting PEG onto a covalently-
immobilized branched poly(ethylenimine) macromolecule on stainless steel, the surfaces 
were able to reduce bacterial adhesion by 2—4 orders of magnitude over a 5-h period.35 
 The current state-of-the-art in PEG surfaces utilizes peptides to strengthen the bond 
between PEG and an underlying substrate. Using a process known as phage display, peptides 
with highly specific binding affinity for a biomedical titanium alloy were identified, isolated, 
and then modified with PEG.
36
 The strength of attachment is further increased by utilizing 
multivalent peptides.
37
 Tetravalent peptides (i.e., four linkages to the Ti substrate) were 
found to remain attached in serum for up to 14 d (the longest duration tested). In contrast, 
monovalent binding peptides lost over 90% of the PEG coating over the same time period. 
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The tetravalent PEG materials were able to resist S. aureus adhesion and subsequent biofilm 
formation.
36, 37
  
 Even if PEG is stably bound to a substrate, other issues arise with the PEG moiety 
itself. In oxygenated conditions, or those where transition metal ions are present, the PEG 
surface may degrade through oxidation.
38
 PEG hydroxyl groups are also enzymatically 
converted to aldehydes in vivo.
38
 As such, coatings less susceptible to degradation may be 
more appropriate for preventing bacterial adhesion.  
1.2.2  Superhydrophobic materials 
 Superhydrophobic materials exhibit unique water contact properties. Such interfaces 
are characterized by large water contact angles (>150
o
) and low water-roll off angles. While 
the existence of such surfaces has been known since at least 1907, research in this area 
underwent a massive resurgence when Barthlott and Neinhuis discovered that 
superhydrophobicity led to the self-cleaning effects of the Lotus plant.
39
 The authors 
determined that this self-cleaning property resulted from the combination of low surface 
energy (from its waxy epicuticular coating) and an innate surface roughness. The behavior of 
water droplets on rough surfaces had been previously described in two separate models by 
Cassie and Wenzel.
40, 41
 In the Cassie model, a pocket of air is trapped within the recesses of 
the rough surface. Thus, the droplet sits on a pocket of air (known as a “Cassie state” 
droplet). Because of the extremely low contact area between the droplet and the surface, the 
droplet will roll off at negligibly small tilt angles, cleaning the surface in the process.
40
 In the 
Wenzel model, the water droplet makes contact with all of the microscopic and sub-
microscopic features of the surface (a “Wenzel state” droplet).41 The contact angle is then 
dictated by the droplet minimizing its contact with the low surface energy material. Droplets 
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obeying the Wenzel model remain pinned to the interface even at high tilt angles (a “Wenzel 
state” droplet). In practice, Wenzel state droplets occur when water impregnates the valleys 
of the roughened surface, giving water droplets direct contact with the material itself rather 
than air (Figure 1.3). For a surface to be effective in self-cleaning and fouling prevention, the 
surface properties need to be tailored so that the droplets remain in the Cassie state. This 
condition is most effectively achieved through hierarchal roughness that exhibits both 
microscale and nanoscale dimensions.
42
 
 Water droplets on a surface become inadequate descriptors of the surface/water 
interaction when a superhydrophobic material is fully submerged in aqueous media (as would 
be the case for an implanted biomaterial). Instead, a pocket of entrapped air referred to as a 
plastron spans the divide between the solid-liquid interface when these materials are 
submerged.
43
 Materials housing an air plastron are evident by a silvery-sheen present on the 
superhydrophobic surface, and are indicative of a Cassie-Baxter wetting state.
44
 Contact with 
the surrounding water is limited, and thus opportunities for bacterial interactions are 
minimized. Supporting this hypothesis, Truong et al. found reduced S. aureus adhesion on 
superhydrophobic surfaces. Areas of the substrate with the most entrapped air contained the 
fewest number of bacteria.
45
 Bacterial adhesion increased at extended immersion times, most 
likely a result of air dissolution into the surrounding aqueous layer. Indeed, 
superhydrophobic surfaces slowly lose their plastron through gas exchange with the 
surrounding aqueous media dependent on immersion depth, dissolved gas concentration, and 
other factors.
46
 Even after complete plastron loss, evidence suggests that the nanoscale 
features present on many superhydrophobic surfaces reduce bacterial adhesion even in the 
absence of a plastron.  Ma et al. forced complete wetting of a Taro leaf (a naturally occurring 
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Figure 1.3 A water droplet atop a rough surface obeying the (A) Wenzel or (B) Cassie 
model.  
A B
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superhydrophobic plant) such that no plastron remained, and still observed a resistance to P. 
aeruginosa adhesion. This anti-adhesive effect was attributed to surface architecture, as areas 
featuring dense nanostructures tended to have the fewest adhered bacteria. Those bacteria 
that did adhere were mostly located in the boundary regions between nanostructures.
44
 
Spatial variations in adhesive forces were further corroborated via atomic force microscopy, 
where those areas with high nanostructure densities had less adhesion than areas lacking 
nanostructures. 
 When bacteria require specific proteins to adhere to a surface, their adhesion to 
superhydrophobic substrates may be inhibited through reduced protein adsorption. Stallard 
and co-workers utilized spectroscopic ellipsometry to quantify fibrinogen adhesion to 
surfaces with water contact angles between <5 and >150
o
. Adsorbed fibrinogen was lowest 
on the fluorinated superhydrophobic substrates. To determine if this reduction in protein 
binding led to decreased bacterial adhesion, the authors exposed the substrates to a 
suspension of SH1000, a strain of S. aureus that specifically binds to fibrinogen.
47
 Compared 
to fibrinogen-bound controls, bacterial adhesion was reduced by ~99% for superhydrophobic 
substrates regardless of fibrinogen exposure. These findings indicate that 
superhydrophobicity reduces bacterial adhesion in the absence of proteins, but also reduces 
the adhesion of proteins that bind specifically to bacteria.
48
  
 Until recently, methods for producing superhydrophobic materials utilized processing 
conditions that were either complex, chemically harsh, or difficult to scale (e.g., lithography, 
acid etching, high temperatures). To remedy this, more facile techniques have been 
developed whereby a superhydrophobic material is applied as a thin coating.
49-51
 Our group 
utilized sol-gel chemical techniques to fabricate superhydrophobic materials via mild 
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aqueous reaction conditions and low-temperature drying environments.
49
 We first fabricated 
colloidal silica particles (to impart roughness), and then crosslinked those particles within a 
fluorinated sol-gel film (for low surface energy).
49
 Utilized in chapters 2, 3, and 4 of this 
dissertation, the sol-gel method consists of the hydrolysis and condensation of silane 
precursors to yield a variety of materials depending on the reaction conditions (Figure 1.4). 
For example, low silane concentrations with basic ammonium hydroxide catalysts favor rapid 
silane condensation and tend to form particles. In contrast, sol-gel reactions in acidic 
conditions produce linear chains that further crosslink to form a 3-dimensional network 
(referred to as a “xerogel” when dried).   
 The antimicrobial adhesion potential of the superhydrophobic sol-gel materials 
fabricated by Privett et al. was assessed against Pseudomonas aeruginosa and 
Staphylococcus aureus at concentrations of 10
8
 cfu mL
-1
. A 1.8 and 2.1-log reduction in 
adhered bacteria was observed for the two strains, respectively.
49
 Despite this reduction in 
bacterial adhesion, the materials were not capable of killing adhered bacteria. As such, 
bacteria proliferation and biofilm growth from adhered bacteria are still possible. Methods to 
kill bacteria through active release (or contact killing) are needed for truly anti-adhesive 
coatings to maximize their clinical potential.
52
 Reports of antimicrobial superhydrophobic 
materials are limited. Shateri Khalil-Abad et al. developed superhydrophobic fibers coated 
with antimicrobial silver nanoparticles and evaluated their efficacy against Escherichia coli  
and Staphylococcus aureus using a zone of inhibition assay.
53
  While common practice, these 
assays do not model the irreversible bacterial adhesion events that occur in fluid-submerged 
surfaces. To assess the potential of superhydrophobic materials for biomedical applications, 
implant-relevant antibacterial assays must be carried out in tandem with their development.   
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Figure 1.4 (A) Acid and (B) base-catalyzed sol-gel hydrolysis and condensation reactions.  
A
B
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1.2.3   Superhydrophobic materials for drug release  
 Controlled release of antimicrobials from superhydrophobic coatings remains 
relatively unexplored, but controlled release of cancer drugs from superhydrophobic 
materials has been the subject of recent study by Grinstaff and coworkers.
54-57
 
Superhydrophobic electrospun fiber meshes were doped with the cancer drug SN-38 for 
controlled drug release.
56
 The polymeric meshes were synthesized using a mixture of poly(ε-
caprolactone) and poly(glycerol monostearate-co-ε-caprolactone) (PGC-C18), a hydrophobic 
additive. By controlling the amount of PCG-C18 within the fiber mat, contact angles were 
tunable from roughly 120 (hydrophobic) to 153
o
 (superhydrophobic). The rate of drug release 
from the fibers was substantially slower from the superhydrophobic materials because of 
reduced water uptake. Superhydrophobic meshes doped with SN-38 could kill Lewis lung 
carcinoma (LLC) cells after >60 d incubation, whereas the non-superhydrophobic mats could 
only be incubated for 25 d before losing their cell-killing potential. This phenomenon was 
explained through reduced water uptake. As the mats are placed in aqueous media initially, 
the pocket of air within remains trapped, slowly displacing over time as water migrates into 
the material. The rate of release is controlled by the displacement of air in the material by 
water encompassing the sample. The rate at which water displaces entrapped air seems to be 
a property of the material itself (i.e., through varying the PGC-C18 dopant percentage in this 
particular case), but also can be accelerated by external means. For instance Yohe et al. 
synthesized fiber mats with a larger percentage (30 wt%) of the hydrophobic PGC-C18 
dopant so that no measurable release of SN-38 occurred in aqueous buffer.
57
 Release of the 
drug was then triggered by ultrasound, forcing water into the mat. Consistent with the lack of 
drug release from 30 wt% PGC-C18 fibers, these mats were not toxic towards LLC cells after 
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10 d. However, the cells could be killed (99%) after this period by releasing the entrapped 
drug with ultrasound. In summary, superhydrophobic fiber mats are an elegant approach for 
tuning drug release rates; however, doping drugs into fibers may not be feasible for all drug 
release chemistries. These superhydrophobic fiber mats serve as stand-alone implants (i.e., 
devices) rather than coatings on existing medical implants. A need still exists for a facile 
superhydrophobic coating that can be applied in bulk to a wide range of drug-releasing 
substrates for tuning release of the drug contained within.  
 
1.2.4  Polycationic antimicrobial surfaces  
 Small molecule quaternary ammonium (QA) compounds have seen widespread use as 
antiseptics and disinfectants.
58
 Mechanistically, the cationic charge on QAs promotes 
association of the molecules with the negatively charged surface of bacteria. Once QAs are 
surface-associated, the hydrophobic chains pendant from the ammonium cation cause 
bacterial membrane disruption, ultimately leading to cell death.
59
 Additional antimicrobial 
action may be attributed to diffusion and uptake of the molecules into bacterial cells, but 
membrane-specific mechanisms have inspired the development of coatings with tethered-on 
antimicrobial QA moieties.
58, 60, 61
 
 Isquith and coworkers first developed QA-modified coatings by grafting the silane 3-
(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride onto glass and a variety of 
other surfaces.
58
 These materials killed a broad array of organisms including Gram-negative 
and Gram-positive bacteria, fungi, and algae. When aerosolized onto the QA-functionalized 
glass slides, ~3-log (99.9%) reductions were observed against Streptococcus faecalis. To 
confirm that these antimicrobial effects were attributable to surface-bound QAs rather than 
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slow release of the compound, the surfaces were repeatedly washed in distilled water and 
their antimicrobial efficacy was reexamined. The authors found that the coatings largely 
retained their antimicrobial efficacy after washing, and thus attributed the mechanism of 
action to the surface-bound QAs.  
 Subsequent research of polycationic surfaces was largely stagnant until 2001 when 
the Klibanov laboratory used a graft copolymerization method to create N-hexylated poly(4-
vinylpyridine) (PVP).
62
 In agreement with the above study by Isquith and coworkers, N-
hexylated PVP significantly reduced adhered viable bacteria introduced via aerosolization of 
bacteria suspensions. While such conditions are beneficial for decontaminating “everyday” 
surfaces (including those used in the clinical setting), assessing bacterial killing in this 
manner does not reflect the fluid conditions surrounding implanted devices. In follow-on 
work by Tiller et al., poly(vinyl-N-hexylpyridinium)-functionalized coatings were also found 
to kill waterborne S. aureus and E.coli.
63
 The surfaces were submerged in suspensions of the 
bacteria (~1 x 10
6
 cfu mL) for 2 h, then transferred to sterile phosphate buffered saline 
(PBS). A 1.7—2 log reduction was observed depending on the coated material and the 
bacteria strain. These results suggest that QA-modified coatings are effective for killing 
viable adhered bacteria. However, the low concentration of bacteria employed and the 
solution used (sterile PBS) were far different from the high concentrations of protein and 
cells present in biological milieu. Even in the absence of proteins and debris, bacteria killed 
by the QA coating remain adhered, thus masking the biocidal surface from newly adhered 
bacteria. Researchers in the Klibanov laboratory have studied this phenomenon by evaluating 
the antimicrobial efficacy of QA surfaces after multiple exposures to bacteria.
64
 After 
spraying the surfaces four times with a suspension of S. aureus, the bactericidal activity 
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declined by 42%. While the antimicrobial activity could be restored by cleaning off the dead 
bacteria with surfactants, such a step would be impractical for implanted devices. 
Furthermore, these surfaces are much less effective at killing bacteria when challenged with 
high concentrations of bacteria (>1 x 10
7
 cfu mL
-1
).
65
 The biocidal action of such coatings is 
only considered “permanent” insofar as the surface remains clean, or can be regenerated 
through cleaning. Since even dead bacteria are able to invoke an inflammatory response in 
vivo,
66
 mechanisms that reduce bacterial adhesion in addition to killing bacteria are needed.  
 
1.3 Active release strategies for antimicrobial surfaces 
 The other major branch of antimicrobial materials utilizes the active release of 
biocidal agents from an implant surface.
67
 This approach offers several advantages. First, 
large systemic doses of the biocidal compound in question are avoided because antimicrobial 
concentrations of the agent are relegated to an area close to the device itself. Concentrations 
of a released agent in the stagnant layer immediately adjacent to the implant are several 
orders of magnitude larger than systemic concentrations due to dilution that occurs as the 
agent diffuses outward.
8
 Second, active release mechanisms, unlike passive mechanisms, are 
not typically obstructed by surface fouling or the adhesion of dead cells.
67
  
 By their very nature, the antimicrobial duration of active-release surfaces are finite, 
and will depend on factors such as the size and release rate of the antimicrobial payload 
encapsulated within. While this disadvantage has been highlighted to justify passive 
approaches to antimicrobial materials,
68
 such criticisms may be unnecessary. It has been 
suggested that bacterial killing within a post-operative window of 6 hours following 
implantation is critical for removing pathogens introduced during surgery.
6
 This critical 
period emerges because truly sterile surgical sites are a near-impossibility, and because the 
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host immune response is severely compromised at the implant site due to localized 
inflammation. While longer durations may certainly be beneficial, a finite biocidal duration 
by no means renders the device unusable.  A number of biocidal agents have been explored 
as active release materials, including those that release conventional antibiotics, silver, and 
nitric oxide. Each is discussed in detail below.  
 
1.3.1  Release of antibiotics  
 To reduce the need for systemic antibiotic therapy, researchers have incorporated 
antibiotics into materials to facilitate localized release.
69
 Since release of the drug is dictated 
by diffusion, the water uptake by the polymer significantly impacts release kinetics. Risbud 
et al. reported on amoxicillin-loaded chitosan/polyvinyl pyrrolidone (PVP) hydrogels that 
released a majority (73%) of their contents within 3 h. In a follow on-study, polyacrylamide-
chitosan hydrogels with comparatively lower water uptake were able to slow the release, 
such that only ~75% of the total payload was released over 3 d.
70
  
 Choosing the appropriate drug release vehicle is critical for clinical success, as the 
scaffold itself may interact with surrounding tissue. For example, antibiotic-loaded sol-gel 
films have been utilized in the treatment of bone-related infections.
71-73
 In these systems, the 
sol-gel coatings were selected due to their favorable interaction with bone matrices. The 
antibiotic release inhibited bacterial colonization. Adams et al. developed sol-gel coatings 
that released most of their vancomycin payload within 3 d, but the remaining drug released at 
slower rates over the next 2 weeks. The antibiotic-loaded sol-gels were coated on titanium 
alloy rods, implanted into the femoral canal of Wister rats, and challenged with an inoculum 
of S. aureus. The antibiotic-releasing sol-gels significantly decreased the number of 
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isolatable viable bacterial colonies in addition to improving bone integration and reducing 
osteomyelytis.
74
 After 3 and 4 weeks, the films were no longer able to kill bacteria, 
suggesting that the vancomycin supply was exhausted.
74
 Such findings support the benefit of 
long-term antibiotic release.
75
 Unfortunately, extremely long-term sustained release of 
antibiotics may actually serve as a pitfall to successful treatment. Neut and colleagues 
analyzed a patient whom had been treated with gentamicin-loaded poly(methyl methacrylate)  
beads 5 years prior.
76
 The beads still released residual levels of the antibiotic. This sustained, 
sub-inhibitory release fostered development of a gentamicin-resistant staphylococcal strain of 
bacteria. The authors concluded that antibiotic-loaded materials must be designed to prevent 
long-term sustained release, possibly through biodegradability mechanisms.
77,78
 Similar 
concerns have been brought to light in other systems that release antibiotics. Antibiotic-
loaded bone cements, for instance, were criticized by Hanssen for their ability to encourage 
drug-resistance.
79
 Furthermore, multiple antibiotics are required from these materials to 
successfully inhibit a broad range of microorganisms.
79
 Active release agents that operate via 
less specific pathways (i.e., broad-spectrum agents) and overcome bacterial resistance 
mechanisms may be more suitable candidates for localized antimicrobial release.  
 
1.3.2  Nitric oxide-releasing surfaces 
  Nitric oxide is an endogenously produced molecule involved in a diverse array of 
physiological processes, including the immune response to pathogens.
80-83
 Knockout mice 
lacking inducible nitric oxide synthase (iNOS; an enzyme used by macrophages to produce 
NO) were unable to combat replication of Listeria monocytogenes.
84
 While NO exerts some 
of its antimicrobial efficacy directly, most of its action arises from secondary reactions of NO 
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that form peroxynitrite (by reaction with the superoxide anion), nitrogen dioxide, and 
dinitrogen trioxide (by reaction with oxygen).
85-87
 These species place oxidative and 
nitrosative stress on bacteria, ultimately disrupting membrane, protein, enzyme, and DNA 
function.
88
 Mammalian cells, like those located in the endothelium, are able to combat the 
effects of oxidative stress (especially via peroxynitrite) by lowering superoxide 
concentrations through the superoxide dismutase enzyme.
89
 The wide array of mechanisms 
by which NO kills makes it difficult for bacteria to develop resistance to the molecule, as 
multiple simultaneous genetic mutations would be required for a survival advantage.
90
 Taken 
together, NO’s low toxicity, wide-spread distribution in the mammalian body, antimicrobial 
activity, and lack of demonstrated bacterial resistance make it an ideal candidate for active 
releasing antimicrobial surfaces. 
 Supplying exogenous NO to the body requires a means of delivery that is stable until 
the time of treatment and releases at controlled rates during treatment. A number of chemical 
NO donors exist for this purpose, including organic nitrates and nitrates,
91
 metal nitrosyls,
92
 
S-nitrosothiols,
93
 and N-diazeniumdiolates.
94, 95
 While the clinical use of organic nitrates and 
metal nitrosyls is well-established (and in fact predates knowledge of NO’s biological 
activity), the mechanisms by which these donor classes decompose into NO are highly 
dependent on host-specific factors such as enzyme activity.
96-99
 At least some of the action of 
organic nitrates and metal nitrosyls involves the formation of S-nitrosothiol intermediates.
100
 
Thus, N-diazeniumdiolate (Figure 1.5) and S-nitrosothiol NO donors remain the most 
promising donors for their well-understood NO release triggers, rates, and mechanisms. 
 N-diazeniumdiolate NO donors were first synthesized by Drago and coworkers in the 
early 1960s,
101, 102
 and then largely neglected until NO’s physiological importance was 
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Figure 1.5 N-diazeniumdiolate formation on a secondary amine following exposure to 
NO and base. In the presence of a proton, the N-diazeniumdiolate decomposes to yield 
two equivalents of NO and the parent amine. 
2 NO
base
H+
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established in the late 1980s.
103
 Formed via the reaction of secondary amines and NO under 
basic conditions, these compounds exhibit pH-dependent decomposition to two NO 
equivalents and the parent (i.e., precursor) amine. The decomposition rate (i.e., NO-release 
rate) is dependent on the structure, with certain chemical groups capable of stabilizing the N-
diazeniumdiolate.
94
 To control the release of NO and target bacteria directly, these functional 
groups have been incorporated within larger macromolecular scaffolds such as silica particles 
and dendrimers.
104-110
 Like small molecules, the NO-release kinetics from such scaffolds are 
controllable by varying the environment surrounding the N-diazeniumdiolate (Figure 1.6). 
 The active release of NO from a surface can be achieved in a number of ways, but the 
first studies to demonstrate the antimicrobial effects of NO-releasing surfaces utilized amine-
modified xerogels synthesized via the sol-gel process (Figure 1.7).
111-113
 Researchers in the 
Schoenfisch laboratory covalently incorporated amine-functionalized silanes into a xerogel 
matrix. Upon exposure to high pressure NO (5 atm), the 2
o
 amines within were converted to 
N-diazeniumdiolates. Surrounding amines in the xerogel network served as the necessary 
base for N-diazeniumdiolate-formation. Nitric oxide-releasing xerogels were demonstrated to 
reduce the adhesion of biomedical pathogens such as P. aeruginosa, S. aureus (and its 
antibiotic-resistant counterpart, Methicillin Resistant S. aureus), S. epidermidis, Eschericia 
coli, and Eschericia faecalis by 80-95% depending on the bacterial exposure time and NO 
flux at the surface.
111, 114-117
 Furthermore, bacteria that did adhere to the NO-releasing 
surfaces were effectively killed by NO after prolonged exposure.
115, 116
 Recently, Cai et al. 
demonstrated significant reductions in biofilm formation on surfaces that slowly released NO 
for  >7 d.
118
 They hypothesized that the reduced biofilm formation was due to NO’s ability to  
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Figure 1.6 (A) Poly (amido amine) (PAMAM) dendrimers display 1
o
 amines, the number 
of which depends on the dendrimer generation (Generation 0 is shown).  (B) Conversion 
of the 1
o
 to 2
o
 amines allows for N-diazeniumdiolate modification, with subsequent NO-
release kinetics determined by the precursor used to form the 2
o
 amine. 
A
B
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Figure 1.7 Nitric oxide-releasing xerogels synthesized via sol-gel chemical approaches. 
Amine-modified silanes are incorporated into a silica matrix and then exposed to high 
pressure NO to convert the 2
o
 amines to N-diazeniumdiolate NO donors. 
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initiate biofilm dispersal.
119
 The ability for NO-releasing materials to both resist bacterial 
adhesion and kill adhered bacteria suggest that NO may be a suitable active release agent for 
reducing infection in medical implants.  
 Follow-on work demonstrated NO’s ability to combat infection in vivo.120, 121 Nablo 
et al. implanted NO-releasing xerogels into the subcutaneous tissue of male rats and 
inoculated the wound site with S. aureus (1 x 10
6
 cfu). Compared to controls, an 82% 
reduction in infection incidences was observed in rats with NO-releasing implants.
120
 
Building upon this work, Holt et al. coated NO-releasing xerogels onto external fixation pins 
implanted into the tibia of rats. Because external fixators are percutaneous (i.e., exposed 
through skin), such devices are prone to infection as bacteria are able to migrate through the 
pin tract following implantation (Figure 1.8). Following 28 d implantation, significant 
reductions in bacterial colonies and clinical signs of infection were observed at the NO-
releasing pins compared to controls.
121
 Together, these studies illustrate NO’s ability to 
reduce infection in implants. 
 While not the central aim of this research, it is important to note that NO-releasing 
materials also mitigate certain non-microbial fouling events such as platelet adhesion and the 
foreign body response (FBR).
122-126
 The FBR is the cumulative host immune response that 
occurs when a device is implanted.
1, 126, 127
 Frustrated cells that are unable to phagocytose an 
implant form a dense, avascular collagen capsule around the device, walling it off from 
surrounding tissue. This capsule often causes device failure through poor implant-tissue 
integration.
127
 The deleterious consequences of the FBR have hindered the development of 
implantable sensors that monitor analytes such as glucose continuously in real-time.
126
  Such 
devices would improve treatment outcomes for diabetics, but the events of the FBR (namely  
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Figure 1.8 (A) Fixation pins coated with non-NO-releasing xerogels become infected as 
foreign microbes migrate into the pin tract and proliferate in tissue. (B) Fixation pins 
coated with NO-releasing xerogels are killed by NO, and infection incidences are reduced. 
NO
NO
NO
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acute inflammation and inhibited analyte diffusion by collagen encapsulation) lead to erratic 
responses. Nitric oxide-release may alleviate some of these pitfalls. Unfortunately, sensor 
membranes made to release NO from xerogels are mostly impermeable to glucose. Thus 
while they reduce the FBR, they are not analytically useful. More permeable (to glucose) 
NO-releasing sensor membranes would enable the development of better performing 
continuous monitoring glucose sensors.   
 
1.3.3  Antimicrobial silver-releasing materials 
 Silver’s origins as a broad-spectrum antimicrobial agent date back to ancient times, 
where Persians, Greeks, Romans and Egyptians used it to preserve water and food.
128
 
Modern-day silver releasing biomaterials hold distinction as one of the few active release 
systems with demonstrated success in clinical trials.
129
 Current Food and Drug 
Administration (FDA) approved devices include wound dressings for burn patients and 
coatings for urinary and intravascular catheters.
130-132
 Most often, silver is impregnated into 
(or on) materials/devices in the form of ionic silver (e.g., silver nitrate,
133, 134
 silver 
sulfadiazine,
135
 etc.), silver metal,
136
 or silver colloids and nanoparticles.
73, 137
  
 Mechanistically, the bactericidal action of Ag
+
 occurs via three pathways: 1) direct 
membrane damage (i.e., detachment of the cytoplasm from the cell wall);
138
 2) inhibition of 
enzymatic activity following binding between Ag
+
 and protein thiol residues; and 3) 
prevention of DNA replication.
139
 The latter two mechanisms are contingent upon successful 
diffusion of Ag
+
 into the cell. The thick peptidoglycan layer enveloping Gram-positive 
bacteria causes these strains to be less susceptible to silver than their Gram-negative 
counterparts.
139
 The antimicrobial effects of silver metal and colloids in the Ag (0) oxidation 
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state are largely indirect, relying on oxidation of the metals to free Ag
+
. Xiu et al. added 
convincing support to this theory by testing silver nanoparticles against bacteria in anaerobic 
conditions (i.e., conditions precluding the formation of Ag
+
). They found that the  toxicity of 
these materials against bacteria was drastically inhibited,
140
 and ultimately concluded that 
differences in antimicrobial activity between different shapes and sizes of silver 
nanoparticles are intrinsically intertwined with differences in the rate of Ag
+
 production.  
 These findings have since guided the development of silver releasing materials.  For 
example, Marini et al. doped sol-gel films with both silver nitrate and silver nanoparticles, 
finding almost no antimicrobial efficacy from the nanoparticle-doped silica materials despite 
high antimicrobial activity from silica doped with silver nitrate.
133
  The authors concluded 
that diffusion of Ag
+
 from the tortuous silica network, combined with the slow release of Ag
+
 
from the nanoparticles resulted in a silver release rate too low for antimicrobial activity. 
Antimicrobial fluxes from silver nanoparticle-doped materials may be achieved if the 
materials are thin and/or the surrounding framework is open.
137, 141
 However, direct addition 
of a silver salt is a simpler approach. 
 The potential cytotoxicity of silver compounds is well-known. Ionic silver 
compounds exhibit a dose-dependent toxicity towards fibroblasts.
142, 143
 Other forms of 
silver, such as silver nanoparticles, are toxic to zebrafish embryos at antimicrobial 
concentrations.
144
 However, reports of toxicity from silver-coated medical devices are 
conflicting. Bosetti and colleagues utilized a commercial vapor phase coating process to 
apply silver metal onto external fixation pins via ion beam deposition. No toxicity or 
genotoxicity towards fibroblasts (NIH3T3) was noted, but the study did not specify 
concentrations of silver released from the material nor its corresponding antimicrobial 
 29 
 
relevance.
136
 Hardes et al. examined the long-term toxicity of an implanted anti-infective 
silver megaprosthesis in humans over a mean period of 19 months. No damage to liver or 
kidneys (or any systemic side effects for that matter) was noted. Some bioaccumulation of 
silver occurred, with blood silver concentrations around 56.4 ppb (compared to basal levels 
of 2 ppb in untreated patients
145
) but these concentrations would not be expected to produce 
systemic toxic effects.
146
 Trop et al. reported agyria-like symptoms, liver toxicity, and 
elevated levels of silver in plasma and urine for a burn patient treated with silver sulfadiazine 
(SSD)-coated polyethylene meshes.
147
 These conflicting results likely emerge from the 
varied Ag
+
 release rates of different materials. The Ag
+
 release rate may also change for a 
specific material due to changes in localized pH,
128
 ionic strength,
148
 and dissolved oxygen 
content.
149
 Nonetheless, clear evidence of dose-dependent toxicity for Ag
+
 and its associated 
compounds exists.  Given silver’s ability to accumulate systemically, it is best to pursue 
strategies that minimize overall silver release while maximizing localized antimicrobial 
activity.  
 While intuition would suggest that silver’s broad-spectrum nature makes bacterial 
resistance unlikely, silver-resistant bacteria have emerged from environments rich in the 
element (e.g., mining sites).
130
 Resistant bacteria have also been isolated in clinical settings 
that make extensive use of silver in treatment.
150
 Mechanisms for bacterial resistance 
primarily occur at the membrane, ultimately preventing Ag
+
 entry into the cell. Both Ag
+
-
specific periplasmic binding proteins and cationic efflux pumps have been observed in silver-
resistant bacteria.
150, 151
 Despite these findings, current evidences suggests that widespread 
emergence of silver-resistant bacteria is unlikely.
152
 Still, isolated incidents of resistance are 
undesirable and strategies to reduce such occurrences are needed. 
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 Opportunities for resistance can be reduced through combination therapies (i.e., the 
use of multiple drugs to kill bacteria via multiple mechanisms).
153
 Release of silver in 
conjunction with the antiseptic compound chlorhexidine has been used as an effective 
antimicrobial combination therapy, but its use is best avoided as it causes severe 
hypersensitivity reactions in some patients.
132
 In addition to limiting opportunities for 
bacterial resistance, combination therapies may also reduce the overall concentrations of each 
agent necessary for an identical antimicrobial effect. This principle is especially pertinent to 
coatings that release silver, as even localized release can cause a systemic build up of silver 
concentrations throughout the body.
146, 147
 Privett  et al. demonstrated the synergy of silver 
(via silver sulfadiazine) and nitric oxide (via the small molecule NO donor PROLI/NO)  
against a number of Gram-positive and –negative bacteria. The membrane damage evoked by 
either silver (I) or NO facilitated entry of the other species into the cell. Oxidative stress 
resulting from silver likely caused an excess of superoxide anions in the vicinity of the 
bacterial cell. The NO then reacts with these superoxide anions to form peroxynitrite, an even 
more potent antimicrobial agent. As described in Section 1.4.2, NO’s bactericidal effects in 
the absence of silver are largely attributed to an oxidative stress cascade that produces 
peroxynitrite from its reaction with superoxide. It is expected that increased superoxide 
concentrations would enhance NO’s antimicrobial efficacy. Translating this work towards 
clinical applications requires the development of coatings that actively release both NO and 
silver. The multiple bactericidal mechanisms from such coatings would limit opportunities 
for bacterial resistance. Furthermore, synergy with NO would reduce the overall 
concentrations of silver necessary for bactericidal efficacy, and limit both toxicity and 
systemic accumulation of the metal. 
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1.4  Summary of dissertation research 
 The goal of my research was to design antimicrobial coatings that both resist bacterial 
adhesion and kill adhered bacteria. Rational approaches were employed to reduce toxicity to 
healthy cells. Specifically, my research aims included: 
1. the development of NO-releasing coatings via facile sol-gel techniques that can easily 
be applied to functional glucose sensors; 
2. the synthesis of superhydrophobic NO-releasing xerogels that combine passive and 
active antimicrobial strategies, exhibit superior resistance to bacterial adhesion and 
kill adhered bacteria;  
3. the development of coatings that simultaneously release Ag+ and NO for the 
synergistic killing of adhered bacteria; and 
4. utilization of NO-releasing dendrimers as dopants within polyurethane films and 
fibers to create materials that release low levels of NO over prolonged periods of 
time. 
 This introductory chapter has provided a survey of the most promising passive and 
active approaches towards antimicrobial surfaces for reducing bacterial adhesion and 
implant-associated infections. Passive surfaces that resist adhesion (e.g., PEGylated and 
superhydrophobic coatings) provide no means to kill bacteria. Contact-killing passive 
surfaces that feature QA groups kill bacteria, but are inactivated by fouling. Surfaces that 
actively release biocidal agents kill bacteria, but could be improved via combination with 
other strategies that reduce adhesion or kill bacteria more effectively. Nitric oxide-
releasing coatings are particularly beneficial due to their ability to both resist adhesion 
and kill adhered bacteria, but the utility of current NO-releasing substrates could be 
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improved. In Chapter 2, N-diazeniumdiolate-modified silane precursors are used to create 
NO-releasing xerogel membranes that can be applied to orthopedic metals such as 
titanium, release bactericidal concentrations of NO for up to 4 d, and function as glucose 
sensors. In Chapter 3, superhydrophobic NO-releasing xerogels are introduced as a 
strategy for reducing and killing adhered bacteria via passive and active mechanisms. 
Chapter 4 details the preparation of surfaces that release both Ag
+
 and NO for potential 
synergistic antimicrobial benefits. In Chapter 5, NO-releasing poly (amido amine) 
dendrimers are doped within polyurethane films and fibers to create low-flux materials to 
reduce the FBR and formation of biofilms. The ability for superhydrophobic coatings to 
control NO-release kinetics is also demonstrated. Lastly, Chapter 6 summarizes my 
dissertation work and suggests additional approaches for preparing antimicrobial surfaces 
in the future. 
  
 33 
 
REFERENCES 
1. Ratner, B.D.; Bryant, S.J., "Biomaterials: Where we have been and where we are 
going." Annu. Rev. Biomed. Eng. 2004, 6, 41-75. 
2. Campoccia, D.; Montanaro, L.; Arciola, C.R., "The significance of infection related 
to orthopedic devices and issues of antibiotic resistance." Biomaterials 2006, 27, 
2331-2339. 
3. Katsikogianni, M.; Missirlis, Y.F., "Concise review of mechanisms of bacterial 
adhesion to biomaterials and of techniques used in estimating bacteria-material 
interactions." Eur. Cells. Mater. 2004, 8, 37-57. 
4. Tiesenhausen, K.; Amann, W.; Koch, G.; Hausegger, K.; Thalhammer, M., 
"Endovascular stentgraft infection—a life-threatening complication." Vasa 2000, 29, 
147-150. 
5. Gristina, A.G., "Implant failure and the immuno-incompetent fibro-inflammatory 
zone." Clin. Orthop. Relat.R. 1994, 106-18. 
6. Poelstra, K.A.; Barekzi, N.A.; Rediske, A.M.; Felts, A.G.; Slunt, J.B.; Grainger, 
D.W., "Prophylactic treatment of gram-positive and gram-negative abdominal 
implant infections using locally delivered polyclonal antibodies." J. Biomed. Mater. 
Res. A 2001, 60, 206-215. 
7. Berbari, E.F.; Hanssen, A.D.; Duffy, M.C.; Steckelberg, J.M.; Ilstrup, D.M.; 
Harmsen, W.S.; Osmon, D.R., "Risk factors for prosthetic joint infection: Case-
control study." Clin. Infect. Dis. 1998, 27, 1247-1254. 
8. Schierholz, J.M.; Beuth, J., "Implant infections: A haven for opportunistic bacteria." 
J. Hosp. Infect. 2001, 49, 87-93. 
9. Kaplan, S.S.; Basford, R.E.; Kormos, R.L.; Hardesty, R.L.; Simmons, R.L.; Mora, 
E.M.; Cardona, M.; Griffith, B.L., "Biomaterial associated impairment of local 
neutrophil function." ASAIO J. 1990, 36, M172-174. 
10. Sapatnekar, S.; Kao, W.J.; Anderson, J.M., "Leukocyte—biomaterial interactions in 
the presence of Staphylococcus epidermidis: Flow cytometric evaluation of leukocyte 
activation." J. Biomed. Mater. Res. 1997, 35, 409-420. 
11. Marrie, T.J.; Nelligan, J.; Costerton, J., "A scanning and transmission electron 
microscopic study of an infected endocardial pacemaker lead." Circulation 1982, 66, 
1339-1341. 
12. Stewart, P.S.; Costerton, J.W., "Antibiotic resistance of bacteria in biofilms." Lancet 
2001, 358, 135-8. 
 34 
 
13. Mukherjee, P.K.; Zhou, G.; Munyon, R.; Ghannoum, M.A., "Candida biofilm: A 
well-designed protected environment." Med. Mycol. 2005, 43, 191-208. 
14. Zhang, T.C.; Bishop, P.L., "Evaluation of substrate and pH effects in a nitrifying 
biofilm." Water Environm. Res. 1996, 1107-1115. 
15. Tack, K.J.; Sabath, L., "Increased  minimum inhibitory concentrations with 
anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, 
piperacillin, chloramphenicol, and clindamycin." Chemotherapy 1985, 31, 204-210. 
16. Tuomanen, E.; Cozens, R.; Tosch, W.; Zak, O.; Tomasz, A., "The rate of killing of 
Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial 
growth." J. Gen. Microbiol. 1986, 132, 1297-1304. 
17. Mah, T.F.; O'Toole, G.A., "Mechanisms of biofilm resistance to antimicrobial 
agents." Trends Microbiol. 2001, 9, 34-9. 
18. Zimmerli, W., "Infection and musculoskeletal conditions: Prosthetic-joint-associated 
infections." Best. Prac. Res. Cl. Rh. 2006, 20, 1045-1063. 
19. Parsek, M.R.; Greenberg, E., "Sociomicrobiology: The connections between quorum 
sensing and biofilms." Trends Microbiol. 2005, 13, 27-33. 
20. Mermel, L.A.; Farr, B.M.; Sherertz, R.J.; Raad, I.I.; O'Grady, N.; Harris, J.S.; Craven, 
D.E., "Guidelines for the management of intravascular catheter-related infections." 
Clin. Infect. Dis. 2001, 32, 1249-1272. 
21. Harriott, M.M.; Noverr, M.C., "Candida albicans and Staphylococcus aureus form 
polymicrobial biofilms: Effects on antimicrobial resistance." Antimicrob. Agents Ch. 
2009, 53, 3914-22. 
22. Peters, B.M.; Ward, R.M.; Rane, H.S.; Lee, S.A.; Noverr, M.C., "Efficacy of ethanol 
against Candida albicans and Staphylococcus aureus polymicrobial biofilms." 
Antimicrob. Agents Ch. 2013, 57, 74-82. 
23. Cheng, G.; Zhang, Z.; Chen, S.; Bryers, J.D.; Jiang, S., "Inhibition of bacterial 
adhesion and biofilm formation on zwitterionic surfaces." Biomaterials 2007, 28, 
4192-9. 
24. Krishnan, S.; Weinman, C.J.; Ober, C.K., "Advances in polymers for anti-biofouling 
surfaces." J. Mater. Chem. 2008, 18, 3405-3405. 
25. Andrade, J.; Hlady, V.; Jeon, S., "Poly(ethylene oxide) and protein resistance: 
Principles, problems, and possibilities." Advances in Chemistry 1996, 248, 51-60. 
26. Park, K.D.; Kim, Y.S.; Han, D.K.; Kim, Y.H.; Lee, E.H.; Suh, H.; Choi, K.S., 
"Bacterial adhesion on PEG modified polyurethane surfaces." Biomaterials 1998, 19, 
851-9. 
 35 
 
27. Zhang, M.; Desai, T.; Ferrari, M., "Proteins and cells on PEG immobilized silicon 
surfaces." Biomaterials 1998, 19, 953-960. 
28. Alcantar, N.A.; Aydil, E.S.; Israelachvili, J.N., "Polyethylene glycol-coated 
biocompatible surfaces." J. Biomed. Mater. Res. 2000, 51, 343-51. 
29. Wei, J.; Ravn, D.B.; Gram, L.; Kingshott, P., "Stainless steel modified with 
poly(ethylene glycol) can prevent protein adsorption but not bacterial adhesion." 
Colloid Surface B. 2003, 32, 275-291. 
30. Raeber, G. P.; Lutolf, M. P.; Hubbell, J. A., "Molecularly engineered PEG hydrogels: 
A novel model system for proteolytically mediated cell migration." Biophys. J. 2005, 
89, 1374-88.31.  
31. Jeon, S.; Andrade, J., "Protein—surface interactions in the presence of polyethylene 
oxide: II. Effect of protein siz." J. Colloid. Interface Sci. 1991, 142, 159-166. 
32. Jeon, S.; Lee, J.; Andrade, J.; De Gennes, P., "Protein-surface interactions in the 
presence of polyethylene oxide: I. Simplified theory." J Colloid. Interf. Sci. 1991, 
142, 149-158. 
33. Sheth, S.R.; Leckband, D., "Measurements of attractive forces between proteins and 
end-grafted poly(ethylene glycol) chains." Proc. Natl. Acad. Sci USA 1997, 94, 8399-
404. 
34. Ostuni, E.; Chapman, R.G.; Liang, M.N.; Meluleni, G.; Pier, G.; Ingber, D.E.; 
Whitesides, G.M., "Self-assembled monolayers that resist the adsorption of cells." 
Langmuir 2001, 17, 6336-6343. 
35. Kingshott, P.; Wei, J.; Bagge-ravn, D.; Gadegaard, N.; Gram, L., "Covalent 
attachment of poly(ethylene glycol) to surfaces, critical for reducing bacterial 
adhesion." Langmuir 2003, 209, 6912-6921. 
36. Khoo, X.; Hamilton, P.; O'Toole, G.A.; Snyder, B.D.; Kenan, D.J.; Grinstaff, M.W., 
"Directed Assembly of PEGylated-Peptide Coatings for Infection-Resistant Titanium 
Metal." J. Am. Chem. Soc. 2009, 131, 10992-10997. 
37. Khoo, X.; O'Toole, G.A.; Nair, S.A.; Snyder, B.D.; Kenan, D.J.; Grinstaff, M.W., 
"Staphylococcus aureus resistance on titanium coated with multivalent PEGylated-
peptides." Biomaterials 2010, 31, 9285-92. 
38. Ostuni, E.; Chapman, R.G.; Holmlin, R.E.; Takayama, S.; Whitesides, G.M., "A 
survey of structure-property relationships of surfaces that resist the adsorption of 
protein." Langmuir 2001, 17, 5605-5620. 
39. Barthlott, W.; Neinhuis, C.; Verlot, H.; Schott, C.L., "Purity of the sacred lotus , or 
escape from contamination in biological surfaces." Planta 1997, 202, 1-8. 
 36 
 
40. Cassie, A.; Baxter, S., "Wettability of porous surfaces." T. Faraday Soc. 1944, 40, 
546-551. 
41. Wenzel, R.N., "Resistance of solid surfaces to wetting by water." Ind. Eng. Chem. 
1936, 28, 988-994. 
42. Bhushan, B.; Koch, K.; Jung, Y.C., "Fabrication and characterization of the 
hierarchical structure for superhydrophobicity and self-cleaning." Ultramicroscopy 
2009, 109, 1029-34. 
43. Shirtcliffe, N.J.; McHale, G.; Newton, M.I.; Perry, C.C.; Pyatt, F.B., "Plastron 
properties of a superhydrophobic surface." Appl. Phys. Lett. 2006, 104106, 1-10. 
44. Ma, J.; Sun, Y.; Gleichauf, K.; Lou, J.; Li, Q., "Nanostructure on taro leaves resists 
fouling by colloids and bacteria under submerged conditions." Langmuir 2011, 27, 
10035-10040. 
45. Fadeeva, E.; Truong, V. K.; Stiesch, M.; Chichkov, B. N.; Crawford, R. J.; Wang, J.; 
Ivanova, E. P., "Bacterial retention on superhydrophobic titanium surfaces fabricated 
by femtosecond laser ablation." Langmuir 2011, 3012-3019. 
46. Poetes, R.; Holtzmann, K.; Franze, K.; Steiner, U., "Metastable underwater 
superhydrophobicity." Phys. Rev. Lett. 2010, 105, 166104. 
47. Corrigan, R.M.; Rigby, D.; Handley, P.; Foster, T.J., "The role of Staphylococcus 
aureus surface protein SasG in adherence and biofilm formation." Microbiology 2007, 
153, 2435-2446. 
48. Stallard, C. P.; McDonnell, K. A.; Onayemi, O. D.; O'Gara, J. P.; Dowling, D. P., 
"Evaluation of protein adsorption on atmospheric plasma deposited coatings 
exhibiting superhydrophilic to superhydrophobic properties." Biointerphases 2012, 7, 
1-12. 
49. Privett, B. J.; Youn, J.; Hong, S. a.; Lee, J.; Han, J.; Shin, J. H.; Schoenfisch, M. H., 
"Antibacterial fluorinated silica colloid superhydrophobic surfaces." Langmuir 2011, 
27, 9597-601. 
50. Yu, M.; Gu, G.; Meng, W.-D.; Qing, F.-L., "Superhydrophobic cotton fabric coating 
based on a complex layer of silica nanoparticles and perfluorooctylated quaternary 
ammonium silane coupling agent." Appl. Surf. Sci. 2007, 253, 3669-3673. 
51. Ogihara, H.; Xie, J.; Okagaki, J.; Saji, T., "Simple method for preparing 
superhydrophobic paper: spray-deposited hydrophobic silica nanoparticle coatings 
exhibit high water-repellency and transparency." Langmuir 2012, 28, 4605-4608. 
52. Banerjee, I.; Pangule, R.C.; Kane, R.S., "Antifouling coatings: Recent developments 
in the design of surfaces that prevent fouling by proteins, bacteria, and marine 
organisms." Adv. Mater. 2011, 23, 690-718. 
 37 
 
53. Shateri Khalil-Abad, M.; Yazdanshenas, M. E., "Superhydrophobic antibacterial 
cotton textiles." J. Colloid Interface Sci. 2010, 351, 293-8 
54. Wolinsky, J. B.; Yohe, S. T.; Colson, Y. L.; Grinstaff, M. W., "Functionalized 
hydrophobic poly(glycerol-co-ε-caprolactone) depots for controlled drug release." 
Biomacromolecules 2012, 13, 406-411. 
55. Yohe, S. T.; Freedman, J. D.; Falde, E. J.; Colson, Y. L.; Grinstaff, M. W., "A 
Mechanistic Study of Wetting Superhydrophobic Porous 3D Meshes." Adv. Funct. 
Mater. 2013, 23, 3628-3637. 
56. Yohe, S.T.; Colson, Y.L.; Grinstaff, M.W., "Superhydrophobic Materials for Tunable 
Drug Release: Using Displacement of Air To Control Delivery Rates." J. Am. Chem. 
Soc. 2012, 134, 2016-2019. 
57. Yohe, S. T.; Kopechek, J. a.; Porter, T. M.; Colson, Y. L.; Grinstaff, M. W., 
"Triggered drug release from superhydrophobic meshes using high-intensity focused 
ultrasound." Adv. Healthc. Mater. DOI: 10.1002/adhm.201200381, [Available online 
April 17, 2013] 
58. Isquith, A.J.; Abbott, E.A.; Walters, P.A., "Surface-bonded antimicrobial activity of 
an organosilicon quaternary ammonium chloride." Appl. Microbiol. 1972, 24, 859-63. 
59. Denyer, S.P., "Mechanisms of action of antibacterial biocides." Int. Biodeter. 
Biodegr. 1995, 36, 227-245. 
60. Gottenbos, B.; van der Mei, H.C.; Klatter, F.; Nieuwenhuis, P.; Busscher, H.J., "In 
vitro and in vivo antimicrobial activity of covalently coupled quaternary ammonium 
silane coatings on silicone rubber." Biomaterials 2002, 23, 1417-1423. 
61. Oosterhof, J. J. H.; Buijssen, K. J. D. A.; Henk, J.; Laan, B. F. A. M. V. D.; Van, H. 
C.; Mei, D.; Busscher, H. J.; Mei, H. C. V. D., "Effects of quaternary ammonium 
silane coatings on mixed fungal and bacterial biofilms on tracheoesophageal shunt 
prostheses." ACS Nano 2006, 12, 7699-7707. 
62. Tiller, J.C.; Liao, C.J.; Lewis, K.; Klibanov, a.M., "Designing surfaces that kill 
bacteria on contact." Proc. Natl. Acad. Sci USA 2001, 98, 5981-5. 
63. Tiller, J.C.; Lee, S.B.; Lewis, K.; Klibanov, A.M., "Polymer surfaces derivatized with 
poly(vinyl-N-hexylpyridinium) kill airborne and waterborne bacteria." Biotechnol. 
Bioeng. 2002, 79, 465-71. 
64. Mukherjee, K.; Rivera, J.J.; Klibanov, A.M., "Practical aspects of hydrophobic 
polycationic bactericidal "paints"." Appl. Biochem. Biotech. 2008, 151, 61-70. 
65. Murata, H.; Koepsel, R.R.; Matyjaszewski, K.; Russell, A.J., "Permanent, non-
leaching antibacterial surfaces--2: How high density cationic surfaces kill bacterial 
cells." Biomaterials 2007, 28, 4870-4879. 
 38 
 
66. de Man, P.; van Kooten, C.; Aarden, L.; Engberg, I.; Linder, H.; Svanborg Edén, C., 
"Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection." 
Infect. Immun. 1989, 57, 3383-3388. 
67. Hetrick, E.M.; Schoenfisch, M.H., "Reducing implant-related infections: Active 
release strategies." Chem. Soc. Rev. 2006, 35, 780-9. 
68. Wong, S.Y.; Li, Q.; Veselinovic, J.; Kim, B.-S.; Klibanov, A.M.; Hammond, P.T., 
"Bactericidal and virucidal ultrathin films assembled layer by layer from polycationic 
N-alkylated polyethylenimines and polyanions." Biomaterials 2010, 31, 4079-4087. 
69. Nelson, C.L.; Hickmon, S.G.; Skinner, R.A., "Treatment of experimental 
osteomyelitis by surgical debridement and the implantation of bioerodable, 
polyanhydride-gentamicin beads." J. Orthopaed. Res. 1997, 15, 249-255. 
70. Risbud, M.V.; Bhonde, R.R., "Polyacrylamide-chitosan hydrogels: In vitro 
biocompatibility and sustained antibiotic release studies." Drug. Deliv. 2000, 7, 69-
75. 
71. Radin, S.; El-Bassyouni, G.; Vresilovic, E.J.; Schepers, E.; Ducheyne, P., "In vivo 
tissue response to resorbable silica xerogels as controlled-release materials." 
Biomaterials 2005, 26, 1043-1052. 
72. Radin, S.; Ducheyne, P., "Controlled release of vancomycin from thin sol-gel films 
on titanium alloy fracture plate material." Biomaterials 2007, 28, 1721-1729. 
73. Simchi, A.; Tamjid, E.; Pishbin, F.; Boccaccini, A.R., "Recent progress in inorganic 
and composite coatings with bactericidal capability for orthopaedic applications." 
Nanomed-Nanotechnol. 2011, 7, 22-39. 
74. Adams, C.S.; Antoci, V.; Harrison, G.; Patal, P.; Freeman, T.A.; Shapiro, I.M.; 
Parvizi, J.; Hickok, N.J.; Radin, S.; Ducheyne, P., "Controlled release of vancomycin 
from thin sol-gel films on implant surfaces successfully controls osteomyelitis." J. 
Orthopaed. Res. 2009, 27, 701-709. 
75. Gao, P.; Nie, X.; Zou, M.; Shi, Y.; Cheng, G., "Recent advances in materials for 
extended-release antibiotic delivery system." J. Antibiot. 2011, 64, 625-34. 
76. Neut, D.; van de Belt, H.; van Horn, J.R.; van der Mei, H.C.; Busscher, H.J., 
"Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads 
after 5 years of implantation." Biomaterials 2003, 24, 1829-1831. 
77. Gürsel, I.; Korkusuz, F.; Türesin, F.; Alaeddinoglu, N.G.; Hasirci, V., "In vivo 
application of biodegradable controlled antibiotic release systems for the treatment of 
implant-related osteomyelitis." Biomaterials 2001, 22, 73-80. 
 39 
 
78. Gerhart, T.N.; Roux, R.D.; Horowitz, G.; Miller, R.L.; Hanff, P.; Hayes, W.C., 
"Antibiotic release from an experimental biodegradable bone cement." J. Orthopaed. 
Res. 1988, 6, 585-92. 
79. Hanssen, A., "Prophylactic use of antibiotic bone cement: an emerging standard--in 
opposition." J. Arthroplasty 2004, 19, 73. 
80. Nathan, C.F.; Hibbs, J.B., "Role of nitric oxide synthesis in macrophage antimicrobial 
activity." Curr. Opin. Immunol. 1991, 3, 65-70. 
81. MacMicking, J.; Xie, Q.-w.; Nathan, C., "Nitric oxide and macrophage function." 
Annu. Rev. Immunol. 1997, 15, 323-350. 
82. Bogdan, C., "Nitric oxide and the immune response." Nat. Immunol. 2001, 2, 907-16. 
83. Fang, F.C., "Perspectives series : Host / pathogen interactions." J. Clin. Invest. 1997, 
99, 2818-2825. 
84. MacMicking, J.D.; Nathan, C.; Hom, G.; Chartrain, N.; Fletcher, D.S.; Trumbauer, 
M.; Stevens, K.; Xie, Q.W.; Sokol, K.; Hutchinson, N., "Altered responses to 
bacterial infection and endotoxic shock in mice lacking inducible nitric oxide 
synthase." Cell 1995, 81, 641-50. 
85. Brunelli, L.; Crow, J.P.; Beckman, J.S., "The comparative toxicity of nitric oxide and 
peroxynitrite to Escherichia coli." Arch. Biochem. Biophys. 1995, 316, 327-334. 
86. Xia, Y.; Zweier, J.L., "Superoxide and peroxynitrite generation from inducible nitric 
oxide synthase in macrophages." Proc. Natl. Acad. Sci USA 1997, 94, 6954-8. 
87. Carpenter, A.W.; Schoenfisch, M.H., "Nitric oxide release: part II. Therapeutic 
applications." Chem. Soc. Rev. 2013, 41, 3742-52. 
88. Jones, M.L.; Ganopolsky, J.G.; Labbé, A.; Wahl, C.; Prakash, S., "Antimicrobial 
properties of nitric oxide and its application in antimicrobial formulations and 
medical devices." Appl. Microbiol. Biot. 2010, 88, 401-7. 
89. Beckman, J.S.; Beckman, T.W.; Chen, J.; Marshall, P.A.; Freeman, B.A., "Apparent 
hydroxyl radical production by peroxynitrite: Implications for endothelial injury from 
nitric oxide and superoxide." Proc. Natl. Acad. Sci USA 1990, 87, 1620-1624. 
90. Privett, B.J.; Broadnax, A.D.; Bauman, S.J.; Riccio, D.A.; Schoenfisch, M.H., 
"Examination of bacterial resistance to exogenous nitric oxide." Nitric Oxide-Biol. 
Ch. 2012, 26, 169-173. 
91. Feelisch, M.; Kelm, M., "Biotransformation of organic nitrates to nitric oxide by 
vascular smooth muscle and endothelial cells." Biochem. Bioph. Res. Co. 1991, 180, 
286-293. 
 40 
 
92. Ford, P.C.; Bourassa, J.; Miranda, K.; Lee, B.; Lorkovic, I.; Boggs, S.; Kudo, S.; 
Laverman, L., "Photochemistry of metal nitrosyl complexes. Delivery of nitric oxide 
to biological targets." Coordin. Chem. Rev. 1998, 171, 185-202. 
93. Arnelle, D.R.; Stamler, J.S., "NO
+
, NO
.
, and NO
-
 donation by S-nitrosothiols: 
Implications for regulation of physiological functions by S-nitrosylation and 
acceleration of disulfide formation." Arch. Biochem. Biophys. 1995, 318, 279-285. 
94. Hrabie, J.A.; Klose, J.R.; Wink, D.A.; Keefer, L.K., "New nitric oxide-releasing 
zwitterions derived from polyamines." J. Org. Chem. 1993, 58, 1472-1476. 
95. Keefer, L.K., "Fifty years of diazeniumdiolate research. From laboratory curiosity to 
broad-spectrum biomedical advances." ACS Chem. Biol. 2011, 6, 1147-1155. 
96. Page, I.H.; Corcoran, A.C.; Dustan, H.P.; Koppanyi, T., "Cardiovascular actions of 
sodium nitroprusside in animals and hypertensive patients." Circulation 1955, 11, 
188-198. 
97. Chen, Z.; Zhang, J.; Stamler, J.S., "Identification of the enzymatic mechanism of 
nitroglycerin bioactivation." Proc. Natl. Acad. Sci USA 2002, 99, 8306-8311. 
98. Chen, Z.; Foster, M.W.; Zhang, J.; Mao, L.; Rockman, H.A.; Kawamoto, T.; 
Kitagawa, K.; Nakayama, K.I.; Hess, D.T.; Stamler, J.S., "An essential role for 
mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation." Proc. Natl. 
Acad. Sci USA 2005, 102, 12159-12164. 
99. Sydow, K.; Daiber, A.; Oelze, M.; Chen, Z.; August, M.; Wendt, M.; Ullrich, V.; 
Mülsch, A.; Schulz, E.; Keaney, J.F., "Central role of mitochondrial aldehyde 
dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-
tolerance." J. Clin. Invest. 2004, 113, 482-489. 
100. Ignarro, L.J.; Lippton, H.; Edwards, J.C.; Baricos, W.H.; Hyman, A.L.; Kadowitz, 
P.J.; Gruetter, C.A., "Mechanism of vascular smooth muscle relaxation by organic 
nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-
nitrosothiols as active intermediates." J. Pharmacol. Exp. Ther. 1981, 218, 739-749. 
101. Drago, R.S.; Paulik, F.E., "The reaction of nitrogen (I1) oxide with diethylamine." J. 
Am. Chem. Soc. 1960, 82, 96-98. 
102. Drago, S.R.K., B.R., "The reaction of nitrogen (II) oxide with various primary and 
secondary amines." J. Am. Chem. Soc. 1961, 83, 1819-1822. 
103. Ignarro, L.J.; Buga, G.M.; Wood, K.S.; Byrns, R.E., "Endothelium-derived relaxing 
factor produced and released from artery and vein is nitric oxide." P. Natl. Acad. Sci. 
USA 1987, 84, 9265-9269. 
 41 
 
104. Carpenter, A.W.; Slomberg, D.L.; Rao, K.S.; Schoenfisch, M.H., "Influence of 
scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles." 
ACS Nano 2011, 5, 7235-44. 
105. Riccio, D.A.; Nugent, J.L.; Schoenfisch, M.H., "Stöber synthesis of nitric oxide-
releasing S-nitrosothiol-modified silica particles." Chem. Mater. 2011, 23, 1727-
1735. 
106. Shin, J.H.; Metzger, S.K.; Schoenfisch, M.H., "Synthesis of nitric oxide-releasing 
silica nanoparticles." J. Am. Chem. Soc. 2007, 129, 4612-4619. 
107. Shin, J.H.; Schoenfisch, M.H., "Inorganic/organic hybrid silica nanoparticles as a 
nitric oxide delivery scaffold." Chem. Mater. 2007, 20, 239-249. 
108. Stasko, N.A.; Schoenfisch, M.H., "Dendrimers as a scaffold for nitric oxide release." 
J. Am. Chem. Soc. 2006, 128, 8265-8271. 
109. Stasko, N.A.; Fischer, T.H.; Schoenfisch, M.H., "S-nitrosothiol-modified dendrimers 
as nitric oxide delivery vehicles." Biomacromolecules 2008, 9, 834-841. 
110. Lu, Y.; Sun, B.; Li, C.; Schoenfisch, M.H., "Structurally diverse nitric oxide-releasing 
poly(propylene imine) dendrimers." Chem. Mater. 2012, 23, 4227-4233. 
111. Nablo, B.J.; Chen, T.Y.; Schoenfisch, M.H., "Sol-gel derived nitric-oxide releasing 
materials that reduce bacterial adhesion." J. Am. Chem. Soc. 2001, 123, 9712-3. 
112. Marxer, S.M.; Rothrock, A.R.; Nablo, B.J.; Robbins, M.E.; Schoenfisch, M.H., 
"Preparation of nitric oxide (NO)-releasing sol-gels for biomaterial applications." 
Chem. Mater. 2003, 15, 4193-4199. 
113. Nablo, B.J.; Rothrock, A.R.; Schoenfisch, M.H., "Nitric oxide-releasing sol-gels as 
antibacterial coatings for orthopedic implants." 2005, 26, 917-924. 
114. Nablo, B.J.; Schoenfisch, M.H., "Antibacterial properties of nitric oxide-releasing 
sol-gels." J. Biomed. Mater. Res. A 2003, 67, 1276-83. 
115. Nichols, S. P.; Schoenfisch, M. H., "Nitric oxide flux-dependent bacterial adhesion 
and viability at fibrinogen-coated surfaces." Biomater. Sci. 10.1039/C3BM60130G 
[Available online July 17, 2013]. 
116. Hetrick, E.M.; Schoenfisch, M.H., "Antibacterial nitric oxide-releasing xerogels: Cell 
viability and parallel plate flow cell adhesion studies." Biomaterials 2007, 28, 1948-
1956. 
117. Nablo, B. J.; Rothrock, A. R.; Schoenfisch, M. H., "Nitric oxide-releasing sol-gels as 
antibacterial coatings for orthopedic implants." Biomaterials 2005, 26, 917-924. 
 42 
 
118. Cai, W.; Wu, J.; Xi, C.; Meyerhoff, M.E., "Diazeniumdiolate-doped poly(lactic-co-
glycolic acid)-based nitric oxide releasing films as antibiofilm coatings." 
Biomaterials 2012, 33, 7933-7944. 
119. Barraud, N.; Hassett, D.J.; Hwang, S.-H.; Rice, S.A.; Kjelleberg, S.; Webb, J.S., 
"Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa." J. 
Bacteriol. 2006, 188, 7344-7353. 
120. Nablo, B.J.; Prichard, H.L.; Butler, R.D.; Klitzman, B.; Schoenfisch, M.H., 
"Inhibition of implant-associated infections via nitric oxide release." Biomaterials 
2005, 26, 6984-6990. 
121. Holt, J.; Hertzberg, B.; Weinhold, P.; Storm, W., Schoenfisch, M.; Dahners, L. 
"Decreasing bacterial colonization of external fixation pins via nitric oxide release 
coatings." J. Orthop. Trauma 2011, 25, 432-437. 
122. Mowery, K.A.; Schoenfisch, M.H.; Saavedra, J.E.; Keefer, L.K.; Meyerhoff, M.E., 
"Preparation and characterization of hydrophobic polymeric films that are 
thromboresistant via nitric oxide release." Biomaterials 2000, 21, 9-21. 
123. Riccio, D.A.; Dobmeier, K.P.; Hetrick, E.M.; Privett, B.J.; Paul, H.S.; Schoenfisch, 
M.H., "Nitric oxide-releasing S-nitrosothiol-modified xerogels." Biomaterials 2009, 
30, 4494-4502. 
124. Hetrick, E.M.; Prichard, H.L.; Klitzman, B.; Schoenfisch, M.H., "Reduced foreign 
body response at nitric oxide-releasing subcutaneous implants." Biomaterials 2007, 
28, 4571-80. 
125. Nichols, S.P.; Le, N.N.; Klitzman, B.; Schoenfisch, M.H., "Increased in vivo glucose 
recovery via nitric oxide release." Anal. Chem. 2011, 83, 1180-4. 
126. Nichols, S.P.; Koh, A.; Storm, W.L.; Shin, J.H.; Schoenfisch, M.H., "Biocompatible 
materials for continuous glucose monitoring devices." Chem. Rev. 2013, 113, 2528-
49. 
127. Ratner, B.D., "Reducing capsular thickness and enhancing angiogenesis around 
implant drug release systems." J. Control. Release 2002, 78, 211-8. 
128. Chernousova, S.; Epple, M., "Silver as antibacterial agent: Ion, nanoparticle, and 
metal." Angew. Chem. Int. Edit. 2013, 52, 1636-53. 
129. Stickler, D.J., "Biomaterials to prevent nosocomial infections: Is silver the gold 
standard?" Curr. Opin Infect. Dis. 2000, 13, 389-393. 
130. Silver, S.; Phung, L.T.; Silver, G., "Silver as biocides in burn and wound dressings 
and bacterial resistance to silver compounds." J. Ind. Microbiol. Biot. 2006, 33, 627-
34. 
 43 
 
131. Bologna, R.A.; Tu, L.M.; Polansky, M.; Fraimow, H.D.; Gordon, D.A.; Whitmore, 
K.E., "Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract 
infection rates in intensive care unit patients: A multicenter study." Urology 1999, 54, 
982-987. 
132. Wu, P.; Grainger, D.W., "Drug/device combinations for local drug therapies and 
infection prophylaxis." Biomaterials 2006, 27, 2450-67. 
133. Marini, M.; De Niederhausern, S.; Iseppi, R.; Bondi, M.; Sabia, C.; Toselli, M.; Pilati, 
F., "Antibacterial activity of plastics coated with silver-doped organic-inorganic 
hybrid coatings prepared by sol-gel processes." Biomacromolecules 2007, 8, 1246-
1254. 
134. Stobie, N.; Duffy, B.; McCormack, D.E.; Colreavy, J.; Hidalgo, M.; McHale, P.; 
Hinder, S.J., "Prevention of Staphylococcus epidermidis biofilm formation using a 
low-temperature processed silver-doped phenyltriethoxysilane sol-gel coating." 
Biomaterials 2008, 29, 963-969. 
135. Brun-Buisson, C.; Doyon, F.; Sollet, J.-P.; Cochard, J.-F.; Cohen, Y.; Nitenberg, G., 
"Prevention of intravascular catheter-related infection with newer chlorhexidine-
silver sulfadiazine-coated catheters: A randomized controlled trial." Intens. Care. 
Med. 2004, 30, 837-843. 
136. Bosetti, M.; Massè, A.; Tobin, E.; Cannas, M., "Silver coated materials for external 
fixation devices: In vitro biocompatibility and genotoxicity." Biomaterials 2002, 23, 
887-892. 
137. Kumar, A.; Vemula, P.K.; Ajayan, P.M.; John, G., "Silver-nanoparticle-embedded 
antimicrobial paints based on vegetable oil." Nat. Mater. 2008, 7, 236-241. 
138. Jung, W. K.; Koo, H. C.; Kim, K. W.; Shin, S.; Kim, S. H.; Park, Y. H., 
"Antibacterial activity and mechanism of action of the silver ion in Staphylococcus 
aureus and Escherichia coli." Appl. Environ. Microb. 2008, 74, 2171-2178. 
139. Feng, Q. L.; Wu, J.; Chen, G. Q.; Cui, F. Z.; Kim, T. N.; Kim, J. O., "A mechanistic 
study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus 
aureus." J. Biomed. Mater. Res. 2000, 52, 662-668. 
140. Xiu, Z.-m.; Zhang, Q.-b.; Puppala, H. L.; Colvin, V. L.; Alvarez, P. J. J., "Negligible 
particle-specific antibacterial activity of silver nanoparticles." Nano Lett. 2012, 12, 
4271-4275. 
141. Dubas, S.T.; Kumlangdudsana, P.; Potiyaraj, P., "Layer-by-layer deposition of 
antimicrobial silver nanoparticles on textile fibers." Colloid Surface A. 2006, 289, 
105-109. 
142. Cortese-Krott, M.M.; Münchow, M.; Pirev, E.; Heβner, F.; Bozkurt, A.; 
Uciechowski, P.; Pallua, N.; Kröncke, K.-D.; Suschek, C.V., "Silver ions induce 
 44 
 
oxidative stress and intracellular zinc release in human skin fibroblasts." Free Radical 
Bio. Med. 2009, 47, 1570-1577. 
143. Hidalgo, E.;  om  nguez, C., "Study of cytotoxicity mechanisms of silver nitrate in 
human dermal fibroblasts." 1998, 98, 169-179. 
144. Asharani, P.; Wu, Y.L.; Gong, Z.; Valiyaveettil, S., "Toxicity of silver nanoparticles 
in zebrafish models." Nanotechnology 2008, 19, 255102. 
145. Wan, A.T.; Conyers, R.A.; Coombs, C.J.; Masterton, J.P., "Determination of silver in 
blood, urine, and tissues of volunteers and burn patients." Clin. Chem. 1991, 37, 
1683-7. 
146. Hardes, J.; Ahrens, H.; Gebert, C.; Streitbuerger, A.; Buerger, H.; Erren, M.; Gunsel, 
A.; Wedemeyer, C.; Saxler, G.; Winkelmann, W.; Gosheger, G., "Lack of 
toxicological side-effects in silver-coated megaprostheses in humans." Biomaterials 
2007, 28, 2869-2875. 
147. Trop, M.; Novak, M.; Rodl, S.; Hellbom, B.; Kroell, W.; Goessler, W., "Silver-coated 
dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn 
patient." J. Traum. Ac. Care. Surg. 2006, 60, 648-652. 
148. Liu, J.; Hurt, R.H., "Ion release kinetics and particle persistence in aqueous nano-
silver colloids." Environ. Sci. Technol. 2010, 44, 2169-2175. 
149. Xiu, Z.-m.; Zhang, Q.-b.; Puppala, H.L.; Colvin, V.L.; Alvarez, P.J.J., "Negligible 
particle-specific antibacterial activity of silver nanoparticles." Nano Lett. 2012, 12, 
4271-4275. 
150. Silver, S., "Bacterial silver resistance: Molecular biology and uses and misuses of 
silver compounds." FEMS Microbiol. Rev. 2003, 27, 341-353. 
151. Gupta, A.; Matsui, K.; Lo, J.-F.; Silver, S., "Molecular basis for resistance to silver 
cations in Salmonella." Nat. Med. 1999, 5, 183-188. 
152. Chopra, I., "The increasing use of silver-based products as antimicrobial agents: a 
useful development or a cause for concern?" J Antimicrob. Chemoth. 2007, 59, 587-
590. 
153. Schierholz, J.; Rump, A.; Pulverer, G.; Beuth, J., "Anti-infective catheters: Novel 
strategies to prevent nosocomial infections in oncology." Anticancer Res. 1998, 18, 
3629-3638. 
 
  
 
Chapter 2: 
Nitric Oxide-Releasing Xerogels Synthesized from N-Diazeniumdiolate-Modified 
Silane Precursors 
2.1 Introduction 
 For more than half of a century, researchers have developed materials capable of 
controllably releasing bioactive agents in vivo.
1
 While timed pharmacological release of a 
drug or gene were initial goals,
2
 much of the recent work has focused on the release of 
therapeutics from surfaces/coatings in an effort to enhance the function and 
biocompatibility of medical implants or devices.
3
 For example, surfaces that release 
antibiotics and antimicrobial agents have been studied extensively as a strategy for 
reducing hospital-acquired infections associated with medical devices such as stents, 
catheters, and orthopedic implants.
4
 By foregoing traditional means of administration 
(e.g., oral and intravenous) and relegating the drug or agent to the drug-releasing surface, 
therapeutic concentrations are maintained in the immediate vicinity of the implant while 
toxicity common to systemic delivery is avoided. Nitric oxide (NO) has garnered recent 
attention as an active release agent due to its broad activity, short half-life, and 
established presence in human physiology.
4-6
 
Nitric oxide is a reactive radical that modulates a seemingly interminable number 
of physiological processes.
7, 8
 Surface-generated  NO has been shown to reduce bacterial 
adhesion and viability, platelet adhesion, and several deleterious consequences of the 
foreign body response (e.g., inflammation, avascularization and collagen capsule 
formation).
5, 6, 9-12
 As NO is a gas at ambient pressures and temperatures, its controlled 
 46 
release from a device or coating is best achieved chemically using donor species that 
decompose into NO. To this end, researchers have designed macromolecular scaffolds 
modified with N-diazeniumdiolate or S-nitrosothiol functional groups capable of 
generating NO at controlled rates (Scheme 2.1).
13-21
  
Surfaces that slowly release NO are of particular importance for developing more 
biocompatible medical device coatings due to their ability to reduce biofouling and 
mitigate the foreign body response. The sol-gel synthesis of xerogel materials represents 
one method for facilitating NO release. Xerogels are attractive as biomaterials due to 
inherently mild synthetic conditions (e.g., aqueous solvents, low temperature), a high 
degree of material tailorability, and the capacity for enzyme immobilization with retained 
enzyme activity.
22, 23
 Xerogels may be prepared using any number of precursor silanes, 
including those necessary for storing NO (e.g., amine- and thiol-bearing silanes that offer 
sites for N-diazeniumdiolate or S-nitrosothiol formation, respectively).
18, 21, 24
  Careful 
selection of organically modified precursors provides a route to control surface area, pore 
structure, and hydrophobicity.
25
 These attributes allow for the release of NO (and other 
therapeutic agents)
26,27,28 
from the xerogel network while simultaneously allowing 
diffusion of external species into the xerogel. Coupling the beneficial attributes of NO 
release with glucose sensor membranes has thus been proposed as a means for 
developing more functional sensors.
29-31
 
Previously, NO-releasing xerogels were prepared by forming an amine-
functionalized matrix that was subsequently exposed to high pressures of NO (5 bar) to 
facilitate N-diazeniumdiolate formation.
5,10,13,22
 While these films liberated NO under 
physiological conditions (37 
o
C, pH 7.4) at fluxes sufficient to reduce bacterial 
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Scheme 2.1 Formation of N-diazeniumdiolates on secondary amines and pH-
dependent decomposition to produce NO. 
 48 
Adhesion (> ~1.5 pmol NO cm
-2
 s
-1
),
12
 lower the incidence of implant infections,
5, 32
 and 
mitigate the FBR,
11
 practical issues with their synthesis limited their potential utility. 
First, the conversion of amines to N-diazeniumdiolates after film synthesis required that 
the underlying substrate be exposed to high pressures of NO, an impractical step for 
many materials and medical devices. Secondly, the N-diazeniumdiolate conversion 
efficiencies from the secondary amines to NO donors for stable compositions were only 
5-25%.
21
 Finally, glucose oxidase-based sensors formed using these materials had low 
glucose sensitivities and limited hydrogen peroxide permeability due to network 
densification caused by the N-diazeniumdiolate formation process.
31, 33
   
We hypothesize that the formation of N-diazeniumdiolates on aminosilane 
precursors prior to film formation may improve glucose sensor attributes while increasing 
NO loading (Scheme 2.2). The use of different N-diazeniumdiolate precursors may also 
enable improved tuning of both NO release totals and durations from these materials. In 
contrast to post-diazeniumdiolated materials that are generally impermeable to small 
polar analytes such as hydrogen peroxide, we expect that pre-diazeniumdiolated xerogels 
not requiring exposure to high pressures of NO will function more effectively as glucose 
sensor membranes 
 
2.2 Materials and methods 
 N-2-(aminoethyl)-aminopropyltrimethoxysilane (AEAP), N-
ethylaminoisobutyltrimethoxysilane (EAiB), N-methylaminopropyltrimethoxysilane 
(MAP),  N-6-(aminohexyl)aminopropyltrimethoxysilane (AHAP), n-
propyltrimethoxysilane (PTMOS), and isobutyltrimethoxysilane (BTMOS) were 
 49 
 
 
 
Scheme 2.2 Synthesis of the “pre-diazeniumdiolated” NO-releasing xerogels. After 
reacting AEAP with NO to yield AEAP/NO, the N-diazeniumdiolated precursor is 
reacted with PTMOS, and cast onto an appropriate substrate. Subsequent 
drying/curing results in the formation of an N-diazeniumdiolate-modified xerogel film.  
 50 
purchased from Gelest (Tullytown, PA). Methyltrimethoxysilane (MTMOS), glucose 
oxidase, and D-glucose were purchased from Sigma Aldrich (St. Louis, MO). Nitric oxide 
gas was purchased from Praxair (Bethlehem, PA). Nitric oxide calibration (26.85 ppm, 
balance N2) and argon gasses were purchased from Airgas National Welders (Durham, 
NC). Sodium methoxide (5.4 M in methanol) was purchased from Acros Organics 
(Fairlawn, NJ). Milli-Q water with a resistivity of <18.2 mΩ cm and a total organic 
content of <6 ppb was prepared by purifying distilled water using a Millipore Milli-Q UV 
Gradient A-10 system (Bedford, MA). Fibroblast L929 cells were acquired from the 
UNC tissue culture facility (Chapel Hill, NC). Dulbecco’s modified essential media 
(DMEM), (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS) and phenazine methosulfate (PMS) were acquired from Becton, 
Dickinson and Company (Sparks, MD). All other reagents were analytical grade and used 
as received. 
2.2.1 Synthesis of N-diazeniumdiolate-modified silanes and xerogels 
Silanes functionalized with N-diazeniumdiolates were prepared by dissolving 250 
μL of the aminosilane (i.e., AEAP, EAiB, MAP) into 1750 μL of methanolic sodium 
methoxide (1 molar equivalent of sodium methoxide per secondary amine). The vials 
were placed in a 250 mL stainless steel Parr bomb, flushed with 100 psi argon for 6 
cycles (three rapid, three for 10 min each), and then held at 10 bar NO for 3 d to yield the 
N-diazeniumdiolate silane form, or AEAP/NO, EAiB/NO and MAP/NO. After 3d, the 
vessel was purged with 100 psi argon for an additional 6 cycles (three rapid, three 10 
min) prior to sample removal. Both prior to and following NO addition, great care was 
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taken to purge the vessel slowly (~50 psi min
-1
) to avoid solvent evaporation. Indeed, no 
solvent loss was observed during the N-diazeniumdiolate-modification process. The 
solutions were transferred as-is into sealed vials, placed in vacuum-evacuated foil bags 
(“vacuum sealed”) using a commercial MiniPack-Torre MV31 vacuum sealer (Orange, 
CA) and stored at -20 
o
C until further use.  
 Commercially pure, grade 3 titanium substrates (10 mm x 10 mm x 1 mm) were 
etched in 50% v/v sulfuric acid at 60 
o
C for 1 h with intermittent agitation. The substrates 
were then rinsed copiously with deionized water and their surfaces activated by exposing 
them to a solution of piranha (3 parts conc. sulfuric acid to 1 part 30% v/v hydrogen 
peroxide) for 10 min. Due to the highly reactive nature of this solution, care was taken to 
ensure that secondary containment and full personal protective equipment were used. 
Following additional rinsing, the substrates were ultrasonicated for 10 min in milli-Q 
water and stored in clean milli-Q until use.  
 Xerogel films containing covalently bound N-diazeniumdiolate precursors were 
synthesized via a two-step, one-pot reaction by combining either AEAP/NO, MAP/NO, 
or EAiB/NO with pre-hydrolyzed PTMOS. First, PTMOS (117, 111, or 105 μL for 5, 10, 
15%, respectively) was prehydrolyzed by adding 100 μL ethanol and 0.1 M hydrochloric 
acid (10 μL) and mixing for 1 h. Following pre-hydrolysis of the backbone silane, water, 
ethanol, base catalyst (at an excess to the initial amount of acid added so that the solution 
was basic) and N-diazeniumdiolate-modified silanes were added as follows for each 
system: 15 mol% MAP/NO-PTMOS: 196 μL ethanol, 79.6 μL water, 36 μL 0.5M KOH, 
and 164.8 μL MAP/NO; 15 mol% EAiB/NO-PTMOS: 166 μL ethanol, 43.6 μL water, 72 
μL 0.5 M KOH, 194.8 μL EAiB/NO; 15 mol% AEAP/NO-PTMOS: 174 μL ethanol, 23 
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μL water, 36 μL 0.5 M KOH, 184.8 μL AEAP/NO. For 5 and 10 mol% xerogels, one- or 
two-thirds volumes of the silane/NO solutions were added instead of the amounts listed 
above, with total volumes kept constant via the addition of pure ethanol.  Following 
reaction, 20 μL aliquots of the resulting sol was cast onto titanium substrates, pre-dried at 
60 
o
C for 10 min, and then further cured under vacuum at 60 
o
C for 3 d.  
2.2.2 Characterization of N-diazeniumdiolate-modified silanes and xerogels 
 Release of NO from N-diazeniumdiolate-modified precursor silanes and xerogels 
was measured using a Sievers 280 Nitric Oxide Analyzer (NOA; Boulder, CO). The 
NOA instrument was first calibrated using an NO zero tube (0 ppm NO) and an NO 
calibration tank (26.85 ppm, balance N2). Approximately 30 mL of phosphate buffered 
saline (PBS; 10 mM, pH 7.4) was placed in a flask fitted with a porous frit and 
deoxygenated with nitrogen. During NO analysis, the instrument’s flow uptake of 200 
mL min
-1
 was matched by supplying nitrogen through the submerged frit at a flow rate of 
80 mL min
-1 
with the remaining 120 mL min
-1
 supplied to the headspace of the vessel 
through a glass side arm, sweeping any liberated NO into the instrument’s reaction cell. 
To calculate the conversion efficiency of the N-diazeniumdiolate NO donors, the 
following equation was used: 
             
                        
                  
                
 Conversion of amines to N-diazeniumdiolate NO donors was confirmed using a 
Thermo Scientific Evolution Array UV-visible spectrophotometer. After reaction with 
NO, the aminosilane solutions were diluted to 50 μM total silane (i.e., by using the 
concentration of the parent aminosilane before charging) in 1.0 M sodium hydroxide. To 
calculate the molar absorptivity coefficient (ε), the total N-diazeniumdiolate content was 
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assumed to be equal to half of the total NO release (as determined via 
chemiluminescence).   
 ESI/MS was employed in positive ion mode to confirm formation of the N-
diazeniumdiolate-modified aminosilanes. Sodiated product ions for MAP/NO, EAiB/NO 
and AEAP/NO were observed at m/z 298.03 (theor. 298.08), 326.11 (theor. 326.11) and 
327.10 (theor. 327.11), respectively.  
 To assess the stability of the NO-releasing xerogels, substrates were submerged in 
5 mL PBS and incubated at 37 
o
C. Films were transferred to new soak solutions after 4 
and 7 d and ultimately removed after 14 d. To quantify material stability, the Si 
concentrations within the soak solutions were determined using inductively coupled 
plasma optical emission spectrometry (ICP-OES). A standard calibration curve was 
constructed using 0, 500, 1000, 5000, and 10000 ppb Si (via sodium silicate) in PBS. 
Each mole of silicon in solution was assumed to correlate directly with silanes that 
disassociated from the scaffold through rehydrolysis of siloxane bonds or unreacted 
silanes that leached out of the matrix. Total % leaching was determined by integrating the 
total Si leaching concentration over the 14 d period and dividing by the number of moles 
of Si in each film. To determine surfaces areas, nitrogen adsorption isotherms were 
acquired using a Micromeretics TriStar II 3020 (Norcross, GA) and analyzed via the 
Brunauer-Emmet-Teller (BET) method.
34
 Elemental analysis was carried out using a 
PerkinElmer CHN/S O elemental analyzer Series 2400 (Waltham, MA). For both 
elemental and BET measurements, samples were prepared by casting an equivalent 
volume of sol per unit area substrate onto pre-cleaned (10 min sonication in water, 
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ethanol, and acetone) glass slides, drying accordingly, and mechanically removing the 
resulting films from the substrate via scraping.  
2.2.3 Cytotoxicity 
 Leachate solutions (i.e., solutions that the xerogels were submerged in) from pre-
diazeniumdiolated xerogels were evaluated for toxicity against L929 fibroblast cells. 
Leachate solutions were prepared by incubating the films for 1 week in 10 mL PBS at 37 
o
C. Cells were grown to confluence at 37 
o
C in a 5% CO2/95% O2 humidified 
environment in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS) and 1 
wt% penicillin/streptomycin. Following surface desorption of the cells by trypsinization, 
the suspension was diluted with additional DMEM, centrifuged for 10 min (1200 rpm, 4 
o
C), and resuspended in an equivalent volume of media. Cells were seeded in a 96-well 
plate, supplying additional media and an equal volume of leachate solutions so that the 
total cell concentration was 3 x 10
5
 cells mL
-1
. Following two days of incubation at 37 
o
C, cell viability was determined by removing excess media and replacing with 
MTS/PMS reagents in DMEM. After an additional 1 h of incubation at 37 
o
C, the 
absorbance of the MTS product was measured spectrophotometrically at 490 nm using a 
Thermo Scientific Multiskan EX plate reader. After accounting for the absorbance from 
blank wells (i.e., those containing no MTS), the results were normalized to PBS controls.  
2.2.4 Fabrication and performance NO-releasing glucose sensors 
 Xerogel-coated enzymatic glucose sensors were prepared on insulated platinum 
disc macroelectrodes (total radius of 0.30 cm). Sol-gel immobilized glucose oxidase 
(GOx) was first deposited on the bare polished electrodes as described previously.
30, 31
 
After allowing the sensing layer to dry, 6.43 μL (20 μL cm-2) 15 mol% AEAP/NO-
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PTMOS sols were cast over the sensing layer, dried at 40 
o
C for 10 min and dried in 
vacuo at 40 
o
C for 3 d. Following curing, the sensors were stored at -20 
o
C under N2 until 
further use.  
 The analytical performance of both post-diazeniumdiolated and pre-
diazeniumdiolated AEAP/NO glucose membranes was assessed using a CH Instruments 
1030A potentiostat configured with a 3-electrode platform; the glucose sensor, an 
Ag/AgCl electrode and a platinum wire served as the working, reference, and counter 
electrodes, respectively. Electrodes were submerged in 50 mL of 10 mM PBS at room 
temperature and pre-hydrated for one hour at a potential of +0.6 V vs. Ag/AgCl. The 
permeability (       of each xerogel-modified electrode was determined in 10 μM H2O2 
solution from the oxidation current at both bare            and AEAP/NO-PTMOS-
coated            ) electrodes using the following equation: 
       
          
        
         (eq 2.2) 
The glucose sensing properties of the membranes were determined by adding 
successive aliquots of 1.0 M D-Glucose in 3 μM increments until reaching a final 
concentration of 30 μM.   
 2.3 Results and discussion  
2.3.1 N-diazeniumdiolate formation on aminosilanes 
 Prior to xerogel formation, it was first necessary to prepare and characterize the 
N-diazeniumdiolate-functionalized aminosilane precursors. We hypothesized that 
significant NO loading would occur on the aminosilane precursors when exposed to NO 
in the presence of exogenous base. Solvent type as well as aminosilane and sodium 
methoxide concentrations were varied to maximize amine to N-diazeniumdiolate NO 
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donor conversion efficiencies while minimizing the formation of byproducts. Initially, 
ethanol and methanol were tested; however, ethanol formed an NO-releasing byproduct 
under the conditions used herein.
35
 Thus, only methanol was employed. Methanol proved 
superior as the solvent as it dissolved both the sodium methoxide base and each 
aminosilane (structures illustrated in Figure 2.1) successfully. In the absence of sodium 
methoxide, intramolecular amines in the AEAP precursor are able to serve as bases. 
Nevertheless, negligible diazeniumdiolate formation was observed as calculated from 
NO-release data (~5.3% conversion efficiency), indicating the need for a stronger base to 
optimize NO loading in methanol. Although reports have indicated the formation of 
sodium formate from methoxide and NO,
36
 this byproduct does not decompose to release 
NO and is thus considered benign for our purposes. The alternative base suggested by 
DeRosa and coworkers (i.e., sodium trimethylsilanolate) is not compatible with silanes as 
it reacts to form polysiloxanes.
37
 As such, all further N-diazeniumdiolate-modified silane 
preparation was carried out using 12.5% (v/v) aminosilane in methanol with 1.0 molar 
equivalent sodium methoxide per secondary amine.   
 Nitric oxide release totals and kinetics from N-diazeniumdiolate-modified silanes 
were characterized using chemiluminescence.
38
 As provided in Table 2.1, N-
diazeniumdiolate formation and subsequent NO release (theoretical release of two mol 
NO per mol of N-diazeniumdiolate NO donor) varied significantly with the structure of 
the precursor aminosilane. The conversion of secondary amines to N-diazeniumdiolate 
NO donors was greatest for the monoamines (MAP and EAiB at ~70%) and least for the 
diamine AEAP (~50%). The lower conversion for AEAP is attributed to stabilization of 
2
o 
amines by neighboring 1
o
 amines. While changes in chemical structure may impact the 
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Figure 2.1 Chemical structures of the N-diazeniumdiolate-modified aminosilanes used 
to fabricate NO-releasing xerogels. 
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Table 2.1 Nitric oxide release, conversion efficiency, and spectroscopic parameters of 
N-diazeniumdiolate-modified silanes. 
aminosilane 
[NO]t  
(μmol NO μmol-1 silane)a 
half-life 
(min) 
λmax(nm) ε (mM
-1
 cm
-1
)
b
 
AEAP 0.98 ± 0.17
c
 130 ± 20 251 14.4 ± 2.5 
MAP 1.47 ± 0.21 2.0 ± 0.3 249 10.0 ± 0.1 
EAiB 1.38 ± 0.07 7.9 ± 1.7 249 9.5 ± 0.1 
a
 Theoretical maximum of 2 mol NO per mol amine-functionalized silane 
b
 Concentration of N-diazeniumdiolate-modified silane taken from chemiluminescent NO release totals 
c  
Values are given as the mean ± standard deviation from at least n=3 independent syntheses 
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NO addition efficiency, they also control the resulting NO-release kinetics. For example, 
the NO release from EAiB/NO had a slightly longer t1/2 than MAP/NO (7.9 and 2.0 min, 
respectively), due to increased organic character protecting the N-diazeniumdiolate from 
proton-initiated decomposition. The diamine-based aminosilane in this study, AEAP/NO, 
exhibited an NO release half-life of more than an order of magnitude longer (120 min) 
than either of the monoamine silanes as a result of hydrogen-bonding stabilization from 
the 1
o
 amine.
39
 
 The presence of a strong UV absorption band at a wavelength of ~250 nm 
confirmed successful N-diazeniumdiolate NO donor formation (Figure 2.2).  Molar 
absorptivity coefficients (ε, Table 4.1) were calculated by using the absorbance at λmax 
along with N-diazeniumdiolate concentrations inferred through chemiluminescent NO 
release totals. For all silanes, the molar absorptivity coefficients proved to be within the 
range of previously observed values (7 – 20 mM-1 cm-1).40, 41 
 The long-term stability of the precursor solutions was evaluated by measuring 
their NO release after approximately 6 months of storage in a vacuum sealed container at 
-20 
o
C. The change in the resulting NO-release profiles was minimal for each system 
(Figure 2.3). As a result, long-term storage did not hamper NO-release capacity from the 
xerogels formed using these precursors.  
2.3.2 Xerogel synthesis 
 Successful formation of stable N-diazeniumdiolate-modified xerogels required 
study of several reaction parameters in the initial sol including backbone silane identity, 
aminosilane concentration, acid and base catalyst concentration, water:silane ratio, and 
reaction time. Both the stability of the resulting xerogel framework and the N-
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Figure 2.2 A) UV-vis spectra and B) NO-release curves of AEAP/NO (blue dashed 
line), MAP/NO (red solid line), and EAiB/NO (black dotted line) precursors. 
Absorption spectra were obtained at a concentration of 50 mM  in 1 M NaOH. Nitric 
oxide release was measured in PBS (pH 7.4, 10 mM).  
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Figure 2.3 Nitric oxide release from (A) AEAP/NO, (B) MAP/NO and (C) EAiB/NO 
either immediately after synthesis (red line) or vacuum sealed at -20 
o
C for 
approximately 6 months (black line).  
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diazeniumdiolate groups contained within were evaluated upon all synthetic variations. 
Titanium was chosen as the substrate for the materials due to its common use in 
biomedical implants and ability to stably adhere the xerogel films.
42
   
 Although sol-gel synthesis of xerogels often employs only an acid catalyst, a base 
catalyst had to be incorporated during this synthesis to avoid proton-initiated 
decomposition of the N-diazeniumdiolate NO donors. Initially, a one-step hydrolysis and 
co-condensation of the backbone and N-diazeniumdiolate-modified silanes under basic 
conditions was attempted. While films synthesized in this manner appeared well-cured on 
the benchtop, xerogels made from this procedure were unstable when submerged in PBS 
(~20% total Si leached into solution). This instability is attributed to inadequate 
connectivity between the backbone silane (PTMOS) and the aminosilane. Indeed, 
previous reports have indicated the importance of well-matched reaction kinetics when 
co-condensing alkoxysilanes via the sol-gel method.
43
 To remedy this instability, a two-
step reaction was adapted to fabricate xerogels with N-diazeniumdiolated silane 
concentrations of up to 15 mol%. Of note, larger concentrations yielded physically 
unstable xerogels regardless of the synthetic strategy employed. As aminosilanes exhibit 
faster gelation times than n-alkylated silanes,
44
 the PTMOS backbone was first pre-
hydrolyzed in 4.9 mM HCl prior to the addition of the N-diazeniumdiolated aminosilane. 
Further increasing acid concentrations to 24.5 mM and 49.0 mM HCl destabilized the 
xerogel (as determined via leaching), suggesting that hydrolysis and condensation rates 
are well-matched at the optimal acid concentration of 4.9 mM. Experiments conducted 
with other backbone silanes also illustrated the need for similar hydrolysis and 
condensation rates. For example, the xerogels displayed a significant amount of cracking, 
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even at relatively low water:silane ratios (3.2) and reaction times (1 h), when 15 mol% 
AEAP/NO, MAP/NO, and EAiB/NO films were synthesized using an MTMOS 
backbone. Conversely, films synthesized using bulkier BTMOS did not adequately cure 
and remained highly viscous and tacky even after catalyst-assisted reaction and drying. 
When using PTMOS as the backbone, stable, non-tacky films were synthesized by 
adjusting water:silane ratios. For AEAP/NO-PTMOS, 3.2 H2O:Si was ideal, while 10:1 
ratios of H2O:Si were necessary to form stable MAP/NO-PTMOS and EAiB/NO-PTMOS 
xerogels. Reactions involving EAiB/NO were particularly torpid, requiring an additional 
increase in base catalyst concentration for adequate cocondensation. The bulky, 
hydrophobic nature of EAiB/NO-PTMOS, and to a lesser extent MAP/NO-PTMOS, 
xerogels was further evidenced by xerogel opacity that developed after extended soaking 
in PBS. As these films were translucent in dry, ambient conditions, this is strong 
evidence of microsyneresis—a phenomenon that occurs in organic gels when a polymer 
exhibits greater affinity for itself than its surrounding solvent (i.e., a hydrophobic 
polymer surrounded by water).
45
  
2.3.3 Xerogel NO-release characterization 
 We hypothesized that xerogels synthesized from N-diazeniumdiolate-modified 
silanes would provide enhanced NO loading per amine relative to post-diazeniumdiolated 
xerogels. Post-diazeniumdiolated xerogels rely on deprotonation of 2
o 
amines by 
neighboring amines within the scaffold to facilitate xerogel formation. Thus, NO release 
is limited by base (i.e., internal amine) availability. Addition of exogenous bases is not 
feasible, as silica constructs are often unstable in high pH conditions.
25
 Since the xerogels 
in this work were synthesized from silanes converted to N-diazeniumdiolates prior to 
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network formation, conversion of secondary amines to N-diazeniumdiolates was 
enhanced without compromising network stability.  To confirm this hypothesis, the NO 
release from pre-diazeniumdiolated xerogels was measured in physiologically relevant 
conditions (PBS at 37 
o
C and pH 7.4) using chemiluminescence (NOA) and compared to 
that of post-diazeniumdiolated xerogels.  
As expected, 15 mol% pre-diazeniumdiolated xerogels released orders of 
magnitude more NO than post-diazeniumdiolated xerogels at equivalent aminosilane mol 
percentages (Table 2.2). This increase was greatest for MAP/NO-PTMOS and EAiB/NO-
PTMOS xerogels due to their low NO donor conversion efficiencies when post-
diazeniumdiolated—a finding consistent with the hypothesis that amines within the 
xerogels are responsible for deprotonation necessary for N-diazeniumdiolate formation. 
When diamine-containing xerogels are post-diazeniumdiolated, the overall amine content 
is larger and the close proximity of intramolecular amines makes deprotonation more 
likely. In turn, post-diazeniumdiolated AEAP/NO-PTMOS xerogels release more NO 
than post-diazeniumdiolated MAP/NO-PTMOS and EAiB/NO-PTMOS. Nonetheless, 
each pre-diazeniumdiolated xerogel system studied released greater levels of NO than 
post-diazeniumdiolated systems (at equivalent mol%).  
With respect to NO totals, the pre-diazeniumdiolated AEAP/NO-PTMOS, 
MAP/NO-PTMOS, and EAiB/NO-PTMOS xerogels released 2.6, 2.4, and 3.2 μmol NO 
cm
-2
, respectively. When synthesized with 15 mol% N-diazeniumdiolated silane 
precursors, the NO storage capacity (i.e., the percentage of secondary amines that are N-
diazeniumdiolate-modified) of these xerogels was 52.8% for EAiB/NO-PTMOS and 
approximately ~40% for both AEAP/NO-PTMOS and MAP/NO-PTMOS xerogels. 
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Table 2.2 Nitric oxide release characteristics from N-diazeniumdiolate modified 
xerogels measured using chemiluminescence 
Silane 
mol% 
silane 
total NO max flux half-life duration
a
 
(μmol cm-2) (pmol cm-2 s-1) (h) (h) 
AEAP 5 0.55 ± 0.05
b
 73.8 ± 5.0 5.7 ± 0.2 29.2 ± 7.6 
AEAP 10 1.75 ± 0.53 193 ± 83 6.4 ± 2.1 52.4 ± 13.4 
AEAP 15 2.60 ± 0.60 307 ± 101 4.0 ± 0.5 41.7 ± 4.0 
MAP 5 0.39 ± 0.04 162 ± 71 1.7 ± 1.3 11.1 ± 0.95 
MAP 10 1.41 ± 0.35 262 ± 93 3.1 ± 1.3 27.7 ± 7.4 
MAP 15 2.40 ± 0.51 590 ± 174 1.9 ± 0.7 35.7 ± 6.4 
EAiB 5 0.45 ± 0.04 126 ± 8 3.8 ± 1.2 20.4 ± 1.9 
EAiB 10 1.48 ± 0.09 439 ± 9 2.6 ± 0.5 48.8 ± 10.5 
EAiB 15 3.13 ± 0.40 312 ± 142 4.2 ± 1.7 90.8 ± 22.6 
a 
Time until flux drops below a threshold of 1.5 pmol cm
-2
 s
-1
, i.e., the flux required to inhibit bacterial 
adhesion. 
b 
Values are given as the mean ± standard deviation from at least n=3 independent syntheses 
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These losses are a result of both incomplete conversion of the precursors and N-
diazeniumdiolate degradation during synthesis (Tables 2.1 and 2.3). Of note, AEAP/NO-
PTMOS and MAP/NO-PTMOS released equivalent levels of NO (2.40 and 2.60 μmol 
cm
-2
, respectively)
 
despite the much greater 74% conversion efficiency of secondary 
amines to N-diazeniumdiolates in the MAP/NO precursor (compared to 49% for 
AEAP/NO). This disparity is best explained by the fast release kinetics of the MAP/NO 
small molecule. While NO donor degradation during reaction of the sol was negligible 
(Figure 2.4), a significant loss of NO occured during the initial 10 min of drying. Such 
NO loss ceases once the materials/coatings are placed under vacuum. Thus, NO loss 
during synthesis will be most drastic for those systems with rapid N-diazeniumdiolate 
decomposition kinetics. As such, NO retention (i.e., the percentage of N-
diazeniumdiolates remaining after xerogel synthesis) is greatest for AEAP/NO-PTMOS 
and EAiB/NO-PTMOS xerogels at 80.7 and 74.9%, respectively, and least (56.8%) for 
MAP/NO-PTMOS xerogels (Table 2.3).  
Elemental analysis of the xerogel films (Table 2.4) confirmed that the mass 
percentage of nitrogen (%N) in the xerogels increased with increasing mol% of N-
diazeniumdiolated precursors. As expected from its diamine structure, 15 mol% 
AEAP/NO-PTMOS xerogels were found to have the largest %N. In using the %N in each 
xerogel to calculate a theoretical NO release, it was found that CHN overestimated NO 
totals by 16-35%. We attribute this difference to residual nitrite in the matrix that is 
present from NO loss during synthesis.  Supporting this hypothesis, the magnitude by 
which this overestimation occurs for each system trends remarkably well with the amount 
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Table 2.3 Nitric oxide release totals and conversion efficiency from both pre- and 
post-diazeniumdiolated xerogels.  
xerogel 
(15 mol%) 
storage capacity
a
 (%) NO retention
b
 (%) 
balance 
PTMOS 
post- 
diazeniumdiolated 
pre- 
diazeniudiolated 
pre-
diazeniumdiolated 
AEAP 0.40 ± 0.12
c 
39.6 ± 9.1 80.7 ± 18.6 
MAP 0.034 ± 0.01 41.7 ± 8.9 56.8 ± 12.1 
EAiB 0.078 ± 0.03 51.6 ± 6.6 74.9 ± 9.6 
a
 Percentage of N-diazeniumdiolates in the film compared to the total amount of secondary amines 
contained within 
b 
Percentage of N-diazeniumdiolates in the film compared to the total amount of N-diazeniumdiolate-
modified precursors added 
c 
Values are given as the mean ± standard deviation from at least n=3 independent syntheses 
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Figure 2.4 Total NO release from MAP/NO, EAiB/NO, and AEAP/NO sols before 
(black bar; left) and after (red bar; right) the sol-gel reaction. Data is normalized to the 
“0” reaction time, which was acquired immediately after addition of the N-
diazeniumdiolate NO donor (n=1). 
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Table 2.4 Carbon, hydrogen, and nitrogen content of pre-diazeniumdiolated xerogels 
as determined via elemental combustion analysis. 
Xerogel %C %H %N 
5% MAP/PTMOS 36.11 ± 1.01
a
 7.42 ± 0.03 1.19 ± 0.24 
10% MAP/PTMOS 35.24 ± 0.18 7.02 ± 0.14 2.80 ± 0.17 
15% MAP/PTMOS 33.84 ± 0.32 6.85 ± 0.08 4.26 ± 0.58 
15% AEAP/PTMOS 32.63 ± 0.27 6.67 ± 0.09 5.91 ± 0.33 
15% EAiB/PTMOS 33.96 ± 3.73 6.55 ± 0.13 4.06 ± 0.09 
a 
Values are given as the mean ± standard deviation from at least n=3 independent syntheses
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of NO lost during synthesis for the respective systems (MAP/NO-PTMOS > EAiB/NO-
PTMOS > AEAP/NO-PTMOS) (Table 2.5). 
The NO release from the N-diazeniumdiolate-modified xerogels synthesized in 
this work was tunable by varying the aminosilane identity. As shown in Table 2.2, 
MAP/NO-PTMOS xerogels have the shortest NO release half-lives (1.9 h) and durations 
(35.7 h), consistent with the rapid decomposition of the MAP/NO precursor. While 
MAP/NO has an NO-release half-life nearly 60 times lower than AEAP/NO (2.0 and 130 
min, respectively), this difference is much less pronounced from the xerogels themselves. 
The NO-release half-life of the AEAP/NO-PTMOS xerogels was only twice as long as 
MAP/NO-PTMOS xerogels, demonstrating that the hydrophobicity of the xerogel matrix 
has a significant influence on the NO release rates versus any intramolecular N-
diazeniumdiolate stabilization by 1
o
 amines. The non-polar EAiB/NO precursor clearly 
increased matrix hydrophobicity (evidenced by the microsyneresis phenomenon 
described above), slowing NO release kinetics. Others have reported the accumulation of 
hydroxide ions within hydrophobic NO-donor matrices as the N-diazeniumdiolates 
decompose.
6
 This phenomenon would further contribute to prolonged NO release due to 
enhanced N-diazeniumdiolate donor stability at elevated pH. The longer NO-release 
duration (90.8 h) for 15 mol% EAiB/NO-PTMOS xerogels would thus be expected 
relative to the other systems.  
 The largest maximum NO flux obtainable using these materials (590 pmol cm
-2
 s
-
1
) exceeds the flux required for a ~90% reduction in bacterial adhesion in vitro (25–30 
pmol cm
-2
 s
-1
 for E. coli, S. aureus, and P. aeruginosa).
4, 46
 The maximum NO fluxes 
from each film (Table 2.2 and Figure 2.5) potentially raise concerns, as large NO 
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Table 2.5 Comparison of NO release totals measured directly using 
chemiluminescence with NO release totals predicted by elemental analysis. 
Xerogel (15 
mol%) 
predicted 
μmol NO mg-1 
experimental 
μmol NO mg-1 
% 
error 
MAP/PTMOS 1.35
a
 1.03 35.0 
AEAP/PTMOS 1.21 1.00 17.5 
EAiB/PTMOS 1.45 1.22 18.9 
a
 Values are given as the mean from at least n=3 independent syntheses 
 72 
 
Figure 2.5 The initial 12 h of NO release from 15 mol% MAP/NO-PTMOS (red), 
EAiB/NO-PTMOS (black) and AEAP/NO-PTMOS (blue). During measurement, 
films submerged in 30 mL PBS (pH 7.4) at 37 
o
C. 
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concentrations may promote undesirable inflammation.
47
 However, previous studies have 
assesed the FBR as a function of NO-release kinetics, and demonstrated no ill effect on 
localized inflammation for materials with far greater maximum NO fluxes (~1440 pmol 
cm
-2
 s
-1 
vs. 700 pmol cm
-2
 s
-1 
for the xerogels herein).
10
 Of note, the 15 mol% xerogel 
systems presented above have NO-release properties and kinetics comparable to NO-
releasing polyurethane membranes reported to reduce in vivo inflammation and collagen 
capsule thickness (total NO = 3.0 μmol cm-2 and NO flux at 48 h = 1.13 pmol cm-2 s-1).10 
 As detailed earlier, xerogels synthesized using N-diazeniumdiolate-modified 
silanes exhibited physical instability (i.e., fragmentation in aqueous solution) when 
formed with concentrations exceeding of 15 mol%. In contrast, stable post-
diazeniumdiolated xerogels have been reported up to concentrations of approximately 30 
mol%.
21
 As such, the NO release of pre-diazeniumdiolated xerogels at their highest mole 
percentage were compared to materials containing even greater mole percentages of post-
diazeniumdiolated xerogels. Using a similar two-step reaction, post-diazeniumdiolated 
xerogels prepared using AHAP (40 vol%, 31 mol%) and BTMOS demonstrated efficacy 
in combatting bacterial and fungal adhesion in vitro, preventing infection, and alleviating 
the foreign body response in vivo.
5, 11, 12, 48
 This system released a total of 3.3 ± 0.6 μmol 
NO cm
-2
, nearly equivalent to the 15 mol% EAiB/NO xerogels synthesized herein. The 
similar NO release totals between these two systems illustrates the larger conversion 
efficiency of pre-diazeniumdiolated xerogel systems, despite the difference in total 
aminosilane incorporation.  
2.3.4 Xerogel stability 
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  To assess the physical stability of the N-diazeniumdiolate-modified xerogels, 
films were immersed in PBS (pH 7.4, 37 
o
C) for 4, 7, and 14 d. Subsequent analysis of 
the soak solutions was carried out using ICP-OES. The amount of silicon in the solutions 
was assumed to correlate to silane leaching from the silica network, and would represent 
poor physical integrity of the xerogels upon solution immersion. As shown in Figure 2.6 
and Table 2.6, the xerogels leached <5 mol% of their total silicon content, indicating 
excellent stability under these solution conditions. Marxer and coworkers characterized 
leaching in a similar manner from post-diazeniumdiolated xerogels.
21
 While one 
composition (40% AEMP/BTMOS) only exhibited <0.5 mol% Si loss after two weeks, 
40% AHAP/BTMOS films lost 8.3 mol% Si content after two weeks in 37 
o
C PBS.
21
 To 
evaluate the potential cytotoxicity of these systems, we tested leaching solutions from the 
largest mol% xerogel of each aminosilane (corresponding to the films with the greatest 
degree of instability) against L929 murine fibroblast cells. After 24 hours of exposure to 
an equal volume of leachate solution and media, no significant toxicity was observed 
relative to PBS controls (Figure 2.7) indicating negligible leaching.   
In addition to the physical stability of the silica network, the chemical stability of 
the N-diazeniumdiolate functionalities within the xerogel was also considered. Release of 
NO from pre-diazeniumdiolated 15 mol% AEAP/NO-PTMOS xerogels was measured 
immediately following xerogel synthesis and again following 10 d of vacuum-sealed 
storage at -20 
o
C, vacuum sealed storage at room temperature, and storage under ambient 
conditions. No significant reduction in NO storage was observed when the xerogels were 
vacuum sealed, regardless of temperature. Xerogels stored on the benchtop (and thus 
exposed to ambient humidity) lost ~60% NO over the same period (Table 2.7). While 
 75 
 
Figure 2.6 Silicon leaching from pre-diazeniumdiolated xerogels as a function of NO 
donor A) identity and B) concentration. Silicon content was measured at 4, 7, and 14 d 
from A) 15 mol% AEAP/NO-PTMOS (black square), MAP/NO-PTMOS (red 
diamond), and EAiB/NO-PTMOS (blue triangle) and B) 5 (blue triangle), 10 (red 
diamond) and 15 mol% (black square) AEAP. Error bars represent the standard 
deviation of the mean from n=3 independent syntheses. 
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Table 2.6 Total amount of silicon liberated from each xerogel system after 14 d. 
Xerogels were stored in 10 mM PBS (pH 7.4, 37 oC) and transferred to new solutions 
at 4 or 7 d. Cumulative Si concentrations are the integrated totals from each time point 
as determined via ICP-OES.  
Aminosilane 
mol 
% 
Cumulative Si 
concentration 
(ppm) 
% Fragmentation 
AEAP 5 1.08 ± 0.19
a
 0.82 ± 0.14 
AEAP 10 2.28 ± 0.41 1.73 ± 0.31 
AEAP 15 3.03 ± 0.15 2.30 ± 0.11 
MAP 5 1.70 ± 0.33 1.50 ± 0.29 
MAP 10 4.09 ± 0.34 3.60 ± 0.30 
MAP 15 5.46 ± 0.60 4.81 ± 0.53 
EAiB 5 1.57 ± 0.87 1.39 ± 0.76 
EAiB 10 3.69 ± 1.87 3.25 ± 1.65 
EAiB 15 3.40 ± 1.22 3.00 ± 1.08 
a 
Values are given as the mean ± standard deviation from at least n=3 independent syntheses 
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Figure 2.7 Cytotoxicity of AEAP/PT, MAP/PT, and EAiB/PT leachate solutions 
against L929 fibroblast cells. Error bars represent the standard deviation of the mean 
from n=3 independently prepared samples. 
Control AEAP/PT MAP/PT EAiB/PT
0
20
40
60
80
100
120
140
 
R
e
la
ti
v
e
 C
e
ll 
V
ia
b
ili
ty
 (
%
)
 78 
Table 2.7 Nitric oxide release totals from 15 mol% AEAP/PT xerogels when stored in 
different atmospheric conditions and temperatures for 10 d. The control xerogel was 
analyzed immediately after drying. Each film was analyzed in 30 mL PBS (pH 7.4, 37 
o
C) (n=1). 
Storage conditions Temperature NO Total (μmol cm-2) 
Control Control 2.1 
Vacuum sealed -20 
o
C 2.0 
Vacuum sealed 23 
o
C 2.2 
Ambient 23 
o
C 0.8 
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decomposition of the N-diazeniumdiolate NO donors in solution is strongly dependent on 
temperature, elevated temperatures alone were not observed to initiate NO release until a 
certain threshold (typically much larger temperature) is reached. For example, Batchelor 
and coworkers observed the decomposition of lipophilic N-diazeniumdiolate compounds 
at temperatures above 104 
o
C.
49
 Thus, storage in a vacuum-sealed container, free from 
water, is sufficient for maintaining NO storage for the materials described herein.   
2.3.5 Electrochemical glucose sensor membranes 
 Nitric oxide has a number of properties that make it favorable for release from the 
surface of an implanted electrochemical sensor. For example, several problems that 
disrupt these devices such as excessive collagen encapsulation, avascularization, and 
infection are mitigated through the release of NO.
50
 In prior work, we reported that 
glucose biosensors coated with post-diazeniumdiolated xerogels exhibited poor 
sensitivity to glucose.
31, 33
 This result was attributed to decreased analyte permeability 
through the sensor membrane after NO charging. Shin and colleagues hypothesized that 
NO catalyzed xerogel condensation, thus reducing the overall porosity of the material and 
greatly limiting analyte (e.g., glucose permeability.
31
 We hypothesized that these pre-
diazeniumdiolated xerogels might have greater porosity than post-diazeniumdiolated 
xerogels due to slower hydrolysis and condensation reactions. In this respect, the coatings 
would prove useful as outer glucose sensor membranes.
51
 Electrochemical glucose 
biosensors were fabricated with xerogel membranes synthesized from N-
diazeniumdiolate-modified xerogels; specifically, 15 mol% AEAP/NO-PTMOS was used 
as it represented a highly stable system. A two-layer sensor membrane was cast onto a 
platinum disc working electrode with an Ag/AgCl reference. The bottom layer contained 
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glucose oxidase immobilized within an MTMOS sol-gel, while either a pre-
diazeniumdiolated or post-diazeniumdiolated 15 mol% AEAP/NO-PTMOS xerogel 
comprised the outer-most layer. This two-layer approach mirrors previous work carried 
out by our laboratory previously.
30, 31, 33
 
 The hydrogen peroxide (H2O2) permeability of the NO-releasing sensor 
membranes was determined by measuring the oxidation current for the xerogel-modified 
electrodes relative to bare electrodes at +0.6 V (vs. Ag/AgCl). Consistent with previous 
work, post-diazeniumdiolated sensor membranes exhibited responses below our limit of 
detection (      < 0.01%). As expected, the      for pre-diazeniumdiolated xerogels was 
more than an order of magnitude larger. To determine if a larger overall surface area 
explained the enhanced permeability, the specific surface area of pre-diazeniumdiolated 
xerogels was measured and compared to post-diazeniumdiolated xerogels. Indeed, the 
specific surface area of post-diazeniumdiolated 15 mol% AEAP/NO-PTMOS was <0.1 
m
2
 g
-1
 while the specific surface area of its pre-diazeniumdiolated equivalent was 2.1 m
2
 
g
-1
.  
 Next, we determined if the increased permeability led to an improved sensor 
response. Using the same electrode configuration, D-glucose was added to PBS to 
achieve final glucose concentrations from 3 to 30 mM (Figure 2.8) Of note, +0.6 V was 
employed as the working electrode potential to limit interference by oxidation of NO.
29, 30
 
Perhaps not surprising given the increased analyte permeability, sensors fitted with pre-
diazeniumdiolated xerogel membranes featured larger glucose sensitivities than post-
diazeniumdiolated xerogels (3.4 nA mM
-1
 and < 0.1 nA mM
-1
, respectively). Consistent 
with this observation, previously reported post-diazeniumdiolated xerogels (20 mol% 
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Figure 2.8 Representative calibration curve for glucose biosensors coated with 15 
mol% AEAP/NO-PTMOS xerogels, both real-time (main graph) and as a function of 
glucose concentration (inset). Error bars represent the standard deviation of the mean 
from n=3 independently synthesized sensor membranes. 
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AEAP, balance BTMOS) constructed by Schoenfisch and coworkers suffered from a 
similarly low glucose sensitivity (0.14 nA mM
-1
) that was addressed via inclusion of a 
hydrophilic polymer within the xerogel membrane.
33
 When compared to other sensors 
that do not generate NO, the sensitivity observed using 15% AEAP/NO-PTMOS 
membranes was similar in magnitude.
52, 53
  
 To verify the viability of these membranes for continuous glucose monitoring, 
glucose measurements were repeated after soaking the electrodes in PBS for 4 and 7 d. 
As illustrated in Table 2.8, the change in glucose sensitivity was only 3.6% after one 
week of soaking in physiological buffer. With increasing soak time the dynamic range 
increased and the glucose response time decreased, likely a result of greater hydration of 
the enzymatic membrane over time. Nonetheless, the membranes proved functional over 
clinically relevant diabetic patient glucose concentrations without pre-soaking beyond the 
3 h pre-hydration period. The in vitro sensitivity reported here is similar to NO-releasing 
sensors evaluated by Gifford and coworkers (4.88 – 6.77 nA mM-1) that functioned 
reliably when implanted percutaneously in rats.
29
 Although the response times of the 
sensors herein are slower (274 – 530 s compared to 75 s), the NO release durations of 
these sensors are nearly 2.5 times longer. These response times are not prohibitive to 
glucose sensor development; others have reported success (as determined via Clarke error 
grid analysis) using subcutaneously implanted glucose sensors with in vitro response time 
of ~10 min in humans.
54
 
 Of note, functional NO-releasing glucose sensors have been fabricated using other 
synthetic strategies. Silica xerogels doped with poly(vinylpyrrolidone) were shown to 
overcome the permeability limitations resulting from post-diazeniumdiolation.
31
 While 
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Table 2.8 Properties of enzyme-based glucose biosensors coated with pre-
diazeniumdiolated 15 mol% AEAP/NO-PTMOS xerogels after 0, 4 or 7 d immersion 
in PBS.  
immersion time 
(d) 
sensitivity 
(nA mM
-1
) 
response 
time (s) 
dynamic range 
(mM) 
R
2
 
0 3.4 ± 0.8
a
 530 ± 5 1–24 0.9787 
4 3.3 ± 1.1 375 ± 26 1–30 0.9980 
7 3.5 ± 1.3 274 ± 19 1–30 0.9992 
a 
Values are given as the mean ± standard deviation from at least n=3 independently synthesized sensor 
membranes. 
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this strategy improved sensor response (sensitivity) from ~0.14 to 4.6 nA mM
-1
, the NO 
storage was much less than that from the pre-diazeniumdiolated xerogels. As an 
alternative to silica-based xerogels, glucose sensors have also been fabricated using NO-
releasing silica-modified polyurethanes.
30, 31
 Polyurethanes modified with NO-releasing 
nanoparticles demonstrate similar NO-release totals (~2 μmol cm-2 s-1) and glucose 
sensitivities (7.3–14.5 nA mM-1) for sensors covering equivalent dynamic ranges.30 
While both strategies are promising, the direct synthetic route of N-diazeniumdiolate-
modified xerogels offers a more facile approach to preparing the NO-releasing sensor 
membrane.   
 
2.4 Conclusions 
 Sol-gel chemistry allows for the design of surfaces that release bioactive agents 
using facile synthetic methods with mild reaction conditions and easily obtainable 
precursors. Herein, xerogels fabricated from N-diazeniumdiolate-modified silanes were 
demonstrated useful for storing and releasing NO in a concentration-dependent manner, 
with NO-release kinetics dependent on the identity of the donor. At equivalent mole 
percentages, pre-diazeniumdiolated xerogels release significantly more NO (>10x) than 
their post-diazeniumdiolated counterparts and pre-diazeniumdiolated xerogels containing 
15 mol% of the NO donor released similar amounts of NO as ~30 mol % NO donor films 
that are post-diazeniumdiolated. Unlike post-diazeniumdiolated films, the sensors herein 
function as glucose sensor membranes, operating over a clinically relevant glucose range 
with adequate glucose sensitivity and response for up to 1 week. To achieve larger NO-
storage capacity without compromising matrix stability, future work should focus on 
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methods for isolating the N-diazeniumdiolate-modified silanes before using the 
precursors to form xerogels. If longer NO-release durations are desired, the purification 
of more stable intramolecular N-dizeniumdiolate-modified silanes may be an important 
strategy. Overall, the one-pot reaction used herein provides a simple and effective 
strategy for fabricating NO-releasing glucose sensors. To further demonstrate the utility 
of these coatings for other applications, future work should make use of alternative 
coating methods (i.e., spraycoating and dipcoating) with a variety of substrate types and 
geometries.  
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Chapter 3: 
Superhydrophobic Nitric Oxide-Releasing Xerogels for Tunable Release Kinetics 
and Reduced Bacterial Adhesion 
 
3.1 Introduction 
 A combination of surface roughness and low surface energy yields 
“superhydrophobic” materials characterized by high water contact angles (> 150o).1  Due 
to their non-wetting properties, such surfaces have found use in a wide-array of 
applications, including droplet-direction in microfluidics,
2
 anti-fouling coatings,
3
 and 
drug release.
4, 5
 The characteristics that govern a water droplet’s behavior on 
superhydrophobic surfaces are described by the Cassie-Baxter model.
6
 Water droplets on 
superhydrophobic interfaces rest over a pocket of air trapped within the micro- and/or 
nanoscopic valleys of its surface. This property tends to make these surfaces resistant to 
fouling from debris, cells, and biomolecules.
7-9
  
 The ability for superhydrophobic materials to resist adhesion, specifically of 
bacteria, holds great promise for biomedical applications.
10
 Microbial proliferation on 
medical implants is an undesirable event with indwelling medical devices responsible for 
many of the two million hospital acquired infections that occur annually.
11
 Researchers 
have sought to address this problem by designing surfaces that reduce the incidence of 
adhered bacteria through altered surface composition or through release of antimicrobial 
agents.
12
 While superhydrophobic interfaces have been shown to reduce the adhesion of 
viable bacteria via passive mechanisms, they provide no means to kill bacteria that do 
adhere. In contrast, actively released antimicrobial agents from a surface are able to kill 
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bacteria, but only over finite periods (e.g., duration of drug release). By combining 
passive and active approaches simultaneously, we hypothesize that the resulting interface 
will exhibit improved antimicrobial efficacy by both preventing adhesion and killing 
bacteria. 
 Nitric oxide (NO) is a broad-spectrum antimicrobial agent with a proven ability to 
reduce infections.
13
 Due to NO’s high reactivity and short biological half life,14 we and 
others have developed NO-releasing macromolecules and coatings to facilitate controlled 
NO-release.
13
 For example, silica xerogels formed from aminosilane precursors represent 
a template for generating NO. When exposed to high pressures of NO, the secondary 
amine sites within are converted to N-diazeniumdiolate NO donors.
15
 In water, the NO 
donors decompose to yield the parent amine along with two equivalents of NO. In this 
work, this synthesis was modified to develop NO-releasing superhydrophobic interfaces 
using a dual-layer approach (Scheme 3.1). Herein, we evaluate the antimicrobial 
capabilities of superhydrophobic surfaces that actively release nitric oxide (NO), 
assessing the potential of each independent of one another. Moreover, we examine how a 
superhydrophobic coating on top of an NO-storage reservoir controls and extends NO-
release kinetics.  
 
3.2 Materials and methods 
 Isobutyltrimethoxysilane (BTMOS), methyltrimethoxysilane (MTMOS) and low 
molecular weight poly(vinyl chloride) (PVC) were purchased from Sigma Aldrich (St. 
Louis, MO). N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP), 
tetraethylorthosilicate (TEOS), and (heptadecafluoro-1,1,2,2-tetrahydrodecyl) 
trimethoxysilane  (17-FTMS) were acquired from Gelest (Tullytown, PA). Milli-Q water
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Scheme 3.1 (I) Amine-modified xerogels on glass subtrates are (A) exposed to 10 atm NO to 
yield (II) N-diazeniumdiolate-modified xerogels. (B) A fluorinated silica composite is then 
spraycoated onto the xerogels to yield (III) superhydrophobic NO-releasing xerogels. 
I
A
B
II
III
0
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was purified from distilled water to a resistivity of 18.2 MΩ cm and a total organic 
content of <5 ppb using a Millipore Milli-Q UV Gradient A-10 system (Bedford, MA). 
Nitric oxide gas (NO) was purchased from Praxair (Bethlehem, PA). Standardized NO 
(26.85 ppm, balance N2), argon (Ar), and nitrogen (N2) gasses were acquired from Airgas 
National Welders (Durham, NC). Dulbecco’s modified essential media (DMEM), (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (MTS), phenazine methosulfate (PMS), tryptic soy broth and tryptic soy 
agar were obtained from Becton, Dickinson and Company (Sparks, MD). All other 
reagents were analytical grade and used as received.  
3.2.1 Synthesis of NO-releasing xerogels  
 Glass slides served as the underlying substrate for all coatings. Slides were cut to 
dimensions of 9 x 25 mm
2
 and cleaned via successive sonication in water, ethanol, and 
acetone. The substrates were then dried with N2 and UV/O3 cleaned for 20 min using a 
Bioforce TipCleaner (Ames, IA).  
 Secondary amine-modified xerogels were prepared via a two-step, one-pot 
reaction. First, 378 μL of BTMOS was prehydrolyzed in 633 μL ethanol, 190 μL water 
and 31.7 μL 0.5 M hydrochloric acid for 1h. Following prehydrolysis of the backbone 
silane, 255 μL of AHAP was added and mixed for an additional 1 h. Afterwards, 40 μL 
of the resulting sol was cast onto a glass substrate, cured on the bench for 1 h, and further 
dried and cured in an oven at 70 
o
C for 3 d. After drying, films were modified with N-
diazeniumdiolate NO donors via reaction with high pressure NO gas. Amine-modified 
xerogels were placed in a Parr hydrogenation bomb and purged copiously with argon. 
Xerogels were then exposed to 10 atm NO for 3 d to convert 2
o
 amines to N-
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diazeniumdiolate NO donors. The N-diazeniumdiolate NO donor-modified xerogels were 
purged again with argon to remove unreacted NO. For bacteria experiments, non-
superhydrophobic control and NO-releasing xerogels were coated with low molecular 
weight PVC to ensure identical surface attributes between the two groups.
16, 17
 Briefly, 
400 mg of PVC was dissolved in 4 mL tetrahydrofuran, then 300 μL of the resulting 
solution was spin coated on the xerogels at 3000 rpm for 10 s, and then dried in vacuo for 
24 h.  Xerogels were stored under nitrogen at -20 
o
C until further use. 
3.2.2 Preparation of superhydrophobic composite layers 
 Fluorinated silica particles were synthesized via the Stöber method by co-
condensing tetraethylorthosilicate (TEOS) and (heptadecafluoro-1,1,2,2-tetrahydrodecyl) 
trimethoxysilane (17-FTMS). In a 50 mL round-bottom flask, ethanol (30 mL) was 
combined with 12 mL ammonium hydroxide (28 wt% in water). To this solution, a 
mixture of 17-FTMS (690 μL) and TEOS (973 μL) was added via syringe pump (0.056 
mL min
-1
 over 30 min). Following dropwise addition of the silane, the reaction was 
allowed to proceed for an additional 1.5 h to yield 30 mol% 17-FTMS (balance TEOS) 
particles. Particles were collected via centrifugation at 4500 rpm for 5 min, washed three 
times in ethanol via the same centrifugation regimen, and dried under vacuum overnight 
(representative SEM image shown in Figure 3.1) 
 Control and NO-releasing xerogels were made superhydrophobic by spraycoating 
the substrates with a mixture of fluorinated silica particles and silane precursors.  First, 
800 mg 30 mol% 17-FTMS (balance TEOS) particles were suspended in ethanol (9.4 
mL) via 30 min of ultrasonication. To the suspension, 17-FTMS (221.4 μL),  
methyltrimethoxysilane (MTMOS; 199.7 μL), water (2.00 mL), and 0.1 M hydrochloric 
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Figure 3.1 Scanning electron micrograph of 30 mol% 17-FTMS (balance TEOS) colloids. 
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acid (200 μL) were added and allowed to react for 1.5 h. After reaction, the suspension 
was spraycoated using an Iwata HP-BC PLUS airgun with a nitrogen feed pressure of 6 
bar at a distance of 30 cm. The nozzle pass rate over each substrate was approximately 
2.5 cm s
-1
 (i.e., the entire vertical distance of the xerogels was covered in 1 s). Either 6, 
12, 18, or 24 passes were made with the spraygun over each xerogel. Following coating, 
the resulting superhydrophobic xerogels were dried on the bench for 5 min and placed in 
vacuo for 48 h. In addition to the characterization described below, films were imaged 
using a Hitachi S-4700 Cold Cathode Field Emission Scanning Electron Microscope with 
an accelerating voltage of 2 kV.  
3.2.3 Xerogel characterization 
 Static water contact angles were determined from images obtained with a KSV 
Instruments Cam 200 Optical Contact Angle Meter (Helsinki, Finland). For each film, 
measurements were taken in at least n = 3 locations. To assess long-term contact angle 
stability, superhydrophobic NO-releasing xerogels were immersed in 37 
o
C PBS for 7, 
14, 21, or 28 d. For each timepoint, the xerogels were removed from the soak solutions 
and static water contact angles were remeasured. 
 A silicon leaching assay was used to assess the chemical stability of the xerogels. 
18, 19
 Glass substrates, NO-releasing xerogels, and superhydrophobic NO-releasing 
xerogels were submerged in 10 mL PBS for 7, 14, 21, or 28 d at 37 
o
C. At set periods, the 
Si content in each soak solution was analyzed using an inductively coupled plasma 
optical emission spectrometer (Teledyne Leeman Prodigy ICP-OES; Hudson, NH) with 
calibration standards ranging from 0 – 10 ppm Si (present as sodium silicate) at a 
wavelength of 251.611 nm.  
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 Release of NO from the non-superhydrophobic and superhydrophobic xerogels 
was measured using a chemiluminescent nitric oxide analyzer (NOA). Approximately 30 
mL of PBS (pH 7.4, 37 
o
C) was placed in a round-bottom flask, and deoxygenated by 
supplying nitrogen through a porous glass frit at a rate of 80 mL min
-1
. Following 
addition of the xerogels to the buffer, released NO was carried to a pre-calibrated NOA 
by an additional stream of nitrogen gas (120 mL min
-1
) supplied through a glass side arm 
on the round bottom flask. 
3.2.4 Adhered viable bacteria assays 
 To assess the antibacterial properties of superhydrophobic and NO-releasing 
xerogels, Pseudomonas aeruginosa (ATCC #19143) was grown from an overnight 
culture to 10
8
 cfu mL
-1
 (i.e., mid-log growth), centrifuged at 4500 rpm for 10 min, and 
resuspended in an equivalent volume of PBS. Each xerogel was submerged in 4 mL of 
the bacteria suspension and gently agitated using an orbital shaker for 6 h at 37 
o
C. After 
6 h, the xerogel substrates were removed, and then dipped into distilled water to remove 
loosely adhered bacteria. Bare portions of the substrate were swabbed with ethanol for 30 
s to kill bacteria not associated with the xerogel. To determine the number of viable 
adhered bacteria, each xerogel was then submerged in 4 mL sterile PBS and sonicated for 
15 min. The resulting supernatant was serially diluted and enumerated on tryptic soy agar 
plates (IUL Flash & Go colony counter; Farmingdale, NY). To assess the ability of NO to 
kill bacteria over extended periods, the xerogels were rinsed and transferred to sterile 
PBS immediately following the 6 h bacteria suspension exposure. After 12 h gentle 
agitation, the xerogels were removed and their uncoated area was swabbed with ethanol. 
The xerogels were ultrasonicated and plated on tryptic soy agar as described above.  
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3.2.5 Xerogel cytotoxicity 
 The cytotoxicity of superhydrophobic and non-superhydrophobic control and NO-
releasing xerogels was assessed against L929 mouse fibroblasts. First, the cells were 
cultured in DMEM supplemented with 10% (v/v) FBS and 1 wt% penicillin/streptomycin 
in a humidified 5% CO2 environment. After reaching confluency (80% coverage), the 
cells were trypsinized and seeded onto tissue-culture treated 24-well plates. Following an 
additional 72 h of incubation, the supernatant was removed via aspiration and replaced 
with 1 mL fresh DMEM. The xerogels were placed face down on the fibroblast cells and 
incubated for 24 h at 37 
o
C (humidified; 5% CO2). Following removal of the xerogels, the 
supernatant was aspirated and each well was rinsed three times with PBS and replaced by 
a mixture of DMEM/MTS/PMS (1 mL total at a volume ratio of 105/20/1). The cells 
were incubated for 90 min, and 120 μL aliquots of the supernatant were transferred to a 
microtiter plate. The absorbance of the solutions was measured using a Thermoscientific 
Multiskan EX plate reader at a wavelength of 490 nm and compared against blanks (i.e., 
the DMEM/MTS/PMS mixture) and control wells (seeded cells with no xerogel 
substrate). 
 
3.3 Results and Discussion 
 
3.3.1 Xerogel synthesis and characterization 
 Superhydrophobic NO-releasing xerogels were synthesized via a two-layer 
approach (Scheme 3.1). The bottom consists of an amine-modified xerogel that is 
exposed to high pressure NO (10 bar) to convert the secondary amines within to N-
diazeniumdiolate NO donors. Following, the top layer (fluorinated silica particles 
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encased within a low-surface energy fluorocarbon sol-gel matrix; Figure 3.2) is applied. 
Addition of this top layer increased the contact angle of the N-diazeniumdiolated xerogels 
from 92.1
o 
±
 
1.2 (slightly hydrophobic) to 158.7
o 
± 2.3 (superhydrophobic). Upon 
immersion in aqueous media, a silver-hued sheen was observed on the films, indicating 
the formation of an entrapped pocket of air (or plastron) and thus a metastable underwater 
Cassie wetting state.
20, 21
 The thickness of the superhydrophobic topcoat, which had no 
effect on the measured surface contact angle, was altered by increasing the number of 
spray passes made with the spraycoating apparatus. In turn, altering the thickness of the 
superhydrophobic membrane was explored as a method for controlling the NO-release 
kinetics.  
 The release of NO from the non-superhydrophobic and superhydrophobic films in 
physiologically relevant buffer (phosphate buffered saline; PBS, pH 7.4; 37 
o
C) was 
measured using a chemiluminescent nitric oxide analyzer.
22, 23
 The maximum NO flux 
([NO]m) decreased from 102 to 53 pmol cm
-2
 s
-1 
as the number of superhydrophobic 
passes increased (Table 3.1). Mechanistically, the ensuing plastron (i.e., a thin metastable 
pocket of air entrapped between the superhydrophobic surface and the surrounding 
water
20
)  for the superhydrophobic materials acted as a barrier to water uptake, slowing 
the rate of proton-initiated N-diazeniumdiolate NO donor decomposition. The total NO 
([NO]t) decreased when increasing the thickness of the superhydrophobic layers. This 
behavior was most apparent for films with 18 and 24 layers (Figure 3.3 and Table 3.1). 
This NO loss is most likely a result of N-diazeniumdiolate decomposition during the 
spraycoating process; though mild, a low concentration of HCl (1.67 mM) is required to 
catalyze the reaction of the superhydrophobic composite mixture, prompting NO donor 
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Figure 3.2 Scanning electron micrographs of superhydrophobic xerogels at A) 
300x (scale bar = 100 μm), B) 3,000x (scale bar = 100 μm), and C) 10,000x (scale 
bar = 5 μm) magnification. 
 
 
A B
C
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Table 3.1 Variation in NO-release kinetics as a function of superhydrophobic coating 
thickness.  
# layers 
[NO]t 
μmol cm-2 
[NO]m 
pmol cm
-2
 s
-1
 
half-life 
h 
td 
h 
0 3.3 ± 0.4
a
 102 ± 9 11.4 ± 0.7 59 ± 1.4 
6 2.5 ± 0.6 60 ± 23 13.6 ± 1.4 85
b
 
12 2.6 ± 0.3 56 ± 14 17.8 ± 4.3 105 ± 10 
18 1.9 ± 0.3 53 ± 16 13.2 ± 0.6 83 ± 4 
24 2.3 ± 0.3 53 ± 11 16.3 ± 2.4 91 ± 8 
a 
Values are given as the mean ± standard deviation from at least 3 independent syntheses 
b 
n=1 
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Figure 3.3 Representative integrated NO-release totals from uncoated and 
superhydrophobic-coated xerogels as a function of superhydrophobic layer thickness 
(# layers) and immersion time.  
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degradation. The duration of NO release was tunable by varying the thickness of the 
superhydrophobic membrane. As shown in Table 3.1, increasing the number of 
spraycoated superhydrophobic layers from 0 to 6 extended the NO-release duration (td) 
from 59 to 83 h. Xerogels with 12 coatings showed even longer NO-release durations, up 
to 105 h—nearly a 1.8-fold increase from non-superhydrophobic NO-releasing xerogels. 
Above 12 layers, the duration for 18 or 24 pass films decreased slightly, a phenomenon 
that may be attributed again to a diminished reservoir of total NO. Utilizing 
superhydrophobic topcoats may be a useful strategy to extend the release kinetics of any 
macromolecule or drug. Yohe et al. have demonstrated extended drug-release kinetics by 
including a dopant within a superhydrophobic fiber mesh.
4
 However, the two-layer 
approach utilized herein is more straightforward (e.g., ease of application) and may prove 
useful when utilizing more complex drug-release chemistries.  
 The stability of the coatings is of obvious importance to most applications for 
these materials. As such, the durability of the substrates was evaluated by soaking the 
substrates in 37 
o
C PBS for up to one month. For all superhydrophobic-modified xerogels 
evaluated, water contact angles were maintained up to the longest duration tested (28 d; 
Figure 3.4).  Minor instability in the superhydrophobic layer, specifically leaching of 
fluorinated silanes or particles, may go unnoticed with contact angle measurements alone. 
A leaching assay was thus employed to measure the presence of silicon (Si; indicative of 
leached silicate species) in soak solutions using inductively coupled plasma optical 
emission spectrometry (ICP-OES).
24
 As demonstrated in Figure 3.5, both the NO-
releasing xerogels (with and without a superhydrophobic coating) leached far less Si than 
the glass slide on which they were coated, suggesting that the membranes act as a barrier
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Figure 3.4 Contact angle stability of superhydrophobic-modified NO-releasing 
xerogels after soaking in 37 
o
C PBS up to 28 d. Error bars represent the standard 
deviation of the mean from at least n=7 measurements on n=3 xerogels. 
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Figure 3.5 Cumulative silicon concentrations from superhydrophobic-modified NO-
releasing xerogels after soaking in 37 
o
C PBS for up to 28 d measured by ICP-OES. 
Error bars represent the standard deviation of the mean from n=3 independent 
samples. 
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to silica leaching from glass substrates—as reported previously for highly stable 
xerogels.
19
 Combined with contact angle measurements, these results indicate excellent 
material stability in physiological buffer solutions. 
3.3.2 Antibacterial efficacy  
 In terms of antibacterial potential, our hypothesis was that the combination of 
superhydrophobicity and NO release would result in even greater antibacterial adhesion 
action compared to either alone. Although superhydrophobic textiles coated with silver 
nanoparticles have been reported previously, only the killing effect of silver was 
examined.
25 
Moreover, the assay conditions utilized by Shateri Khalil-Abad et al. 
(placement of substrates directly onto a bacterial-laden agar plate) did not account for the 
adhesion events that occur in fluid.
26
 To assess both bacterial adhesion and killing, 
control and NO-releasing xerogels were coated with 24 layers of the superhydrophobic 
composite. Non-superhydrophobic xerogels were coated with a thin layer of poly(vinyl 
chloride) (PVC) to ensure that any differences in the surface chemistries between control 
and NO-releasing xerogels were not responsible for observed anti-adhesive effects.
17, 27
 
Previous studies from our laboratory have shown this PVC layer (static water contact 
angle of 91.9 ± 0.9
o
) to have only a minor effect on NO-release kinetics (<20% change in 
maximum NO flux).
27
 The xerogels were submerged in a 10
8
 cfu mL
-1 
suspension of 
Pseudomonas aeruginosa (P. aeruginosa) for 6 h. Following exposure to the bacterial 
suspension, adhered colonies were removed via sonication and enumerated on agar.
28
 As 
shown in Figure 3.6, the number of viable adhered colonies was reduced for all 
superhydrophobic and NO-releasing systems versus controls. Reduction in adhesion for 
the superhydrophobic surface alone (0.80 ± 0.02 log) was lower than that reported 
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Figure 3.6 Reduction in viable P. aeruginosa adhesion vs. controls for (NO) NO-
releasing xerogels, (SH) superhydrophobic xerogel controls and (NO/SH) NO-
releasing superhydrophobic-modified xerogels after (red) 6 h exposure in 10
8
 cfu mL-
1 PA and (grey) an additional 12 h in PBS. Error bars represent the standard deviation 
of the mean from at least n=3 independent experiments. 
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previously.
10
  This discrepancy may be attributed to the bacterial adhesion assay. The 
experiments described herein were performed under static conditions (to more accurately 
model the environment surrounding prosthetic implants)
29
 whereas the prior report 
utilized a flow cell configuration to assess bacterial adhesion.
30
 In a related study, Koc et 
al. also observed increased detachment of adhered biomolecules on superhydrophobic 
surfaces under flow conditions.
9
 Nevertheless, the combination of passive and active 
approaches proved more effective at reducing viable P. aeruginosa adhesion than either 
individually, with the greatest reduction in bacterial adhesion (number of viable colonies) 
observed for the NO-releasing superhydrophobic membranes (2.1 ± 0.3 log). 
 In the experimental conditions used in the assay in this work, the reduction in 
adhered viable bacteria caused by NO release is likely a result of reduced bacterial 
adhesion rather than bacterial killing.
17, 31
 Hetrick et al. exposed NO-releasing xerogels 
with similar NO-release fluxes to P. aeruginosa for 2 h.
17
 After allowing bacteria to 
adhere, killing was monitored in real-time using propidium iodide (i.e., a fluorescent dye 
indicating membrane damage) while keeping the bacteria in PBS. No bacterial membrane 
damage was observed until >7 h, a longer period than the 6 h assay used for the assays in 
this work. Thus, to more directly examine the role that NO had on bacterial killing, the 
xerogels herein were transferred to sterile PBS for an additional 12 h following exposure 
to bacteria. Nitric oxide-release decreased the number of viable adhered bacteria by an 
additional ~1.5 log for both superhydrophobic and non-superhydrophobic xerogels (no 
such reduction was observed on superhydrophobic membranes without NO). Over this 
period, the two approaches reduced viable adhered PA by 3.8 ± 0.3 log, a 1-log 
improvement over the NO-releasing substrate alone. Reducing the overall population of 
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viable surface-adhered bacteria in this manner may prove useful for combating infections 
and biofilm growth.  
3.3.3 Cytotoxicity 
 Unfortunately, NO-releasing xerogels have demonstrated mild cytotoxicity 
towards L929 fibroblasts, attributed both to NO (at fluxes > 50 pmol cm
-2
 s
-1
) and the 
amine-modified xerogel scaffold itself.
16
 In this work, it was hypothesized that the 
reduced NO fluxes from the superhydrophobic-coated materials would reduce dose-
related toxicity of NO. The superhydrophobic layer may also act as a barrier to reduce 
toxicity from the amine-modified xerogel itself. Consistent with reports by Nablo et al. 
mild toxicity against L929 fibroblasts was observed for both the NO-releasing (~68 ± 
4.5% viable) and non-NO-releasing (78 ± 1.5% viable) xerogels (Figure 3.7). Addition of 
the superhydrophobic layer reduced associated toxicity for both sets of films. After 
applying 24 layers of the superhydrophobic composite, a 13.3 and 11.1% increase in cell 
viability was observed for non-NO-releasing and NO-releasing xerogels, respectively. 
We attribute this to the slight decrease in leached matrix components from the xerogel 
scaffold upon application of the superhydrophobic layer (Figure 3.5). Reductions in the 
maximum NO flux of superhydrophobic NO-releasing materials (Table 3.1) likely 
decreases dose-dependent toxicity resulting from NO. Indeed, Nablo et al. observed that 
maximum NO fluxes of ~50 pmol cm
-2
 s
-1
 (i.e., similar to the 24 layer superhydrophobic 
xerogels herein) resulted in little cytotoxicity towards L929 fibroblasts. In contrast, 
maximum NO fluxes of ~95 pmol cm
-2
 s
-1
 (i.e., identical to the 0-layer superhydrophobic 
xerogels herein) resulted in toxicity. In whole, these results indicate that the application 
of a superhydrophobic coating to NO-releasing xerogels may reduce toxicity by both 
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Figure 3.7 Relative viability of L929 fibroblasts exposed to (grey) non-NO-releasing 
and (blue) NO-releasing superhydrophobic xerogels as a function of superhydrophobic 
layer thickness. Viability was determined using the MTS assay. Error bars represent 
the standard deviation of the mean from n=3 measurements of n=1 samples. 
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preventing leaching of amine-based xerogel matrix components and reducing the NO 
dose delivered from these materials over a given period.  
3.4 Conclusions   
 Herein, NO-releasing superhydrophobic coatings were prepared to examine how 
the combination of passive and active antimicrobial strategies function in tandem may be 
used to reduce adhesion and kill adhered bacteria. Superhydrophobic topcoats 
synthesized under aqueous, low-temperature conditions prolonged NO-release from N-
diazeniumdiolate NO donor-modified xerogels. Such an approach may be beneficial for 
controlling the release rates of other drugs from anti-fouling biomedical coatings. In 
terms of antibacterial performance, the passive antifouling approach of 
superhydrophobicity and the active release of NO enhanced antibacterial activity while 
reducing cytotoxicity towards L929 fibroblasts. Future studies should examine the anti-
bacterial adhesion and killing characteristics of these interfaces using a library of 
infection-causing bacteria.  Other architectures that incorporate the NO donors within the 
superhydrophobic matrix itself should also be investigated to examine the versatility of 
this approach.  Yohe and coworkers were able to trigger the release of a cancer drug from 
superhydrophobic meshes using ultrasound.
32
 Such a strategy may prove useful for NO 
donors and eradicating slower proliferating, less virulent bacteria or biofilms that develop 
at extended periods after implantation.  
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Chapter 4: 
Dual-Action Antimicrobial Surfaces: Silver and Nitric Oxide-Releasing Xerogels 
 
4.1 Introduction 
 Despite modern advances in surgical care, many medical device infections occur 
each year due to several confounding factors: 1) native bacteria residing on the skin of 
medical personnel and patients make a truly sterile wound site impossible in practice;
1
 2) 
the introduction of a foreign device into host tissue causes a localized inflammatory 
response that inhibits the pathogen-killing efficacy of immune cells;
2
 and 3) bacteria 
readily colonize surfaces and form a protective exopolysaccharide matrix known as a 
biofilm.
3-5
 As a result, the tissue surrounding indwelling medical devices such as 
catheters and orthopedic implants succumbs to infection more readily than normal 
tissue.
1,6
 The bacterial biofilms that result are resistant to conventional antibiotic 
treatments and cause recurrent infections through the release of planktonic bacteria.
7
 To 
address this issue, researchers have developed antimicrobial coatings that resist bacterial 
adhesion or  kill adhered bacteria before biofilm formation ever occurs.
8
  
 Silver-releasing materials have been used successfully to kill bacteria and prevent 
biofilm formation.
9, 10
 However, growing concern has emerged regarding the potential 
toxicity of silver-releasing compounds and the emergence of silver-resistant pathogens.
9, 
11-15
 Systemic concentrations of the metal may become elevated even when silver is 
released locally from a material.
16, 17
 One case report describes argyria-like symptoms in 
a burn patient treated with silver-releasing wound dressings.
11
 Even in light of these 
concerns, the clinical efficacy of silver-releasing materials against a broad range of 
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nosocomial pathogens necessitates their use. Thus, new strategies are needed that 
circumvent silver-associated toxicity and limit opportunities for antimicrobial resistance 
to these compounds. 
 Delivering two or more biocidal agents in tandem may limit opportunities for 
resistance and lower dose-associated toxicity.
16,18, 19
 Certain biocidal combinations may 
also lead to synergy, where two agents acting in tandem are more effective than the sum 
of their individual biocidal activities.
20
 Combination therapies have emerged that utilize 
silver compounds in tandem with traditional antibiotics or broad-spectrum 
antimicrobials.
21-23
  Privett et al. reported synergistic killing of bacteria co-treated with 
silver sulfadiazine (SSD) and a small molecule nitric oxide (NO)-donor (“PROLI/NO”). 
Nitric oxide (NO) is a potent broad-spectrum agent itself, utilized by macrophages and 
other immune cells to kill foreign microbes.
24
  Controlled release of NO reduces bacterial 
adhesion,
25, 26
 kills bacteria,
27, 28
 prevents biofilm formation,
29
 and reduces the likelihood 
of infection in vivo.
30, 31
 The previously studied combination of SSD and PROLI/NO 
exhibited synergytic bactericidal efficacy against multiple standard and drug-resistant 
pathogens, resulting in lower overall concentrations needed for each biocidal agent.
22
  
 Combined release of NO and silver from a surface may enable the fabrication of 
interfaces with superior anti-adhesive and biocidal efficacy. Combining two broad-
spectrum antimicrobials would limit opportunities for bacterial resistance by promoting 
additional mechanisms for cell death. Likewise, the potential for synergistic killing 
between NO and silver could lead to enhanced bacterial killing without causing 
unnecessary mammalian cell toxicity. Herein, dual-action silver/NO-releasing xerogels 
are prepared utilizing sol-gel chemistry.  We hypothesize that this combination of agents 
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would lead to a more effective biocidal surface while minimizing unneeded mammalian 
cell toxicity. Herein, amine-modified xerogels are coated with a silver nitrate-loaded sol. 
Following conversion of these internal amines to N-diazeniumdiolate NO donors, the 
materials simultaneously release antimicrobial concentrations of Ag
+
 and NO. The 
antifouling/antimicrobial efficacy of the films is assessed against two biomedically 
relevant bacteria. 
 
4.2 Materials and methods 
Ethyltrimethoxysilane (ETMOS), propyltrimethoxysilane (PTMOS), and N-(6-
aminohexyl)aminopropyltrimethoxysilane (AHAP) were purchased from Gelest, Inc. 
(Morrisville, PA). Glass micro slides were acquired from Gold Seal (Portsmouth, NH). 
Methyltrimethoxysilane (MTMOS), isobutyltrimethoxysilane (BTMOS), and silver 
nitrate (AgNO3; analysis grade) were purchased from Sigma Aldrich (St. Louis, MO). 
Milli-Q water was purified from distilled water using a Millipore Milli-Q UV Gradient 
A-10 system (Bedford, MA) to a resistivity of 18.2 MΩ cm and a total organic content of 
<5 ppb. Nitric oxide gas (NO) was purchased from Praxair (Bethlehem, PA). 
Standardized NO (26.85 ppm, balance N2) and nitrogen gasses were acquired from 
Airgas National Welders (Durham, NC). Silver nitrate (analysis grade) was purchased 
from Acros Organics (Geel, Belgium). Pseudomonas aeruginosa (P. aeruginosa; ATCC 
#19413) and Staphylococcus aureus (S. aureus; ATCC #29213) were acquired from 
American Type Tissue Culture Collection (Mannasas, VA). Tryptic soy broth (TSB) and 
agar were obtained from Becton, Dickinson and Company (Sparks, MD). L929 fibroblast 
cells were acquired from the UNC tissue culture facility (Chapel Hill, NC). Dulbecco’s 
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modified essential media (DMEM), (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) and phenazine 
methosulfate (PMS) were acquired from Becton, Dickinson and Company (Sparks, MD). 
All other reagents were analytical grade and used as received. 
4.2.1 Synthesis of amine-modified xerogels 
 Glass microscope slides used as substrates for the xerogels were cut to dimensions 
of 9 x 25 mm, cleaned via successive 10 min bouts of sonication in water, ethanol, and 
acetone, and dried in ambient conditions. To facilitate adhesion between subsequent 
xerogel layers and the glass substrate, the slides were cleaned and oxidized via UV/O3 for 
30 min with a Bioforce TipCleaner (Ames, IA). 
 Dual-action silver/NO-releasing xerogels were synthesized via a 3-layer 
approach. The bottom layer consisted of an amine-modified xerogel (serving as the NO-
release layer) while the top layer was the AgNO3-doped xerogel (serving as the silver-
release layer). A xerogel barrier layer was placed between each to minimize interactions 
between Ag
+
 and the underlying amines. Amine modified xerogels were synthesized 
from AHAP and BTMOS as previously described.
32
 Briefly, BTMOS (378 μL) was 
prehydrolyzed by adding the silane to ethanol (633 μL), water (190 μL) and 0.5 M HCl 
(31.7 μL) and reacting for 1 h. Following, 255 μL AHAP was added to the pre-
hydrolyzed sol, allowing the silane to crosslink with BTMOS for an additional 1 h. After 
this time, 45 μL of the resulting amine-modified sol was cast on the glass substrates 
prepared above, dried for 1 h in ambient conditions and cured at 70 
o
C for 3 d, yielding 
crack-free, clear AHAP/BTMOS xerogels. 
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 Barrier layers were synthesized from an alkyl-functionalized silane (MTMOS, 
ETMOS, or PTMOS). Equal volumes of ethanol and the silane (120 μL) were combined 
and reacted under acidic conditions by adding 16.8 μL H2O and 7.5 μL 0.5 M HNO3 and 
mixing for 2 h. Following, 20, 40 or 60 μL of the sol was cast on the AHAP/BTMOS 
xerogels prepared above, dried at room temperature for 1 h and cured at 80 
o
C for 24 h. 
 Silver-releasing xerogels were prepared by including AgNO3 as a dopant within a 
PTMOS sol. PTMOS (180 μL) and ethanol (219 μL) were mixed briefly prior to the 
addition of 78.6 μL of AgNO3 in MilliQ water at different concentrations to control the 
amount of Ag
+
 within the sol. Silver nitrate concentrations in the aliquot were 0, 22.8, 
57.1, 114.2, or 171.3 mg mL
-1
 resulting in 0 (AG-0), 1 (AG-1), 2.5 (AG-2.5), 5 (AG-5) or 
7.5 (AG-7.5) mol% AgNO3 (relative to total moles Si) xerogels, respectively. Following 
the addition of a 0.5 M HNO3 catalyst (9.11 μL), the sol was reacted in the dark for 4 h. 
Aliquots of the sol (144 μL) were then spincoated (2000 rpm; 10 s) onto glass or xerogel 
substrates. The PTMOS xerogels were dried for 24 h in the dark at room temperature and 
then cured at 60 
o
C for 48 h. All xerogels were stored over desiccant at room temperature 
until further use. 
4.2.2 N-diazeniumdiolate modification 
 The secondary amines within the AHAP layer were converted to N-
diazeniumdiolate NO donors by exposure to high pressure NO gas. Xerogels were pre-
purged with argon in a Parr hydrogenation bomb then pressurized to 10 bar NO for 3 d. 
Following copious purging to remove unreacted NO, the N-diazeniumdiolate-modified 
xerogels were removed and stored at -20 
o
C until further use. This procedure formed NO 
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donor-modified xerogels (AG-0/NO and AG-(1, 2.5, or 5)/NO from non-silver or silver-
containing xerogels, respectively.) 
4.2.3 Characterization of silver/NO-releasing xerogels 
 Nitric oxide-release from the N-diazeniumdiolate-modified xerogels was 
measured using a chemiluminescent nitric oxide analyzer (NOA; Sievers 280i, Boulder, 
CO). Xerogels were placed in 30 mL deoxygenated phosphate buffered saline (PBS; 37 
o
C; pH 7.4). Nitric oxide evolved from the xerogels was carried to the analyzer via a 
stream of nitrogen supplied via a porous frit submerged in the buffer solution. 
Measurements were halted when the NO flux from the materials fell below ~20 ppb. The 
total amount of NO released was determined by integrating the real-time NO flux (vs. 
time) over the measurement duration. 
 Release of silver from the xerogels was quantified by submerging the silver-
containing xerogels in 10 mL PBS (37 
o
C) and transferring each xerogel to new soak 
solutions at regular time intervals. Silver content within the soak solutions was 
determined using inductively coupled plasma optical emission spectrometry (Teledyne 
Leeman Prodigy ICP-OES; Hudson, NH). Standards were prepared using a TraceCert 
1000 ppm Ag standard (Fluka; Buchs, Switzerland) at concentrations of 0, 50, 100, 500, 
and 1000 ppb. Cumulative silver release over the entire soak duration (4 d) was 
determined by summing the concentrations for each individual time point. Static water 
contact angles were determined from photographs acquired on a KSV Instruments Cam 
200 Optical Contact Angle Meter (Helsinki, Finland). 
4.2.4 Adhered viable bacteria assays 
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 The antimicrobial performance of the NO and silver-releasing xerogels was 
assessed by determining the number of adhered viable bacteria on the substrates after 
static exposure to P. aeruginosa and S. aureus. Overnight cultures of P. aeruginosa and 
S. aureus were initially grown from frozen stocks, reinnoculated in TSB, and then grown 
to a concentration of 10
8 
cfu mL
-1
. Following centrifugation, the bacteria were 
resuspended in PBS (for P. aeruginosa) or 0.5% (v/v) TSB in PBS (for S. aureus) to 
reach a final concentration of 10
8 
cfu mL
-1
. Of note, trace TSB was necessary to maintain 
full survival of S. aureus over the experimental duration. In a manner similar to 
previously developed methods,
28, 33, 34
 the xerogels were placed in 4 mL of the 10
8
 cfu 
mL
-1 
bacterial suspensions and gently agitated at 37 
o
C for 3 h. Following exposure, the 
xerogels were rinsed gently with distilled water to remove loosely adhered bacteria. 
Bacteria on the face of the glass substrate opposite of the xerogel (i.e., the uncoated 
portion) were killed by swabbing with ethanol for 30 s. After drying trace ethanol with a 
laboratory wipe, the substrates were transferred to 4 mL sterile PBS. Adhered bacteria 
were removed via sonication at 60 KHz for 15 min.
27
 Serial 10-fold dilutions of the 
supernatant were plated on tryptic soy agar, grown overnight, and the resulting colonies 
(assumed to equal the number of viable adhered bacteria on the xerogel surface) 
enumerated. 
4.2.5 Confocal microscopy  
 Confocal microscopy was used to quantify bacterial adhesion, intracellular NO 
uptake, and cell death. A Zeiss 510 Meta inverted laser scanning confocal microscope 
equipped with a 488 nm Ar excitation laser (30% power; 2.05% intensity) and a 505-530 
nm bandpass (BP) filter was used to obtain Syto 9 and DAF2-DA (green) fluorescence 
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images. A 543 nm HeNe laser (25.3% intensity) and a BP 560—615 nm filter were used 
during acquisition of PI (red) fluorescence images. All images (both fluorescent and 
bright field) were acquired with a 20x objective.   
 For bacterial adhesion studies, xerogels were submerged in suspensions of 10
8
 cfu 
mL
-1
 P. aeruginosa for 3 h. Following exposure, the xerogels were removed, rinsed 
gently in distilled water, and incubated in 10 μM green fluorescent Syto 9 dye for 30 min. 
The xerogels were then transferred to a glass bottom confocal dish containing 5 mL PBS. 
The green fluorescent micrographs were digitally thresholded to create binary color 
images. Bacterial surface coverage was determined by quantifying the relative number of 
white pixels (from green bacteria) over the image frame. DAF-2 DA (green) and 
propidium iodide (PI; red) dyes were used to visualize intracellular NO uptake and 
bacterial membrane damage, respectively. The xerogels were immersed in a 10
8
 cfu mL
-1
 
suspension of P. aeruginosa supplemented with 10 μM DAF-2 DA and 30 μM PI for 1 h, 
rinsed, and placed in glass bottom confocal dishes containing 5 mL PBS. To improve 
visualization, monochromatic images were digitally converted from DAF-2 DA and PI 
fluorescent micrographs following brightness and contrast adjustment. Adjustments were 
applied to all samples equally. 
4.2.6  Xerogel cytotoxicity 
 The cytotoxic potential of NO and Ag xerogels was assessed against L929 mouse 
fibroblasts. First, L929 cells were grown in culture flasks containing DMEM and 
supplemented with 10% (v/v) FBS and 1 wt% penicillin/streptomycin. The flasks were 
incubated in a humidified 5% CO2 environment until reaching confluency (80%), 
removed with trypsin, seeded onto tissue-culture treated 24-well plates, and incubated at 
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37 
o
C for 72 h. After removing the supernatant via aspiration and replacing with 1 mL 
fresh DMEM, the xerogels were placed face down on the fibroblast cells and incubated at 
37 
o
C in 5% CO2 for 24 h. Following aspiration of the supernatant, the wells were rinsed 
thrice with PBS and replaced by a mixture of DMEM/MTS/PMS (1 mL total at a volume 
ratio of 105/20/1). The cells were incubated for an additional 90 min. Following this 
incubation period, 120 μL aliquots of the supernatant were transferred to a microtiter 
plate. The absorbance of the solutions was measured using a Thermoscientific Multiskan 
EX plate reader at 490 nm, and compared against blanks (i.e., the DMEM/MTS/PMS 
mixture) and control AG-0 xerogels. 
 
4.3 Results and discussion 
4.3.1 Synthesis and characterization of silver/NO-releasing xerogels 
 The mild aqueous reaction conditions afforded by the sol-gel method have proven 
useful for drug delivery applications.
10, 35, 36
 We have previously developed NO-releasing 
materials by incorporating amine-modified silanes into xerogel frameworks, and then 
converting those amines to N-diazeniumdiolate NO donors via reaction with NO gas. 
Herein, a two-layer approach was used to combine this chemistry with silver release. 
Amine-modified xerogels were synthesized by co-condensing N-6-
(aminohexylaminopropyl)trimethoxysilane (AHAP) with isobutyltrimethoxysilane 
(BTMOS). This silane system, chosen for its stability in physiological buffer and 
extended NO-release duration,
32, 34, 37
 served as the base layer for the dual Ag+/NO-
release materials. To fabricate the silver-release layer, AgNO3 was doped within an acid-
catalyzed propyltrimethoxysilane (PTMOS) sol at 1, 2.5, or 5 mol% (relative to total Si 
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content in the sol) and subsequently spincast onto dried AHAP/BTMOS xerogels to yield 
AG-1, AG-2.5, and AG-5, respectively.  
 As shown in Figure 4.1 A, cumulative silver release from AG-1 was negligible 
(~10 ppb over 4 d) unless an additional barrier layer was placed between the 
AHAP/BTMOS and AG-1 xerogels. In the absence of a barrier layer, we hypothesize that 
Ag
+
 migrates into the AHAP/BTMOS layer where the ion is complexed by amines. 
Indeed, the tendency of Ag
+
 to complex with amines is well-established.
38-40
 To minimize 
undesirable scavenging of Ag
+
, ethyltrimethoxysilane (ETMOS) sols were prepared and 
cast onto the AHAP/BTMOS xerogels as barrier layers. The use of 
methyltrimethoxysilane and propyltrimethoxysilane were also explored, but ETMOS 
proved best at spreading evenly over the AHAP/BTMOS substrate while also facilitating 
even coating by the AG xerogels. As measured via ICP-OES, increasing the ETMOS 
barrier layer cast volume from 20 to 40 μL resulted in a concomitant increase in silver 
release from AG-1. When the barrier layer volume was increased to 60 μL, the 
subsequent change in cumulative silver-release totals was negligible, indicating a 
leveling-off effect at this volume. Some degree of interaction between Ag
+
 in the silver 
layer and amines in the AHAP/BTMOS layer, then, appears to be inevitable. Cumulative 
silver release from AG-1 in the absence of an underlying AHAP/BTMOS layer (i.e., the 
“best-case-scenario” for silver release totals) was ~1.5x greater than release from AG-1 
on AHAP/BTMOS with a 40 μL barrier layer. Nonetheless, silver concentrations released 
from AG-1 with 40 μL barrier layers have proven sufficient to elicit antimicrobial 
effects.
10
 All other xerogel compositions hereafter were fabricated with 40 μL barrier 
layers separating the AHAP/BTMOS and AG layers. As shown in Figure 4.1B, silver 
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Figure 4.1 (A) Cumulative silver release from AG-1 films with 0 (black), 20 (red), 40 
(green), or 60 μL (red) μL barrier layers separating the xerogel from the underlying 
amine layer. The open-boxed line displays silver-release from AG-1 release in the 
absence of an underlying AHAP/BTMOS film. (B) Silver release from AG-1 (black), 
AG-2.5 (red), and AG-5 (blue) on 40 μL barrier layers. Silver was quantified using 
ICP-OES. Error bars represent the standard deviation of the mean from at least n=3 
independently prepared samples. 
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release totals were tunable by adjusting the mol% of AgNO3 in the PTMOS precursor 
sols. AG-5 xerogels released ~10-fold more silver than AG-1 xerogels over 4 d, with AG-
2.5 xerogels releasing about half that amount. Increasing silver-loading in this manner 
may prove useful for maximizing the antimicrobial efficacy of these materials.  
 To ensure that each active release chemistry (i.e., NO and silver) could be 
controlled independently, the release of silver and NO was evaluated from the materials 
following N-diazeniumdiolate-modification or silver-loading, respectively. 
Representative NO-release curves from AG-0/NO and AG-1/NO xerogels (Figure 4.2 A) 
show that the presence of a silver-layer had no discernible effect on real-time NO-release 
flux. Integrating the curves to determine total amounts of NO indicated a negligible 
difference in NO-release totals, with AG-0/NO and AG-1/NO xerogels releasing 3.90 ± 
0.04 and 3.65 ± 0.05 μmol NO cm-2, respectively. Together, these results suggest that N-
diazeniumdiolate modification and subsequent decomposition to NO is unaffected by the 
presence of a silver layer. 
 Silver release from AG-1, AG-2.5, and AG-5 xerogels was then examined before 
and after N-diazeniumdiolate NO donor. The NO donor formation process (Figure 4.2 B). 
had negligible effect on the silver release from AG-2.5 and AG-5 xerogels. However, 
cumulative silver-release totals from AG-1 xerogels after > 24 h increased following N-
diazeniumdiolate modification of the underlying AHAP/BTMOS layer (96 h totals of 176 
± 6 and 247 ± 7 ppb for AG-1 and AG-1/NO, respectively). This effect may be attributed 
to densification of the AHAP/BTMOS xerogel upon NO exposure. Shin et al. similarly 
reported the permeability of 40% AHAP/BTMOS xerogels to hydrogen peroxide fell 
drastically following N-diazeniumdiolate formation, despite the 
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Figure 4.2 (A) Representative NO-release curves from AG-0/NO (black) and AG-
1/NO (red) xerogels obtained using chemiluminescence. (B) Silver release from AG-1, 
AG-2.5, and AG-5 xerogels following N-diazeniumdiolate NO donor formation 
measured using ICP-OES. Error bars represent the standard deviation of the mean 
from at least n=3 independently prepared samples. 
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xerogels being permeable to the small molecule prior to NO donor addition.
41
 Similar 
densification of the N-diazeniumdiolate-modified AHAP/BTMOS network herein may 
impede diffusion of Ag
+
 into the amine-rich AHAP layer, thereby increasing silver 
release totals. Nonetheless, all bacteria experiments performed herein were evaluated 
over <9 h exposure times so that any changes in release from AG-1 and AG-1/NO 
xerogels after 24 h would not account for differences in antimicrobial effects. 
4.3.2 Anti-adhesion and biocidal efficacy of silver/NO-releasing xerogels  
 The antimicrobial efficacy of AG and AG/NO xerogels was determined under 
static conditions using 10
8
 cfu mL
-1 
suspensions of P. aeruginosa (Gram-negative) and S. 
aureus (Gram-positive), two of the most commonly implicated bacterial strains in 
orthopedic implant infections.42, 43 Xerogels were fully submerged in the suspensions 
upright, allowing the bacteria to adhere to the substrates. Bacteria were removed via 
sonication and the supernatent was plated on TSA for enumeration.  
 To start, the AG-0/NO and AG xerogels were exposed to P. aeruginosa for 3 h. 
As shown in Figure 4.3A, the AG-1 xerogels reduced viable (i.e., living) adhered P. 
aeruginosa by 1.1-log relative to controls. Greater silver concentrations released from 
AG-2.5 and AG-5 killed bacteria more effectively, resulting in a ~3.5 log decrease in 
viable adhered bacteria (i.e., the limit of detection in our assay). Marini et al. and Stobie 
et al. have previously reported more complete killing of S. epidermidis and S. aureus 
from silver-releasing sol-gel materials.
10, 44
 These systems had similar silver-release totals 
and durations to our AG-1 system. Surprisingly, the AG-1 xerogel only reduced viable P. 
aeruginosa by ~1-log or less despite P. aeruginosa being more susceptible to silver (via 
130 
 
 
 
Figure 4.3 (A) Viable adhered colonies on NO- and silver-releasing xerogels after 3 h 
exposure to 10
8
 cfu mL
-1
 P. aeruginosa (B) Viable adhered colonies on AG-0, AG-
0/NO, AG-1, and AG-1/NO in the same conditions. The traced box represents 
theoretical additive killing. Error bars represent the standard deviation of the mean 
from n=3 independent experiments. 
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silver sulfadiazine) than either S. aureus or S. epidermidis.
45
 We hypothesized that this 
discrepancy may be related to the highly concentrated (10
8
 cfu mL
-1
) bacteria suspensions 
used in this work (vs. ~10
6
 cfu mL
-1
).
 
To evaluate the influence of suspension 
concentration on viable adhesion, the antimicrobial activity of AG-1 xerogels was 
assessed after diluting the P. aeruginosa bacterial suspension to 10
6 
or 10
7
 cfu mL
-1
. In 
both cases, AG-1 resulted in complete killing of P. aeruginosa. Following 3 h exposure 
to 10
7
 cfu mL
-1 
of the bacteria, <440 cfu cm
-2
 were found on AG-1 xerogels (i.e., the limit 
of detection) versus 8.3 x 10
5
 cfu cm
-2
 on controls. Likely, excess bacteria in the more 
concentrated 10
8
 cfu mL
-1 
suspensions scavenged some Ag
+
 released from the film that 
would have otherwise interacted with the surface-adhered bacteria. Synergy between NO 
and Ag
+ 
would be impossible to detect if one agent caused complete bacterial killing on 
its own. Thus, 10
8
 cfu mL
-1
 concentrations were used for subsequent studies.  
 AG-1 xerogels were used to study the antimicrobial potential of NO and Ag
+
 
released in tandem (Figure 4.3B and Table 4.1) because viable bacterial counts on AG-
2.5 and AG-5 xerogels were already near the plate counting limit of detection (440 cfu 
cm
-2
). Privett et al. reported a fractional bactericidal concentration (FBC) of 0.63 against 
P. aeruginosa when using silver sulfadiazene and PROLI/NO (a rapidly decomposing 
NO donor) as antimicrobial agents.
22
 While this value is technically above the “synergy” 
threshold of FBC < 0.5, Berenbaum has argued that FBC values between 0.5 and 1 
should be considered moderately synergistic and still clinically relevant.
46
  
 Next, AG-0 and AG-1 xerogels with and without N-diazeniumdiolate 
modification were exposed to a 10
8
 cfu mL
-1
 suspension of P. aeruginosa for 3 h. While 
AG-0/NO and AG-1 each reduced viable adhered bacteria by 1.1-log individually, the 
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Table 4.1 Cumulative NO and silver doses delivered from the dual NO- and silver-
releasing xerogels following 3 h exposure to P. aeruginosa and the resulting log-
decrease in viable adhered bacterial colonies.  
xerogel 
cumulative NO 
delivered (μmol cm-2) 
cumulative [Ag] (ppb) 
log reduction of 
viable bacteria 
AG-0 0.87 ± 0.13
a
 - 1.1 ± 0.3 
AG-1 - 220 ± 9 1.1 ± 0.3 
AG-1/NO 0.86 ± 0.09 223 ± 21 2.9 ± 0.2 
a 
Values are given as the mean ± standard deviation of at least n=3 independent experiments 
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combination of the two agents caused a 2.9-log reduction (i.e., a 0.7-log reduction from 
their summed antimicrobial effects). As shown in Table 4.1, these results could not be 
attributed to differences in silver or NO delivered over the course of the experiment 
(Table 4.1), indicating that the combination Ag
+
 and NO release causes a greater-than-
additive antimicrobial effect against P. aeruginosa.  
 The antifouling and antimicrobial abilities of the xerogels were also assessed 
against Staphylococcus aureus (S. aureus), a Gram-positive pathogen commonly 
implicated in biofilm formation on orthopedic devices.
7
 Figure 4.4A shows adhered 
viable bacteria on NO and silver-releasing xerogels individually when exposed to a 10
8 
cfu mL
-1
 suspension of S. aureus for 3 h. While AG-5 caused a 3.5-log reduction in 
viable adhered P. aeruginosa, the same composition only caused a 1.3-log reduction 
against S. aureus. Previous studies have highlighted decreased silver efficacy against S. 
aureus,
47
 mostly attributed to its thick peptidoglycan layer in conjunction with the 
membrane-dependent biocidal mechanisms of Ag
+
.
48
 Viable adhesion reductions by NO 
were also lessened for S. aureus when compared to P. aeruginosa. Nichols et al. 
demonstrated that reductions in adhered viable S. aureus on NO-releasing surfaces were 
primarily attributed to reduced bacterial adhesion rather than bacterial killing.
28
 
Significant killing (approaching ~1 log) was not observed until much longer 24 h 
exposure times.  
 To overcome these limitations, we assessed the antimicrobial potential of silver 
and NO-releasing xerogels acting in concert. No synergy between the agents was 
observed after 3 h (data not shown), despite Privett et al. reporting a synergistic FBC of 
0.42 for S. auereus when using small molecule donors.
22
 This is best explained by the 
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Figure 4.4 (A) Viable adhered colonies on NO- and silver-releasing xerogels after 3 h 
exposure to 10
8
 cfu mL
-1
 S. aureus. (B) Viable adhered colonies on AG-0, AG-0/NO, 
AG-1, and AG-1/NO following an additional 6 h in bacteria-free PBS (9 h total). The 
traced box represents theoretical additive killing. Error bars represent the standard 
deviation of the mean  for at least n=3 experiments. 
AG-0 AG-0/NO AG-1 AG-1/NO
10
3
10
4
10
5
10
6
 
c
fu
 c
m
-2
A B
AG-0 AG-0/NO AG-1 AG-2.5 AG-5
10
3
10
4
10
5
10
6
 
c
fu
 c
m
-2
135 
 
larger dosage of each agent required to kill S. aureus. Even though silver and NO 
exhibited less synergy against P. aeruginosa than S. aureus (as reported by Privett et al.) 
the overall dosages of the combined agents required for killing were still higher for S. 
aureus. To account this effect on silver/NO-releasing xerogels, we increased the NO and 
silver-release “dose” by transferring the xerogels to fresh PBS after the initial 3 h 
bacterial adhesion event, then incubating for an additional 6 h. Following these longer 
exposure times, a greater-than-additive effect (a further 0.7-log reduction) was observed 
from the combination of NO and silver-release, with a 2.4-log killing observed for the 
two agents in tandem (Figure 4.4B and Table 4.2). Overall, these results support the 
promise of dual-action NO/silver releasing xerogels for killing adhered bacteria while 
minimizing undesirable silver accumulation. 
 Despite potential synergy, it is unclear whether reductions in adhered viabile 
bacteria on the xerogel surfaces were the result of decreased bacterial adhesion, increased 
bacterial killing, or a combination of both. Previous evidence suggests that NO’s action 
(at least over the exposure durations used herein) results from reduced bacterial adhesion 
rather than bacterial killing.
27, 28
 Nablo et al. reported that NO-release at similar fluxes 
caused a ~10-fold reduction in P. aeruginosa surface coverage,
26
 consistent with the 1-
log reduction in viable adhered bacteria observed in Figure 4.3. Hetrick et al. examined 
bacterial killing on NO-releasing AHAP/BTMOS xerogels using live/dead fluorescent 
probes, and found that NO did not begin to damage P. aeruginosa membranes until 7 h of 
continuous exposure.
27
 
 This hypothesis was explored through additional bacterial adhesion studies. The 
xerogels were incubated in Syto 9 (a fluorescent nucleic acid stain for both live 
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Table 4.2 Cumulative NO and silver doses delivered from the NO- and silver-
releasing xerogels during a 9 h exposure to S. aureus a and the resulting log-decrease 
in viable adhered bacterial colonies.  
xerogel 
cumulative NO 
delivered (μmol cm-2) 
cumulative [Ag] 
(ppb) 
log reduction in viable 
adhered bacteria 
AG-0 1.76 ± 0.16
a
 - 0.7 ± 0.2 
AG-1 - 306 ± 13 1.0 ± 0.2 
AG-1/NO 1.70 ± 0.15 334 ± 12 2.4 ± 0.3 
a 
Values are given as the mean ± standard deviation of at least n=3 independent experiments 
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and dead cells) following 3 h exposure to 10
8
 cfu mL
-1
 P. aeruginosa. Of note, 
fluorescent microscopy was utilized instead of bright field microscopy because of optical 
interference caused by salt aggregates on the silver-loaded films. A similar issue was 
reported by Stobie et al. for low-temperature AgNO3-doped sol-gels.
10
 As shown in 
Figure 4.5 and Table 4.3, bacterial coverage on control surfaces was approximately 30%. 
Silver-releasing xerogels (AG-1) reduced the adhesion slightly (30% lower coverage 
relative to the control xerogels), consistent with previous findings that silver does reduce 
the extent of bacterial adhesion.
49, 50
 Compared to silver release at these concentrations, 
NO-releasing xerogels proved more effective at reducing bacterial adhesion. For both 
AG-0/NO and AG-1/NO xerogels the overall surface bacteria coverage was reduced by 
~90% vs. controls (i.e., a 1-log reduction), confirming that the 1.1-log reduction of viable 
P. aeruginosa adhesion on AG-0/NO xerogels (Figure 4.3) results from reduced bacterial 
adhesion rather than bacterial killing. In contrast, AG-1 xerogels only reduced bacterial 
adhesion by ~30% relative to controls despite a 1.1-log reduction in adhered viable 
bacteria. This result suggests that the bulk of silver’s mechanism of action must occur 
through bacterial killing. 
 Confocal microscopy was also utilized to interrogate the antimicrobial 
mechanisms of each agent and gain an understanding of the greater-than-additive effect 
observed from tandem NO and Ag
+
 release. Bacterial membrane damage (indicative of 
cell death) was probed using propidium iodide (PI) while intracellular levels were 
observed using green fluorescent DAF-2 DA. The DAF-2 DA molecule permeates 
bacterial cell membranes where it is then hydrolyzed by bacterial esterases to produce the 
membrane-impermeable fluorescent probe DAF2.
51
 Following reaction with NO and 
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Figure 4.5 Fluorescent images of P. aeruginosa on (A) AG-0 (B) AG-1 (C) AG-
0/NO, and (D) AG-1/NO visualized using the Syto 9 fluorescent probe. Scale bar = 20 
μm. 
A B
DC
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Table 4.3 Bacterial surface coverage on NO- and silver-releasing xerogels following 3 
h immersion in 10
8
 cfu mL
-1
 P. aeruginosa.  
xerogel % bacterial surface coverage contact angle (
o
) 
AG-0 30.1 ± 2.4
a
 92.8 ± 1.7 
AG-0/NO 2.6 ± 0.4 92.6 ± 1.0 
AG-1 20.6 ± 3.2 91.0 ± 3.6 
AG-1/NO 2.5 ± 0.4 85.1 ± 0.7 
a 
Values are given as the mean ± standard deviation from at least n=3 locations on each xerogel 
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associated nitrosative intermediates, the DAF2 probe fluoresces green and is thus an 
indicator of high intracellular NO concentrations.
51
 Propidium iodide is membrane-
impermeable, only entering cells once membrane damage has occurred (i.e., via the 
presence of an exogenous antimicrobial), indicating cell death.  
 Xerogels were incubated in 10
8
 cfu mL
-1
 P. aeruginosa supplemented with 
DAF2-DA and PI and transferred to sterile PBS. The confocal micrographs show 
intracellular NO uptake within bacteria adhered to both the AG-0/NO and AG-1/NO 
xerogels (Figure 4.6).  However, the absence of a strong PI fluorescence signal from AG-
0/NO indicates that associated cell membrane damage had not yet occurred. In a related 
study that evaluated the antimicrobial action of NO-releasing nanoparticles against 
bacteria, Hetrick et al. showed that NO uptake preceded bacterial membrane damage.
27
  
Taken together, this observation supports our hypothesis that reductions in viable adhered 
bacteria on NO-releasing xerogels (without silver) are primarily caused by reduced 
bacterial adhesion. In contrast, PI fluorescence from cells adhered to the AG-1 xerogels 
shows that nearly all of the bacteria are membrane-compromised despite thorough P. 
aeruginosa adhesion. The antifouling capabilities of the silver-releasing xerogels must 
primarily occur through bacterial killing rather than the prevention of bacterial adhesion. 
Bacteria adhered on the AG-1/NO xerogels exhibited bright DAF2-DA and PI-associated 
fluorescence, indicating that significant membrane damage and NO uptake is occurring. 
For AG-1/NO xerogels, we observed only a few bacterial cells exhibiting both green and 
red fluorescence simultaneously; instead, the fluorescence observed from the bacteria 
appears to be biphasic (i.e., either red or green), despite nearly all cells being red on AG-
1 xerogels. Two hypotheses could explain this observation: 1) low levels of exogenously 
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Figure 4.6 Representative confocal micrographs of AG-0/NO, AG-1, and AG-1/NO 
xerogels for visualizing intracellular NO uptake (DAF-2 DA) and cell death (PI). 
Fluorescent images showing DAF-2 DA and PI were converted to grey scale for 
improved visualization. Full-color images are provided in the overlays. Scale bar = 10 
μm.  
AG-0/NO AG-1 AG-1/NO
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supplied NO have a protective effect against oxidative stress induced by Ag
+
 ions (some 
bacteria generate NO for this purpose)
52
; and/or 2) excessive membrane disruption results 
in leaking of the DAF2-DA and PI probes from the bacteria. The first hypothesis seems 
unlikely given the greater-than-additive antimicrobial effect of the two agents in tandem 
against P. aeruginosa. The second mechanism is thus more plausible. Indeed, both PI and 
DAF-2 have been reported to “leak” through highly compromised membranes, especially 
when transferred to fresh, dye-free media, as was the case in our experiments.
27, 53
 
 Collectively, the above bacterial experiments above lead to a hypothesis for the 
greater-than-additive antimicrobial effects observed against P. aeruginosa and S. aureus 
from dual-action NO/silver-releasing xerogels. Individually, NO-release reduces bacterial 
adhesion to the xerogels while silver kills adhered bacteria. When combined, the anti-
adhesive effects of NO are transferred to the silver-releasing xerogels. Silver release from 
these dual-action surfaces causes significant bacterial membrane damage, inducing 
oxidative stress cascades that produce reactive intermediates such as superoxide.
54
  With 
the membranes already compromised, NO is able to enter the bacterium more readily, 
reacting with oxidative intermediates to enhance killing.
54
  
4.3.3 Cytotoxicity of silver/NO-releasing xerogels 
 The silver and NO-releasing xerogels synthesized herein exhibited a greater-than-
additive antimicrobial effect towards P. aeruginosa and S. aureus. However, cytotoxicity 
has been previously observed for each agent individually at concentrations similar to 
those herein.
37, 55, 56
 The toxicity of these materials against L929 mouse fibroblasts was 
thus assessed to ensure that no ensuing “toxic synergy” resulted. As shown in Figure 4.7, 
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Figure 4.7 Cytotoxicity of AG-0, 1, 2.5, and 5 films without (grey bar) and with (blue 
bar) NO-release capability against L929 fibroblasts. Cells are normalized to non-NO-
releasing AG-0 xerogels. Error bars represent the standard deviation of the mean from 
n=3 independent experiments. 
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AG xerogels reduced fibroblast viability with increasing silver content (21—39% vs. 
AG-0 controls), while the percentage of viable cells declined 24.4% for AG-0/NO 
xerogels. When contrasting the toxicity of AG-1, AG-2.5, and AG-5 xerogels with their 
NO-releasing counterparts, cell viability is only reduced by 7.9, 13, and 4.9%, 
respectively, indicating that the toxic effects are less-than-additive. We hypothesize that 
this phenomenon arises from protective mechanisms against oxidative stress in 
mammalian cells. Much of NO’s toxicity occurs indirectly via reaction with superoxide 
to form toxic oxidative intermediates such as peroxynitrite.
57, 58
 Hidalgo et al. observed 
upregulation of superoxide dismutase by L929 fibroblasts in response to oxidative stress 
incurred by AgNO3.
56
 This enzyme scavenges superoxide ions, mitigating toxic effects of 
NO that occur through oxidative intermediates.
59
 These mechanisms may protect 
fibroblasts from any combined toxicity due to Ag
+
 and NO.  
 
4.4 Conclusions 
 Dual-action silver/NO-releasing xerogels synthesized via the sol-gel method 
exhibited a greater-than-additive antimicrobial effect against common biofilm-forming 
pathogens, with no greater-than-additive increase in toxicity. These differences were not 
attributable to changes in NO-release or silver-release following AgNO3 loading or N-
diazeniumdiolate formation, respectively. Considering the lower efficacy of both NO and 
Ag
+
 alone against S. aureus, this strategy may be useful for improving the antimicrobial 
potential of silver-releasing materials against Gram-positive species. The ensuring broad-
spectrum action antimicrobial action should minimize the likelihood of bacterial 
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resistance.  Overall, this dual-action strategy should prove effective at maximizing 
antimicrobial activity while minimizing other harmful consequences.  
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Chapter 5: 
Nitric Oxide-Releasing Poly(Amido Amine) Dendrimer-Doped Polyurethanes 
 
5.1 Introduction  
 The earliest report of a nitric oxide (NO)-releasing coating utilized gaseous NO 
(via a high pressure cylinder) infused into a semi-permeable polymeric membrane.
1
  In an 
effort to create NO-releasing coatings that may be used clinically, researchers have since 
utilized chemical NO donors (i.e., N-diazeniumdiolates and S-nitrosothiols) to 
controllably store and release the small, therapeutic radical.
2-8
 Release of NO from S-
nitrosothiols involves multiple simultaneous mechanisms including light, temperature, 
and copper-mediated decomposition.
9-11
 In contrast, N-diazeniumdiolates decompose 
upon protonation of the secondary amine that coordinates two equivalents of NO.
12
 Since 
decomposition is proton-dependent, NO release from N-diazeniumdiolate-based coatings 
may be tuned by adjusting water uptake into the material.
8
 
  In the simplest method to develop NO-releasing coatings, NO donors are 
dispersed within a dissolved polymer solution and cast on a substrate to yield a dried 
polymer film containing the NO source.
8, 13
 In this manner, NO-releasing polymers have 
been prepared from small molecule N-diazeniumdiolate NO donors,
5
 fine sol-gel 
powders,
4
 and silica nanoparticles.
14
 The simplicity of this approach has been applied to 
other types of materials as well; for example, PROLI/NO and silica nanoparticles have 
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been incorporated within electrospun fibrous mats.
15, 16
 These fibers feature controllable 
diameters and large surface areas.
17
 In the context of biomaterial implants, the rough 
topography and high degree of porosity of the fiber mats promote integration into the 
native host tissue by allowing cell infiltration.
18
 As such, electrospun nanofiber mats are 
able to promote wound healing and mitigate certain aspects of the foreign body response 
(FBR).
18, 19
  
 Despite the clinical promise of NO-releasing films and nanofibers synthesized 
from N-diazeniumdiolates, these polymer dispersions leave several areas for 
improvement. First, the NO donors typically must be hydrophobic to remain within a 
polymer, limiting options for tuning NO release.
8
 Second, NO-release durations are often 
too short in duration for certain clinical applications (e.g., the one-week release above ~1 
pmol cm
-2 
s
-1
 needed to significantly reduce the localized inflammatory response to 
implants).
20
 
 Recently, our laboratory has developed NO-releasing dendrimers capable of 
releasing large NO payloads (> 1 μmol mg-1) with a range of NO-release kinetics (~0.5 h 
to ~4.8 h).
21-23
 The high density of primary amines on these dendrimers allows for 
conversion to secondary amines that may be used to form N-diazeniumdiolate NO 
donors. In this chapter, NO-releasing PAMAM dendrimers were explored as dopants 
within polyurethane dispersions to make both films and electrospun fibers. The ability to 
tune NO release kinetics was evaluated by incorporating different secondary amine 
functionalities on the dendrimer. Furthermore, the use of dendrimers featuring more than 
one secondary amine moiety was studied as a means to adjust NO release and dendrimer 
hydrophobicity.  
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5.2 Materials and methods 
  Acrylonitrile (ACN), 1,2-epoxy-9-decene (ED), and styrene oxide (SO) were 
purchased from Sigma-Aldrich (Milwaukee, WI). Tecoplast TP-470-000 and Tecoflex 
SG-80A (TPU) were gifts from Thermedics (Woburn, MA). Anhydrous N,N-
dimethylformamide, anhydrous tetrahydrofuran (THF), and 5.4 M sodium methoxide 
were purchased from Fisher Scientific (Fairlawn, NJ).  Nitric oxide calibration gas (26.85 
ppm), nitrogen and argon gasses were acquired from Airgas National Welders (Durham, 
NC). Nitric oxide gas (pure) was obtained from Praxair (Bethlehem, PA). Tecoplast TP-
470-000 (TP470) and Tecoflex SG-80A (TPU) were gifts from Thermedics (Woburn, 
MA). L929 fibroblast cells were obtained from the UNC tissue culture facility (Chapel 
Hill, NC). Dulbecco’s modified essential media (DMEM), (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) and phenazine 
methosulfate (PMS) were acquired from Becton, Dickinson and Company (Sparks, MD). 
All other reagents were analytical grade and used as received.  
5.2.1 Synthesis of secondary amine-functionalized PAMAM dendrimers 
 Secondary-amine functionalized poly(amido amine) dendrimers were prepared as 
previously described.
21
 Briefly, ED-, SO-, or 50 mol% ACN/50 mol% SO (hereafter 
referred to as ACN/SO) modified dendrimers were prepared by first dissolving 25 mg of 
G4-PAMAM in THF (750 μL) and methanol (700 μL), while ACN-modified dendrimers 
were prepared by first dissolving 100 mg of the G4-PAMAM the dendrimer in methanol 
(1 mL).  The desired functionality was added at a 1:1 molar ratio relative to the total 
number of primary amines on the dendrimer (i.e., 64 for G4-PAMAM) and allowed to 
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react in a sealed vial for 5 d at room temperature. Following removal of the unreacted 
precursors at reduced pressure, the dendrimers were dissolved again in the same solvent 
mixtures described above to yield G4-ED, G4-SO, G4-ACN, and G4-ACN/SO 
dendrimers (structures shown in Figure 5.1). 
 Proton nuclear magnetic resonance (
1
H NMR) spectra for each dendrimer were 
obtained with a Bruker 400 MHz spectrometer. Representative 
1
HNMR data of G4 
PAMAM dendrimers modified with ACN, ED, and SO (referred to as G4-ACN, G4-ED, 
G4-SO, and G4-ACN/SO) are as follows.  G4-ACN: 
1
HNMR (400 MHz, CD3OD, δ) 
2.82 – 2.80 (t, NHCH2CH2CN), 2.29 (s, NCH2CH2C(O)NH).  G4-ED: 
1
HNMR (400 
MHz, CD3OD, δ) 5.77 – 5.71 (m, CH2CH=CH2), 4.93 – 4.83 (q, CH2CH=CH2), 2.30 (s, 
NCH2CH2C(O)NH).  G4-SO: 
1
HNMR (400 MHz, CD3OD, δ) 7.27 – 7.18 (m, 
CH2CH(OH)Ph), 2.29 (s, NCH2CH2C(O)NH).  G4-ACN/SO: 
1
HNMR (400 MHz, 
CD3OD, δ) 7.27 – 7.18 (m, CH2CH(OH)Ph), 2.82 – 2.80 (t, NHCH2CH2CN), 2.30 (s, 
NCH2CH2C(O)NH). 
5.2.2 N-diazeniumdiolate addition to secondary amine-functionalized PAMAM 
dendrimers 
 Following synthesis of the secondary amine-functionalized PAMAM dendrimers, 
excess solvent was removed in vacuo. G4-SO, G4-ED, and G4-ACN/SO dendrimers 
were then dissolved in a solution of methanol (500 μL) and THF (750 μL), while G4-
ACN dendrimers were dissolved in 100 mL methanol. One molar equivalent of a 5.4 M 
sodium methoxide solution (relative to the total number of primary amines in the 
PAMAM-NH2 dendrimers precursors used initially) was added to each dendrimer 
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Figure 5.1 Structures of the 2
o 
amines formed on (A) PAMAM from (B) 1,2-expoy-9-
decene (ED), (C) styrene oxide (SO), and (D) acrylonitrile (ACN).
 
The PAMAM 
structure provided for reference is G0 (4 primary amines).  
B
C
D
A
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solution. Vials were placed in a 500 mL Parr reaction vessel, purged copiously with 
argon and held under high pressure NO gas (10 bar) for 3 d to convert the secondary 
amines within to N-diazeniumdiolate NO donors. Following additional argon purges to 
remove excess NO, the dendrimer solutions were removed from the vessel. Excess 
solvent was removed by placing the dendrimers under vacuum overnight. The N-
diazeniumdiolate-functionalized PAMAM dendrimers were dissolved in 450 μL 
anhydrous methanol, yielding 94.1, 85.9, 68.8, and 77.3 mg mL
-1 
solutions of G4-ED, 
G4-SO, G4-ACN, and G4-ACN/SO, respectively. The dendrimers were sealed and stored 
at -20 
o
C until further use. 
 For the leaching assays used in this work, G4-PAMAM dendrimers were 
modified with rhodamine B isothiocyanate (RITC). Exactly 100 mg G4-PAMAM
 
was 
dissolved in 1 mL methanol. Triethylamine and RITC were added to the solution at 1:1 
and 1:64 molar ratios relative to the molar amount of G4-PAMAM (i.e., so that each 
dendrimer, on average, only contained one RITC moiety). The reaction was allowed to 
proceed for 24 h in the dark. Following removal of the solvent, the product mixture was 
dissolved in water, dialyzed against water for 3 d and lyophilized.  The resulting G4-
PAMAM-RITC dendrimers were then modified with ED, ACN, SO, or ACN/SO in a 
manner identical to that described above. To avoid photobleaching, care was taken to 
shield the G4-PAMAM-RITC dendrimers from light during storage and handling. 
5.2.3 Synthesis and characterization of NO-releasing PAMAM-doped polyurethane 
films 
 Glass slides cut to dimensions of 9 x 12.5 mm were used as substrates for the 
PAMAM dendrimer-doped polyurethane films. Prior to casting, the slides were 
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roughened using 400-grit silicon carbide (to facilitate adhesion of the films to the 
substrate) and cleaned by successive 10 min bouts of ultrasonication in MilliQ water, 
ethanol, and acetone for 10 min. They were then dried in the ambient. 
 Polyurethane solutions were prepared using two different polyurethanes having 
different water uptake properties: TP470 (water uptake = 0.04 mg H2O mg
-1
 
polyurethane)
14
 and TPU (water uptake = 0.20 mg H2O mg
-1 
polyurethane)
14
 were 
prepared by dissolving dissolution in THF at a concentration of 40 mg mL
-1
. Following, 
433 μL of the polyurethane solution was mixed with 586 μL THF and 1.9, 3.8 or 5.8 mg 
of the N-diazeniumdiolate modified dendrimers were added to make polyurethane 
solutions with 10, 18, or 25 wt% (relative to the total polyurethane mass) of the N-
diazeniumdiolate modified dendrimer, respectively. To ensure dissolution of the 
dendrimer within the polyurethane solution, the mixture was ultrasonicated (120 KHz) 
for 20 min. To fabricate the NO-releasing dendrimer-doped polyurethane films, 15 layers 
of the G4-PAMAM-doped polyurethane solutions were cast (60 μL per layer) onto the 
substrates, allowing 10 min drying time between each layer. For polyurethane films 
utilizing an upper barrier layer, a final 30 μL aliquot of 40 mg mL-1 TP470 solution was 
cast on the films after addition of the NO-releasing layer. For polyurethane films that 
utilized an adhesion layer (i.e., polyurethane films synthesized from G4-ACN and G4-
ACN/SO), four 30 μL aliquots of a 75:25 w/w 40 mg mL-1 TP470:TPU were cast prior to 
the NO-releasing G4-PAMAM dendrimer layers. After casting all layers, the films were 
dried on the benchtop for 30 min, in a nitrogen environment overnight, and then under 
vacuum for 24 h to ensure complete removal of the solvent.   
5.2.4 Preparation of NO-releasing G4-PAMAM-doped electrospun fibers 
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 Electrospun fibers doped with NO-releasing G4-PAMAM dendrimers were 
prepared according to previously described methods.
15, 16
 Briefly, a 6 kV voltage was 
applied to a 22 gauge blunt-tip needle held 15 cm from a grounded steel collector plate 
covered in aluminum foil. A syringe containing an NO-releasing G4-PAMAM 
dendrimer/TP470 solution was affixed to the needle, and the polymer solution loaded 
within was ejected at a rate of 0.015 mL min
-1
 towards the collector using a Kent 
Scientific Genie Plus syringe pump (Torrington, CT). Polyurethane solutions were 
prepared by first dissolving 1360 mg TP470 in a 3:1:1 ratio of THF:DMF:methanol 
(v:v:v). Following, a 200 μL aliquot of each NO-releasing G4-PAMAM dendrimer (in 
methanol) was added to 800 μL of the TP470 solution such that final dendrimer 
concentration was 5 wt% relative to the total mass of TP470 in the polymer solution. 
5.2.5 Materials characterization 
 Nitric oxide release from G4-PAMAM dendrimers and G4-PAMAM-doped films 
and fibers was measured at 37 
o
C in 30 mL PBS according to previously described 
methods using a Sievers Model 280i Chemiluminescent Nitric Oxide Analyzer (Boulder, 
CO).
3, 24, 25
 For G4-PAMAM dendrimers, approximately 0.3-0.6 mg of the dendrimer 
sample was used. Measurement ceased when the NO release fell to below 10 ppb mg
-1
. 
For G4-PAMAM-doped films, the measurement was halted at < 1 pmol cm
-2
 s
-1
. For 
fibers, 20-40 mg of the fiber mat was placed in the sample flask. A small metal clip was 
placed atop the mat to ensure it remained submerged during measurement.  
 Fluorescently tagged dendrimers were utilized to quantify leaching of each 
dendrimer from its respective scaffold. Briefly, the G4-PAMAM-RITC dendrimers 
prepared above were modified with the secondary amine functionality of interest (e.g., -
159 
 
ED, -SO, or –ACN) and N-diazeniumdiolate-modified to yield G4-ED-RITC, G4-SO-
RITC, G4-ACN-RITC, or G4-ACN/SO-RITC. For leaching assays, the G4-PAMAM-
doped films or fibers were prepared as described above, but a portion of the G4-PAMAM 
dendrimers was replaced with G4-PAMAM-RITC dendrimers having the same secondary 
amine modifier. For film leaching assays, the G4-PAMAM-RITC dendrimers comprised 
25% of the overall dendrimer mass. For fiber leaching assays, the RITC-tagged 
dendrimers comprised 50% of the overall dendrimer mass. After drying, each film was 
submerged in 2 mL PBS (37 
o
C), and then transferred to fresh PBS after 1, 4, or 7 d. 
After the specified duration, films were removed from the soak solutions. Calibration 
standards were prepared at concentrations correlating with 0—50% leaching in 2 mL 
PBS. To facilitate dissolution of the dendrimers, 50 μL 1.0 M HCl was added to all 
calibration standards and soak solutions. Fluorescent leaching assays for electrospun 
fibers were performed in a similar manner, with approximately ~10 mg of the electrospun 
fiber mat placed in 2 mL PBS and incubated for 1 week. The fluorescent intensity was 
measured using a BMG PolarStar Omega fluorescence plate reader (Ortenberg, 
Germany). Typical limits of detection were ~0.1-0.3% (w/w) for films and ~1% (w/w) 
for fibers. 
 The preliminary cytotoxic potential of the G4-PAMAM dendrimer doped films 
was assessed against L929 mouse fibroblasts. First, L929 cells were cultured in DMEM 
(37 
o
C, 5% CO2) supplemented with 10% (v/v) FBS and 1 wt% penicillin/streptomycin 
until reaching confluency. The cells were then trypsinized and seeded onto 24-well 
plates. After incubation for 3 d at 37 
o
C, the supernatant was aspirated and replaced with 
1 mL fresh DMEM. The G4-PAMAM-doped polyurethanes were then placed face-down 
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on the fibroblast cells and incubated at 37 
o
C in 5% CO2 for an additional 24 h. After 
removing the substrates, excess media was removed via aspiration and each well was 
rinsed three times with PBS. DMEM/MTS/PMS (105/20/1 v:v:v) was added (1 mL) to 
each well, and the cells were incubated for an additional 90 min. Aliquots (120 μL) of the 
supernatant were then transferred to a microtiter plate and the absorbance was measured 
at 490 nm using a Thermoscientific Multiskan EX plate reader. Absorbance values were 
compared against blank wells (i.e., the DMEM/MTS/PMS mixture) and controls (i.e., 
TP470/TPU polyurethane films containing no G4-PAMAM dendrimers) to determine % 
viability of the cells. 
5.3. Results and discussion 
5.3.1 Synthesis of NO-releasing G4-PAMAM dendrimers 
 The G4-PAMAM dendrimers were synthesized according to previously published 
protocol for poly(propylene imine) (PPI) dendrimers.
21
 Of note, PAMAM dendrimers 
were chosen as the scaffold for this work instead of PPI as PAMAM exhibits less dose-
dependent toxicity against mammalian cells.
26
 The NO-release properties were controlled 
by manipulating the functionality (e.g., ED, SO, ACN, or ACN/SO) used to form the 
secondary amine on the dendrimers. Following exposure to NO, the conversion 
efficiency of secondary amines to N-diazeniumdiolates between the different systems 
spanned a range from 12.5—19.4%, with N-diazeniumdiolate formation and subsequent 
NO release being lowest for the G4-SO dendrimers (Table 5.1). Of note, 
1
H NMR 
confirmed that the total number of secondary amine functionalities on each dendrimer 
precursor were similar for all systems (71-77.5%). Thus, the lower conversion efficiency 
in the G4-SO system was attributable to the N-diazeniumdiolate formation process. 
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Increased steric hindrance by the –SO functionality likely reduces accessibility of base 
(sodium methoxide) to the secondary amine required for N-diazeniumdiolate formation.
21
 
 Nitric oxide-release durations (td) and half-lives (t1/2) were longest for G4-ACN 
dendrimers. Lu et al. proposed that this effect was caused by cationic stabilization of the 
N-diazeniumdiolate by a protonated imidate formed at the ACN moiety (Table 5.1). As 
this stabilization is lacking in G4-ED and G4-SO dendrimers, NO release was markedly 
faster for these dendrimers as indicated by a shorter NO-release half-life and large 
maximum instantaneous NO release ([NO]m). Combining ACN- and SO-modifiers in a 
50:50 ratio on one PAMAM scaffold (G4-ACN/SO) resulted in a material with hybrid  
NO-release kinetics influenced by the –SO and –ACN dendrimers individually. G4-
ACN/SO dendrimers exhibited a large initial burst of NO (similar to G4-SO dendrimers) 
followed by much slower, sustained NO release (similar to G4-ACN dendrimers).  
Tuning the composition of the dendrimer scaffold in this manner may prove useful for 
tailoring kinetics towards specific applications when doped within films (e.g., large 
fluxes for killing bacteria,
27
 or low sustained fluxes for mitigating the FBR
20
) and 
indicates the versatility of dendritic scaffolds as NO-releasing macromolecules. 
5.3.2 Synthesis and characterization of NO-releasing G4-PAMAM-doped polyurethane 
films 
 Following synthesis of the NO-releasing G4-PAMAM dendrimers, the water 
uptake properties of the polyurethane were varied to determine the polymer attributes 
necessary to maximize NO-release durations and totals (i.e., to improve the therapeutic 
potential of these membranes) while minimizing dendrimer leaching (i.e., to avoid 
cytotoxicity). Using G4-ED dendrimers as a dopant, TP470:TPU polymers were 
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Table 5.1 Nitric oxide-release characterization of N-diazeniumdiolate-modified G4-
PAMAM dendrimers. All values were determined using chemiluminescent nitric oxide 
analysis. 
dendrimer 
t[NO]
a
 
μmol mg-1 
t[NO]
b
 
μmol  μmol-1 
[NO]m
c
 
ppb mg
-1
 
t1/2
 
(h)
d
 td (h)
e
 
conversion  
efficiency 
% 
G4-ED 0.90 ± 0.2
g
 20.9 ± 4.3 3500 ± 1100 0.55 ± 0.05 8.4 ± 3.3 16.4 ± 3.4 
G4-SO 0.73 ± 0.26 16.1 ± 5.7 4150 ± 1600 0.7 ± 0.3 10.6 ± 0.5 12.5 ± 4.5 
G4-ACN 1.05 ± 0.06 18.5 ± 1.1 1000 ± 10 3.7 ± 0.9 20.9 ± 4.3 14.4 ± 0.8 
G4-ACNSO 1.4 ± 0.2 27.8 ± 3.6 5100 ± 1900 1.5 ± 0.2 19.4 ± 2.5 19.4 ± 2.5 
a Total μmol nitric oxide released per mg dendrimer  
b Total μmol NO released per μmol dendrimer  
c 
Maximum instantaneous release rate  
d 
half-life 
e 
duration of release above 10 ppb mg
-1 
f 
percentage of  N-diazeniumdiolate NO donors based off of total number of primary amines 
g 
Values are given as the mean ± standard deviation of at least n=3 dendrimer preparations 
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combined in 100:0, 75:25, 50:50, 25:75, and 0:100 ratios (w/w). The G4-ED dendrimer 
system was chosen for this study due to its hydrophobicity. In this manner, leaching 
values should be more indicative of the polymer composition than the dendrimer. It was 
hypothesized that the negligible water uptake of the TP470 polyurethane (0.04 mg H2O
 
mg
-1
 TP470) would result in increased retention of the dendrimers within the 
polyurethane scaffold when compared to the TPU polyurethane (0.20 mg H2O mg
-1
 
TPU). As shown in Figure 5.2, dendrimer leaching was substantial at TP470:TPU ratios 
of 25:75 and 0:100, owing to increased swelling of the polyurethane network following 
water uptake. Furthermore, NO-release from 10 wt% G4-ED polyurethanes using either 
100:0 or 75:25 TP470:TPU ratios revealed that NO release totals from 100:0 TP470 (0.28 
μmol cm-2) were markedly lower than those from 75:25 TP470:TPU polyurethanes (0.54 
μmol cm-2). Increasing TPU content further in the polyurethane mixture had no 
discernible effect on NO-release totals, suggesting that water uptake was not altered. 
Identical experiments performed using 10 wt% G4-ACN/SO dendrimers revealed 
considerable dendrimer leaching for 50:50 TP470:TPU polyurethanes (20 wt% leached 
after 7 d). Extensive swelling of the polyurethane matrix was visually evident, indicating 
that the G4-ACN/SO dopant contributed to swelling by virtue of the more hydrophilic -
ACN modifier (vs. the sizable alkyl chain on -ED). These results suggested an optimum 
TP470:TPU ratio of 75:25 to maximize NO-release while minimizing leaching events 
that may cause toxicity. 
 While the 10 wt% G4-ED doped polyurethanes exhibited maximum flux values 
(29.1 pmol cm
-2
 s
-1
) sufficient for reducing adhesion of several Gram-negative –positive 
bacteria strains by 1-log, the short duration (~25 h) likely renders the material inadequate 
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Figure 5.2 Dendrimer leaching from 10 wt% G4-ED doped polyurethanes as a 
function of time for TP470:TPU ratios of 100:0 (grey square), 75:25 (black square), 
50:50 (red square), 25:75 (grey triangle) and 0:100 (black triangle). Leaching was 
determined through RITC-tagged dendrimers measured using fluorometry. Error bars 
represent the standard deviation of n=3 measurements from n=1 film.  
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for long-term applications, such as more biocompatible implants that mitigate the foreign 
body response. For instance, in vitro NO release durations of 7—14 d durations have 
been observed for films prepared from S-nitrosothiol-based polymer dispersions.
20
 These 
materials reduce the inflammatory response for up to 7 d post-implantation, while those 
releasing NO for shorter durations exhibit no such effect.
20
 To increase NO-release 
durations, concentrations of G4-ED dendrimer within the polyurethane were increased to 
18 and 25 wt%. Unfortunately, substantial leaching of the dendrimer occurred from these 
systems (e.g., 18.9% of the total dendrimer mass after 1 week when using 25 wt% G4-
ED). Again, the leaching was attributed to swelling of the polyurethane network for 25 
wt% G4-ED dendrimers doped into 75:25 TP470:TPU polyurethanes. The expansion of 
the polymer network that occurs when the polyurethane fills with water likely provides a 
route for the otherwise hydrophobic G4-ED dendrimers to diffuse from the polymer 
matrix. Cytotoxicity studies revealed complete killing of L929 fibroblasts cells (24 h 
exposure) at these dendrimer concentrations. To remedy leaching and toxicity that occurs 
when large masses of dendrimers are doped within these polyurethanes, a thin 
hydrophobic barrier layer was used to inhibit water uptake and swelling. A 30 μL layer 
aliquot of a 40 mg mL
-1
 TP470 solution was cast on the 25 wt% G4-ED polymer films. 
Leaching totals at 1 week from the polyurethane network decreased to 2.5%. Increasing 
the concentration of G4-ED doped within the polyurethane to 25 wt% increased the total 
dose of NO delivered to 1.1 ± 0.2 μmol cm-2. The duration of physiologically-relevant (> 
1 pmol cm
-2
 s
-1
)
 
NO increased to 3.2 ± 0.7 d (representative NO-release curves shown in 
Figure 5.3).   
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Figure 5.3 Real-time nitric oxide release from 75:25 TP470:TPU polyurethanes 
containing 10 (light grey), 18 (red), and 25 (black) wt% G4-ED. Measurements were 
acquired through chemiluminescent nitric oxide analysis.  
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 Of the NO-releasing G4-PAMAM dendrimers employed herein, the G4-ED 
dendrimer featured the shortest NO-release half-life and duration. Doping a dendrimer 
with a longer NO-release duration (e.g., G4-ACN or G4-ACN/SO) within a 75:25 
TP470:TPU matrix at 25 wt% would likely increase the NO-release duration from the 
resulting film.
5
 However, significant leaching was observed even in the presence of a 
barrier layer when preparing 25 wt% films from G4-ACN and G4-ACN/SO. Swelling of 
G4-ACN and G4-ACN/SO-doped polyurethanes resulted in “lifting” or detachment of the 
polymer from the substrate. To remedy this, an “adhesive layer” was applied to the 
substrate (i.e., 75:25 TP470:TPU containing no dendrimer) prior to casting the G4-ACN 
or G4-ACN/SO polyurethanes. This layer prevented delamination of the polyurethane 
and subsequently reduced leaching (Figure 5.4). Of note, it was hypothesized that the 
addition of the bulky, hydrophobic styrene oxide in G4-ACN/SO would reduce 
dendrimer leaching by increasing hydrophobic-hydrophobic interactions between the 
polyurethane and the dendrimer. While the G4-ACN/SO dendrimers did leach ~50% less 
than G4-ACN dendrimers both with and without an adhesive layer, the data in Figure 5.4 
clearly demonstrates that swelling of the polymer matrix impacts leaching to a much 
greater extent.  
 Table 5.2 shows the NO-release characteristics of 25 wt% G4-ED, G4-SO, G4-
ACN, or G4-ACN/SO doped within a 75TP470:25TPU polyurethane. The NO-release 
from all 25 wt% systems is sufficient for reducing adhesion of Gram-negative and Gram-
positive bacteria,
7, 27
 reducing platelet adhesion,
3
 reducing collagen capsule thickness
7, 20
, 
reducing collagen capsule thickness in vivo,
20
 and reducing inflammation in vivo.
27
 
Furthermore, G4-ACN and G4-ACN/SO-doped polyurethanes  release NO at levels that 
168 
 
  
 
 
Figure 5.4 Cumulative leaching from G4-ACN/SO (grey) and G4-ACN (blue) with 
(triangle) and without (square) an adhesion layer. Leaching was determined through 
RITC-tagged dendrimers and fluorometry. Error bars represent the standard deviation 
of the mean (n=3 measurements of n=1 film per data point). 
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Table 5.2 Nitric oxide-release characterization of N-diazeniumdiolate-modified dendrimers 
doped within 75TP470:25TPU polyurethanes (25 wt%) and coated with TP470 barrier 
layers (30 μL; 40 mg mL-1). Adhesion layers (75TP470:25TPU) were used for G4-ACN 
and G4-ACN/SO systems.  
dendrimer 
dopant  
(25 wt%) 
[NO]m 
pmol cm
-2
 s
-1
 
t[NO] 
μmol cm-2 
t1/2
 
(h) td (d) 
% leaching 
 (7 d; wt%) 
 
G4-ED 27.0 ± 2.0
a
 1.1 ± 0.2 14 ± 2 3.2 ± 0.7 2.5 ± 0.3  
G4-SO 14.1 ± 1.2 1.1 ± 0.3 20 ± 3 3.4 ± 0.2 3.0 ± 0.4  
G4-ACN
b
 4.4 ± 0.04 1.6 ± 0.4 69 ± 13 6.9 ± 0.9 1.3 ± 0.2  
G4-ACN/SO
b
 17.2 ± 6.4 2.0 ± 0.7 50 ± 14 8.8 ± 3.2 1.0 ± 0.2  
 
a 
Values are given as mean ± standard deviation for n=3 samples 
b 
n=2
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significantly inhibit S. aureus and E. coli biofilm formation over 7 d.
28
 Consistent with 
the NO-release characteristics of the N-diazeniumdiolate-modified G4-PAMAM 
precursors themselves, the release durations from the 25 wt% G4-SO and G4-ED films 
were much shorter than the G4-ACN and G4-ACN/SO films. To the best of our 
knowledge, the duration (8.8 ± 3.2 d) and half-life (50 ± 14 h) of NO release from 25 
wt% G4-ACN/SO is the longest to date for an N-diazeniumdiolate-based film formed 
from a polyurethane dispersion, and the second-longest to date for any N-diazeniudiolate 
surface formulation. Cai et al. achieved a 10 d duration > 1 pmol cm
-2
 s
-1
 by doping a 
small molecule NO donor (N-diazeniumdiolate-modified dibutylhexyldiamine; 20 wt%) 
into a poly(lactic-co-glycolic) acid matrix coated with silicon rubber.
28
 In that 
configuration, the amine-based NO donor was geographically concentrated at the center 
of the film so that the internal pH surrounding the N-diazeniumdiolate increased. Thus, 
the proton-driven decomposition of the N-diazeniumdiolate slows dramatically. Slow 
hydrolysis of the poly(lactic-co-glycolic) scaffold produced lactic and glycolic acids, 
supplementing the internal matrix with protons. In return, NO release continues, albeit 
slowly. Despite the slightly longer NO release kinetics using this approach, our strategy 
may prove more useful for long-term implants and coatings in that it does not rely on 
degradation of the polymer to achieve NO release.  
 As shown in Table 5.2, a slight amount of dendrimer leaching (<3 wt%) occurred 
from the G4-PAMAM dendrimer-doped polyurethanes after immersion in PBS (pH 7.4; 
37 
o
C). To probe the connection between leaching and toxicity (if any), the G4-PAMAM-
doped polyurethanes were incubated atop L929 fibroblasts for 24 h (Figure 5.5). The G4-
ACN/SO-doped polyurethanes did not exhibit any cytotoxicity, in alignment with our 
171 
 
  
 
Figure 5.5 Cytotoxicity of L929 fibroblasts following 24 h exposure to G4-ED, G4-
SO, G4-ACN, or G4-ACNSO-doped polyurethanes. Films are either 10 wt% 
dendrimer; no barrier layer (blue), 10 wt% dendrimer; with barrier layer (white stripe), 
20 wt% dendrimer (light grey) or 30 wt% dendrimer (dark grey). Error bars represent 
the standard deviation of the mean from triplicate measurements of n=1 film. 
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findings that amphiphilic dendrimers are not toxic towards mammalian cells.
29
 In 
contrast, G4-SO (30 wt%) and G4-ED (10 wt%; no barrier layer) systems displayed 
significant toxicity towards the L929 fibroblasts. Our results clearly indicate that the 
polymer composition, barrier layer, and dendrimer must be carefully selected to minimize 
toxicity from polyurethane films.  
5.3.3 Synthesis and characterization of NO-releasing G4-PAMAM-doped electrospun 
polyurethane fibers  
 Electrospun fibers have potential application as wound dressings,
30
 tissue 
engineering scaffolds,
31
 and sensors.
32
 Several overlapping advantages may exist for 
electrospun fibers and NO release. For example, both strategies promote tissue 
integration,
18
 improve the wound-healing response,
19
 and reduce collagen capsule 
thickness.
18, 33
 As such, we hypothesize that NO-releasing electrospun fiber mats may 
further reduce the foreign body response to tissue-based implants. Electrospun fiber mats 
synthesized in our laboratory to date have utilized NO-releasing polymer dispersions of 
PROLI/NO or silica nanoparticles.
15, 16
 While not expected to cause toxicity, electrospun 
fibers doped with PROLI/NO and G4-PAMAM leach most of their contents when 
submerged in phosphate buffer,
6
 thus limiting the extended NO-release durations 
afforded by the polyurethane matrix itself. The NO-releasing G4-PAMAM dendrimers 
may remain entrapped within the electrospun fiber mats more readily than particles or 
PROLI/NO due to improved partitioning. Furthermore, the properties of the G4-PAMAM 
dendrimers synthesized herein would result in fibers with tunable NO-release totals and 
durations. 
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 Koh et al. demonstrated that electrospun fibers synthesized from TP470 exhibited 
less swelling in aqueous solution than those made from TPU or other more hydrophilic 
polyurethanes.
14
 Thus, TP470 was chosen as the polymer for the fibers explored herein. 
Each dendrimer was dissolved within a viscous TP470 solution (12% w/v) at an overall 
concentration of 5 wt% relative to the total amount of TP470. G4-PAMAM-doped fibers 
with nanometer dimensions were produced following extrusion of the dendrimer-doped 
polymer through a needle tip and application of a high voltage electric field (Figure 5.6). 
No significant differences in fiber diameters were observed between the different G4-
PAMAM systems (Table 5.3). Using TP470 with silicon nanoparticles, Koh et al. 
similarly reported that fiber diameter was influenced more by kinematic viscosity (i.e., a 
property of the polymer solution itself) than by the dopant included within. Having 
independent control of fiber diameter (separate from the dopant) in this manner may 
prove useful in future experiments aimed to evaluate the role of NO-release and 
electrospun fibers in tissue. 
 Compared to fibers doped with N-diazeniumdiolate-modified silica particles that 
leach 35-100% of their contents within 7 d, the NO-releasing G4-PAMAM-doped fibers 
herein leached only 7—16% over the same period (Table 5.3). Predictably, the most 
hydrophilic dendrimer (G4-ACN) leached the most. Styrene oxide-modified dendrimers 
(G4-ACN/SO) leached only half of this amount, consistent with observations above for 
G4-ACN and G4-ACN/SO films. Nitric oxide release totals (Table 5.4) from the fibers 
were similar to those reported for NO-releasing silica particle-doped mats. However, the 
NO-release durations for the 5wt% G4-ACN and G4-ACN/SO dendrimers are the longest 
reported for N-diazeniumdiolate-based NO donors within an electrospun
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Figure 5.6 Electrospun TP470 fibers doped with 5 wt% (A) G4-ED, (B) G4-SO, (C) 
G4-ACN, or (D) G4-ACN/SO viewed using SEM. Scale bar = 10 μm.  
A B
DC
175 
 
 
 
Table 5.3 Fiber diameters and dendrimer leaching from NO-releasing G4-PAMAM-
doped electrospun TP470 fibers. Dendrimers were doped at a concentration of 5 wt% 
relative to the TP470 polyurethane. Fiber diameters were determined from SEM and 
leaching was measured through RITC-tagged dendrimers measured using fluorometry. 
dendrimer dopant fiber diameter (nm)
a,b
 % leaching
c
 
G4-ED 470 ± 110 7.2 ± 0.5 
G4-SO 440 ± 130 11.3 ± 0.6 
G4-ACN 480 ± 120 16.2 ± 1.6 
G4-ACN/SO 490 ± 150 9.6 ±1.8 
 
a 
Values are given as the mean ± standard deviation from n=50 random locations on the fiber mat  
b 
Diameters were measured using imageJ software. 
c 
Values are given as the mean ± standard deviation from n=3 fiber samples.  
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Table 5.4 Nitric oxide release properties from G4-PAMAM-doped electrospun TP470 
fibers determined via chemiluminescence. Dendrimers were doped at a concentration 
of 5 wt% relative to the TP470 polyurethane.  
dendrimer 
dopant 
ppb mg
a
 nmol mg
-2
 half-life (h) duration (h) 
G4-ED 52.6 ± 12.9 19 ± 2 0.9 ± 0.1 17 ±  4 
G4-SO 17.5 ± 7.7 12 ± 0.7 1.7 ± 0.5 17 ± 3 
G4-ACN 13.2 ± 4.4 27 ± 5 4.6 ± 1.2 42 ± 14 
G4-ACN/SO 51.9 ± 12.3 34 ± 4 2.1 ± 0.1 38 ± 11 
 
a 
Values are given as the mean ± standard deviation of n=3 fiber samples. 
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fiber mat. Overall, the results indicate that facile surface modification of dendrimer 
scaffolds may be used control dopant-polymer partitioning (i.e., reducing leaching via 
hydrophobic groups) and extend NO-release kinetics. 
5.4 Conclusions 
 Preparing NO-donor/polymer dispersions represents one of the simplest 
approaches to fabricate NO-releasing coatings. However, controlling NO-release kinetics 
(i.e., to enable low NO flux anti-FBR coatings or higher NO flux anti-bacterial coatings) 
while also minimizing NO-donor leaching is difficult because strategies that modulate 
NO release rate may often influence leaching of the dopant from the polymer. In this 
chapter, NO-releasing PAMAM dendrimers were used as polymer dopants. The tunable 
surface hydrophobicity, NO-release kinetics and sizable NO payloads of PAMAM 
dendrimers enabled tailored NO-release kinetics while limiting donor leaching from 
polyurethanes. Future work should explore the potential for covalent dendrimer-polymer 
attachment, instead of the hydrophobic-hydrophobic interactions explored herein, to 
completely eliminate NO donor leaching. 
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Chapter 6: 
Summary and Future Directions 
 
6.1 Summary  
 The preceding chapters have detailed new designs in NO-releasing antimicrobial 
coatings for enhancing the utility and function of biomedical implants. In Chapter 1, the 
circumstances that cause bacterial colonization on implants and strategies for bacterial 
adhesion were described to provide some perspective on non-fouling interfaces. 
Particular attention was given to “passive” and “active” antimicrobial coatings, and the 
strengths and limitations of each.  
 In Chapter 2, the synthesis of NO-releasing xerogels from N-diazeniumdiolate-
modified silane precursors was developed using the sol-gel method. Prior to this 
approach, the route to NO-releasing xerogels first required synthesis of an amine-
modified silica network with subsequent exposure to high pressures of NO gas (≥5 bar). 
This process limited the analytical utility of these xerogels as glucose sensor membranes 
and also required the substrate to be placed under high pressure NO—a requirement that 
may be impractical for some medical devices. Both the size of the nitric oxide payload 
and the kinetics of its release were tunable by varying the identity and concentration of 
the precursor NO donor within the xerogel. To further illustrate the clinical utility of this 
method, AEAP/NO-PTMOS xerogels were developed as outer sensor membranes for 
glucose sensors.  
 In Chapter 3, passive and active antimicrobial strategies were combined to create 
antifouling surfaces. Nitric oxide-releasing xerogels were spraycoated with a mixture of 
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silica and a fluorosilane to provide the microscale roughness and low-surface energy 
required for superhydrophobicity. By adjusting the thickness of the superhydrophobic 
layer, NO-release durations were tuned from 59—105 h, suggesting that these coatings 
may also have utility in controlled drug release applications. The antimicrobial properties 
of these interfaces were measured using 10
8
 cfu mL
-1
 P. aeruginosa. Individually, NO-
release and superhydrophobicity each reduced viable adhered bacteria by ~1-log. 
Xerogels that were both superhydrophobic and released NO decreased viable adhesion by 
~2-log, suggesting an additive antifouling effect for the two strategies. The biocidal 
capabilities of the NO-release layer were demonstrated by incubating the xerogels in PBS 
for an additional 12 h where an additional ~1.8-log reduction in bacteria was observed. 
As the superhydrophobic coating itself was shown to be non-toxic, combining 
superhydrophobicity with NO release maximized the antifouling potential of these 
coatings without negatively affecting cell toxicity.  
 In Chapter 4, the synthesis of xerogels that release silver and NO simultaneously 
was described to study potential antimicrobial synergy. The xerogels were synthesized 
using a multi-layer approach. While the NO-releasing layer was fabricated using an 
amine-modified AHAP xerogel, the silver-releasing layer consisted of an alkylsilane 
loaded with silver nitrate. Release of each agent from its respective layer was 
independently controllable (i.e., silver loading did not alter NO release, and the N-
diazeniumdiolate formation process did alter silver release). The antibacterial potential of 
these xerogels was assessed against P. aeruginosa and S. aureus, common Gram-negative 
and Gram-positive bacteria implicated in orthopedic infections.
1, 2
 Against both bacterial 
strains, a greater-than-additive bactericidal effect was observed when the two agents were 
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released simultaneously. Through confocal microscopy experiments, we found that NO’s 
action could primarily be attributed to reduced adhesion. Silver’s mechanism of action 
was primarily through cellular killing. We hypothesized that membrane damage caused 
by silver allowed NO to permeate the cell more readily, where it could react with 
oxidative stressors (e.g., those that resulted from Ag
+ 
treatment) to form potent 
antimicrobials such as peroxynitrite. Despite the greater-than-additive killing effect 
observed against bacteria, no such effect was observed on L929 mouse fibroblasts. These 
materials may be important tools for limiting the toxicity and bioaccumulation of silver-
releasing materials that are widespread in clinical care.  
 In Chapter 5, NO-releasing poly(amido amine) (PAMAM) dendrimers were used 
as dopants within polyurethane films and nanofibers. By altering the modifier that forms 
secondary amines on the dendrimer (necessary for N-diazeniumdiolate formation), 
materials with a range of NO surface fluxes and durations were achieved. Polyurethanes 
with acrylonitrile (ACN)-modified G4-PAMAM dendrimers released low levels of NO 
(max flux 3—10 pmol cm-2 s-1) for up to 8.8 d with low toxicity to L929 fibroblast cells. 
By incorporating hydrophobic modifiers (e.g., styrene oxide (SO)) on the exterior of 
ACN-modified dendrimers, leaching of the macromolecules from both films and fibers 
was reduced while retaining the longer release characteristics of the ACN systems. As 
films, the sustained NO release from these materials hold promise as antibiofilm 
coatings,
3
 while the fibers may be utilized to create sensor membranes or antimicrobial 
wound dressings.
4, 5
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 6.2 Future directions  
 Chemists have developed a broad-array of biomedical device coatings that 
prevent the adhesion of microbial pathogens or kill adhered microbes.
6
 Despite their 
promise, the inherent limitations present with some types of antimicrobial coatings could 
be overcome by rationally combining different drug-release or surface-modification 
strategies. In this section, new techniques for effective antimicrobial materials are 
introduced. In addition, surfaces that hold promise for others types of fouling will be 
suggested.  
6.2.1 Silver/NO-releasing wound dressings 
 Silver-releasing wound dressings are used extensively to treat infection-prone 
wounds such as burns and diabetic ulcers.
7, 8
 Unfortunately, these materials exhibit 
toxicity towards karatinocyte and fibroblast cells, both of which are critical to the body’s 
wound-healing response.
7, 9
 Large concentrations of silver may accumulate systemically 
from these treatments. In a case report from 2006, a burn patient developed severe 
argyria-like symptoms (i.e., graying of the skin and elevated silver concentrations in the 
liver and plasma) following treatment with silver sulfadiazine-doped wound dressings.
10
 
Therapies are needed that reduce silver toxicity without compromising its antimicrobial 
efficacy. In Chapter 4, dual-action silver/NO-releasing xerogels were shown to exhibit 
greater-than-additive killing of surface-adhered P. aeruginosa and S. aureus. Translating 
this drug-release combination to wound dressings would alleviate some of the pitfalls 
associated with silver release by lowering the overall dose of the metal required for an 
identical antimicrobial effect. 
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 The benefits of a silver/NO-releasing dressing may extend beyond reduced 
toxicity. In vivo, NO regulates wound healing and is an essential factor for collagen 
deposition by fibroblasts.
11
 Exogenous NO has been employed as a treatment to promote 
wound healing.
12, 13
 Hydrogels that release NO enhance extracellular matrix production 
by fibroblasts. Likewise, NO-releasing nanoparticles accelerate the wound healing 
process by promoting angiogenesis.
13
 Exogenous NO therapies are particularly 
efficacious for the two clinical populations treated most with silver-releasing wound 
dressings: diabetics and burn victims.
14, 15
 
 Polyurethane electrospun fibers would be ideal polymer scaffolds for fabricating 
silver/NO-releasing wound dressings.
16, 17
 Khil et al. observed improved epithelialization 
and tissue organization at wounds treated with electrospun polyurethane nanofiber mats. 
These results were attributed to the high oxygen permeability of polyurethanes along with 
their ability to trap moisture at wound sites, lending credence to their potential as wound 
dressings.
16, 17
 To incorporate both NO and silver-release capabilities to such fibers, 
poly(amido amine) dendrimers may be used as macromolecular scaffolds for the effective 
storage of these agents. Generation 4 PAMAM dendrimers are able to solubilize 
transition metal cations such as silver through complexes formed at the internal 3
o 
amines 
of the dendrimers.
18
 Balogh et al. reported that silver-doped dendrimers prepared in this 
manner were bactericidal against S. aureus, E. coli, and P. aeruginosa. Post-
functionalizing silver-containing dendrimers with N-diazeniumdiolate NO donors may 
result in an effective silver/NO-releasing macromolecular scaffold that could be included 
within electrospun polyurethane fiber mats. If the chemistries used for N-
diazeniumdiolate synthesis and silver-loading prove to be incompatible, a two-agent 
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system (i.e., a mixture of N-diazeniumdiolate-modified dendrimers and silver-loaded 
dendrimers) could be loaded into the electrospun fibers instead. The resulting material 
should lower the doses of silver necessary for a specific bactericidal effect while also 
encouraging potent wound-healing properties through NO release. 
6.2.2 Quaternary ammonium (QA)-functionalized superhydrophobic surfaces 
 An ideal antifouling surfaces for medical devices would reduce bacterial 
adhesion, kill bacteria that do adhere, and have a mechanism of action that operates 
indefinitely.
19
 Passive antifouling surfaces (e.g., PEGylated and superhydrophobic 
membranes) resist adhesion, but their inability to kill bacteria still allows for biofilm 
growth. Materials that actively release biocidal agents (e.g., NO or Ag
+
) are able to resist 
adhesion and kill bacteria, but their antimicrobial duration is finite. Polycationic QA-
functionalized surfaces represent a strategy that merges the benefits of each. The 
presence of long, hydrophobic alkyl chains and a dense cationic surface charge disrupts 
the membranes of adhered bacteria without exhibiting marked toxicity to mammalian 
cells.
20, 21
 As the biocide is permanently affixed to the surface, such materials could 
theoretically kill bacteria indefinitely. In practice, the utility of QA-functionalized 
coatings is limited for biomedical applications. Bacteria killed by the QA-groups remain 
adhered, masking the substrate from further bacteria.
22
 The Klibanov group examined 
this phenomenon by spraying aerosolized bacteria (~5x10
6 
cfu mL
-1 
E. coli) onto QA-
modified brush polymers. After four sprays of the bacteria suspension, the bacterial 
killing ability of the coating declined by nearly 45%.
22
 The authors demonstrated that the 
coating could be regenerated by washing with a surfactant, but such a step would be 
impractical for implantable medical devices. 
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 The development of QA-functionalized surfaces that also resist adhesion would 
improve the long-term utility of these materials. A superhydrophobic QA-functionalized 
surface should both reduce bacterial adhesion (through the superhydrophobic component) 
and kill bacteria (through the QA component). Fewer adhered bacteria would translate to 
fewer masked QA moieties on the surface, ultimately extending their biocidal efficacy. 
Furthermore, the self-cleaning properties of superhydrophobic coatings may serve to 
“regenerate” the surface through removal of dead bacteria. 
 In Chapter 3 of this dissertation, a superhydrophobic material was coated on NO-
releasing xerogels. Silica particles were reacted in the presence of a fluorinated sol-gel 
material to create the surface roughness and low surface energy needed for 
superhydrophobicity. In the future, superhydrophobic QA-modified coatings could be 
created by exchanging the silane components in this sol-gel with a QA-modified silane 
(Scheme 6.1). First, QA-modified silanes of varying chain lengths may be synthesized 
via an established nucleophilic aliphatic substitution reaction to create a library of QA 
silane precursors. The effect of alkyl chain length, alkyl chain density, and charge density 
can be explored by adjusting either the identity or the relative concentration of the QA 
silane precursors. Each of these features will likely affect both contact angle and 
bactericidal efficacy. Quaternary ammonium species with longer alkyl chains (10-16 
carbons)
23-26
 have proven more effective at killing bacteria. Longer alkyl chains will 
likely provide the low surface energy necessary for superhydrophobicity. Oosterhof et al. 
reported hydrophobic contact angles (100
o
) on smooth substrates modified with a 
commercially available 18-carbon QA silane.
27
 The same fluorosilane membranes used to 
create the superhydrophobic materials in Chapter 3 feature a static water contact angle of 
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Scheme 6.1 Proposed synthesis of QA-modified surfaces. (A) An alkyl halide-
functionalized silane and tertiary amine are reacted via nucleophilic aliphatic 
substitution to yield QA-modified silanes. (B) QA-modified silanes are co-condensed 
with linker silanes and silica colloids, before  (C) application to a substrate to yield 
superhydrophobic QA-modified surfaces. 
Silica
+
A
B
C
MTMOS
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105
o 
when cast on smooth surfaces.
28
  In preliminary experiments, a commercially 
available QA silane featuring two 10-carbons chains pendant from the quaternary 
ammonium (N,N-didecyl-N-methyl N-(3-trimethoxysilylpropyl) ammonium chloride; 
DDMTS) was incorporated into a silica-particle doped sol at concentrations of 0, 10, or 
20 mol% (balance MTMOS). As shown in Figure 6.1A, increasing the mol% of DDTMS 
within the membrane caused a concomitant increase in the intensity of a characteristic 
QA X-ray photoelectron spectroscopy (XPS) peak at ~400 eV (Figure 1A).
23
 The water 
contact angle of the particle-doped 20 mol% DDTMS composite was 149
o 
(Figure 6.1B), 
indicating near-superhydrophobic behavior. To optimize the anti-wetting properties of 
these materials, longer-chained QAs or fluorosilanes should be incorporated into the 
composite. Subsequent bacteria testing should be two-pronged, with focus given to 
waterborne and airborne assays.
29
 The benefits of the self-cleaning superhydrophobic 
layer could be proved through repeated aerosolized bacteria challenges or pre-immersion 
in a suspension of proteins to model the fouling events that mask the bactericidal action 
of QA moieties.  
6.2.3 Superhydrophobic materials for ultrasound-triggered NO release 
 The superhydrophobic NO-releasing xerogels described in Chapter 3 were 
synthesized by applying a thin superhydrophobic membrane onto an existing (non-
superhydrophobic) NO-releasing xerogel. In contrast, Yohe et al. synthesized releasing 3-
dimensional (3D) superhydrophobic fiber meshes where a cancer drug was doped within 
the superhydrophobic material.
30
 When the mats were submerged in water, entrapped air 
prevented diffusion of the drug payload out into the surroundings. Water was forced into 
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Figure 6.1 (A) Xray photoelectron spectra of 0 (black), 10 (red), and 20 mol% (blue) 
DDTMS (balance MTMOS) silica composites (B) A water droplet (contact angle 
149
o
) on a 20 mol% DDTMS (balance MTMOS) silica composite.  
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the mat by applying ultrasound, effectively creating a controlled external trigger for drug-
release.  
 Triggered release of antimicrobial agents such as NO may prove useful for 
delaying implant associated infections that manifest weeks or months after surgery.
31
 
Nitric oxide is also involved in biofilm dispersal,
32
 so this technique may be useful for 
disrupting mature biofilms that develop on the implant. An NO-releasing material with 
ultrasound-triggered-release could be prepared by using the N-diazeniumdiolate-modified 
silane precursors employed in Chapter 2. By incorporating these precursors into a silica-
fluorosilane sol and applying the membrane as a thick coating on a surface, the N-
diazeniumdiolate NO donors would be distributed throughout the entirety of the 
superhydrophobic silica network. With reduced water uptake into the material, proton-
dependent decomposition of the NO donors would slow, but could later be triggered by 
applying ultrasound much like the fiber mats prepared by Yohe and coworkers. Such a 
material might improve patient care by eradicating infections that form after device 
implantation. 
6.2.4 Superhydrophobic coatings as mold-resistant materials 
 The work presented here has focused on coatings that resist the adhesion of 
virulent bacteria on implanted devices. However, some of these materials may prove 
useful for resisting adhesion and colonization of other medically-relevant microbes. 
Specifically, the spray-on superhydrophobic coatings presented could be used to combat 
fungal growth (i.e., mold) that proliferates on the surfaces of building materials.
33
 Mold 
spores colonize moist surfaces, forming vegetative mycelia and growing through 
extension of hyphae until releasing more spores into the air that further colonize new 
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surfaces.
33-35
 In the hospital setting, spores from pathogenic fungi (e.g., Aspergillus 
spp.)
36
 cause infections in immunocompromised patients (e.g., patients with AIDS, or 
those taking immunosuppressive medications following organ transplants).
37, 38
 
Unfortunately, morbidity and mortality rates for these infections are high despite 
antifungal treatments.
36
   
 Measures that reduce the number of airborne spore counts in hospitals have been 
directly linked to a decreased incidence of nosocomial fungal infections.
39
 Biocidal paints 
are often used for this purpose, and their mechanism mirrors those developed for 
implantable biomaterials (i.e., active release of biocides or surface-grafted QA 
moieties).
40
 The anti-wetting properties of superhydrophobic surfaces should prevent 
mold-growth by limiting the water accessibility needed for fungal replication and 
survival.
41-43
 Moreover, the self-cleaning properties of superhydrophobic materials should 
allow for easy removal of spores that do adhere.
44
  
  In preliminary experiments, an accelerated growth model (ASTM D5590)
45
 was 
employed to measure Aspergillus niger fungal growth on card stock paper spraycoated 
with the 30 mol% 17FTMS (balance MTMOS)/silica superhydrophobic composites used 
in Chapter 3. In this assay, the substrates were placed on nutrient agar, inoculated with 
~4x10
5 
fungal spores, and incubated in the dark for 1 week at 25 
o
C at 93% relative 
humidity. The fungal inoculum is placed outside the perimeter of the substrate, such that 
it grows from the outside of the substrate towards the center. Of note, the conditions used 
in this assay are extremely favorable for mold growth. Controls were either uncoated, 
MTMOS-coated, or 17FTMS/MTMOS-coated cardstock substrates. While all controls 
had significant fungal coverage, the superhydrophobic materials displayed almost no 
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fungal growth (Figure 6.2). These preliminary results demonstrate the promise of 
superhydrophobic materials for resisting fungal growth. It is hypothesized that the anti-
fungal abilities of these materials are partially attributable to low water availability on 
superhydrophobic surfaces. Mold-forming fungi only grow on surfaces when the water 
vapor pressure (Water activity; Aw) at the surface-air interface is sufficiently high.
46
 The 
minimum Aw
 
capable of supporting growth is specific to each fungus. If 
superhydrophobic materials are antifungal by virtue of having an intrinsically low Aw, 
less growth would be expected for water-loving fungi. Future experiments should 
evaluate this hypothesis using fungi implicated in nosocomial infections (i.e., Aspergillus 
fumigatus, Aspergillus terreus, Fusarium moniliforme, and Scedosporium prolificans).  
 
6.3 Conclusions 
 The work presented here highlights the importance of implant coatings that resist 
microbial adhesion and/or kill adhered bacteria. As NO released from a surface is capable 
of doing both, particular focus was given to this species. Methods were developed 
utilizing NO to maximize the antifouling capabilities of surfaces while minimizing 
associated cellular toxicity. These techniques should guide the development of new 
antimicrobial surfaces, especially those that combine multiple antimicrobial strategies to 
overcome the limitations of another. While combating infection is critical, others 
problems also plague clinical devices, such as inadequate wound healing, the foreign 
body response, and excessive inflammation. Concerns about these issues and infection 
almost never exist apart from each other, and the next-generation of biomedical coatings 
must be able to address each. Given NO’s ability to improve all of these implant-related 
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Figure 6.2 Aspergillus niger growth on (A) uncoated (B) MTMOS-coated (C) 30 
mol% 17FTMS (balance MTMOS)-coated and (D) superhydrophobic card stock. 
White areas represent the card stock substrate, and black areas are the spore-laden 
mycelia of the fungus. Each image displays the full area of the substrate (3 cm x 3 
cm). 
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pitfalls, the materials synthesized here may guide future developments of superior anti-
fouling coatings.  
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